
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

36859359
1347
10.1038/s41392-023-01347-1
Review Article
Targeting p53 pathways: mechanisms, structures and advances in therapy
Wang Haolan
Guo Ming
Wei Hudie hudiewei18@163.com

http://orcid.org/0000-0001-8139-6892
Chen Yongheng yonghenc@163.com

grid.452223.0 0000 0004 1757 7615 Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008 China
1 3 2023
1 3 2023
2023
8 921 8 2022
19 12 2022
7 2 2023
© The Author(s) 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has been a major focus of oncology research. The p53 protein is a transcription factor that can activate the expression of multiple target genes and plays critical roles in regulating cell cycle, apoptosis, and genomic stability, and is widely regarded as the “guardian of the genome”. Accumulating evidence has shown that p53 also regulates cell metabolism, ferroptosis, tumor microenvironment, autophagy and so on, all of which contribute to tumor suppression. Mutations in TP53 not only impair its tumor suppressor function, but also confer oncogenic properties to p53 mutants. Since p53 is mutated and inactivated in most malignant tumors, it has been a very attractive target for developing new anti-cancer drugs. However, until recently, p53 was considered an “undruggable” target and little progress has been made with p53-targeted therapies. Here, we provide a systematic review of the diverse molecular mechanisms of the p53 signaling pathway and how TP53 mutations impact tumor progression. We also discuss key structural features of the p53 protein and its inactivation by oncogenic mutations. In addition, we review the efforts that have been made in p53-targeted therapies, and discuss the challenges that have been encountered in clinical development.

Subject terms

Drug development
Drug development
Structural biology
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 81570537 81974074 82172654 82273496 31900880 Wei Hudie Chen Yongheng https://doi.org/10.13039/501100002767 Hunan Provincial Science and Technology Department (Department of Science and Technology of Hunan Province) 2018RS3026 2021RC4012 Chen Yongheng issue-copyright-statement© West China Hospital, Sichuan University 2023
==== Body
pmcIntroduction

The tumor suppressor gene TP53 is the most frequently mutated gene in human tumors.1,2 The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4 p53 protein functions primarily as a transcription factor, which regulates a wide variety of pathways, such as cell cycle arrest, DNA repair, cell apoptosis, autophagy, and metabolism,1,5,6 and determines whether cells die under stress conditions. Over the years, a growing number of studies have revealed the complexity and connectivity of the p53 pathway and by extension its role in metabolic homeostasis, immune microenvironment, stem cell biology and so on. However, mutant p53 can alter DNA-specific binding, disrupt the spatial conformation of the protein and thermostability of the protein, and result in dysfunction of p53 activity.7–10

The high frequency of TP53 mutations in tumors and its intrinsic tumor suppressor function make it a highly promising target for tumor therapy. However, the specificity of the p53 structure,11,12 the smooth surface without an ideal drug-binding pocket,13 and the difficulty to restore p53 function, have stalled drug research against p53 for decades. Nevertheless, researchers still believe that this difficult-to-drug target can be tackled, and have made some progress in recent years. In this review, we aim to provide a comprehensive summary of the biological function of p53, p53 signaling pathway, the structural features of p53 protein, as well as the advances in p53-targeted therapies.

The discovery history of p53

The TP53 gene is located on the short arm of chromosome 17 (17p13.1) and encodes a protein with 393 amino acid residues. p53 was initially identified as a host protein that bound to simian virus 40 large T antigen in virally transformed cells,14 and was named p53 in 1979 because its molecular weight was shown to be approximately 53 kilodalton (kDa) in SDS polyacrylamide gel electrophoresis analysis15 (Fig. 1). The actual molecular weight of p53 is 43.7 kDa, due to the large number of proline residues in the protein that slowed down its migration on SDS polyacrylamide gel electrophoresis. TP53 was initially thought to be an oncogene, and high levels of p53 conferred significant tumorigenic potential to rat embryonic fibroblasts.16,17 Subsequent studies have led to a change in the recognition of TP53. The initial p53 cDNA was synthesized using mRNA from tumor cells as a template, and the p53 cDNA subsequently obtained from normal cells did not transform the cells, but rather inhibited tumor cell growth.18 In tumor cells the TP53 gene is often mutated or lost due to chromosome 17 deletion, whereas in normal cells the gene is intact.19,20 When a missense mutation in TP53 occurs, the obtained p53 protein promotes tumorigenic transformation.21,22 TP53 knockout mice have a high probability of developing tumors.23 Overexpression of the wild-type TP53 gene in cells effectively suppressed the transforming effects exerted on cells by those oncogenes, such as the MYC gene and RAS gene.22,24 This series of studies overturned the established paradigm of TP53, which has since become one of the most studied tumor suppressor genes.Fig. 1 Timeline of some major advances in p53 research

The p53 pathway

p53 is a transcription factor that is distributed in the nucleus and cytoplasm, binds specifically to DNA, and regulates a diversity of genes.25,26 Under normal conditions, cellular p53 protein levels are very low owing to strict control by its negative regulators MDM2 and MDMX, which promote p53 degradation through ubiquitination.27,28 When cells are exposed to internal and external stresses, including DNA damage, hypoxia, nutrient deprivation, and cancer cell risk, p53 ubiquitination is inhibited, triggering a rapid increase in intracellular p53 protein levels. Accumulated p53 is activated and stabilized by posttranslational modifications, including phosphorylation, acetylation and methylation.29–32 Stabilized p53 forms tetramers in the nucleus, binds to target DNA and regulates gene transcription, leading to alterations in downstream signaling pathways.33–37

In response to cellular stress, p53 prevents the differentiation of cells with mutated or damaged DNA and terminates cellular processes by transcriptionally activating various genes involved in apoptosis and cell cycle,38,39 which contributes significantly to its tumor suppressor function and is the most studied.33–37,40–44 Meanwhile, a series of studies have shown that p53 also controls a number of “non-classical” pathways (Fig. 2), including metabolic homeostasis, ferroptosis, stem cell differentiation, autophagy, senescence, tumor microenvironment and so on.45–50Fig. 2 The p53 pathway. Under normal conditions, p53 protein levels are tightly regulated by MDM2/X, which together ubiquitinate p53, leading to proteasomal degradation of p53. Under stress conditions, p53 is activated and stabilized by post-translational modifications. Stabilized p53 forms tetramers in the nucleus, binds to target DNA, regulates gene transcription, and controls many different biological processes. ALDH4 aldehyde dehydrogenase family 4 member A1, ALOX12 arachidonate-12-lipoxygenase, AMPK 5′-AMP-activated protein kinase, APAF1 apoptotic protease-activating factor 1, Atgs autophagy-related genes, ATM ataxia-telangiectasia mutated proteins, ATR ataxia telangiectasia and Rad3-related, BAX apoptosis regulator BAX, CDC cell division cycle, CDK cyclin-dependent kinase, COX-2 cyclooxygenase-2 (also known as PTGS2), CPT1C carnitine palmitoyltransferase 1C, Cyt C Cytochrome C, DDB2 damage specific DNA binding protein 1, DPP4 dipeptidyl peptidase-4, DRAM damage regulated autophagy modulator 2, FANCC fanconi anemia group C protein, FDXR ferredoxin reductase, GADD45 growth arrest and DNA damage-inducible 45, GLS2 glutaminase 2, GLUT glucose transporter type, GPX glutathione peroxidase, G6PDH glucose‑6‑phosphate (G-6‑P) dehydrogenase, HMGB1 high-mobility group box-1, MCD malonyl-coenzyme A decarboxylase, mTOR mammalian target of rapamycin, NOXA superoxide-generating NADPH oxidase, PAI1 plasminogen activator inhibitor 1, PANK1 pantothenate kinase 1, PDK PDH kinase, PIGs p53-induced gene, PML promyelocytic leukemia protein, PRL3 phosphatase of regenerating liver-3, PTPRV protein tyrosine phosphatase receptor type V, PUMA Bcl-2-binding component 3, ROS reactive oxygen species, RRM2 ribonucleoside-diphosphate reductase subunit M2, SAT1 spermine N1-acetyltransferase 1, SLC7A11 solute carrier family7 member11, TFR1 transferrin receptor 1, TIGAR TP53-induced glycolysis and apoptosis regulator, TP53INP1 tumor protein p53 inducible nuclear protein 1, XPC xeroderma pigmentosum group C protein, YAP1 yes-associated protein 1

The biological function of p53 in cancer

p53 controls a wide range of signaling networks. There is no simple and clear answer to the question of exactly how, when, and what p53 does. Nevertheless, what is clear is that p53 has a very flexible and versatile response, with an integrated response to environmental perturbations determining cell death or maintaining cellular homeostasis. p53 serves as a linkage point for multiple cellular signaling pathways, harmoniously and delicately regulating various biological functions through transcriptional regulation and protein-protein interactions.

Genomic stability

p53 is considered as the guardian of the genome. It plays an important role in maintaining genomic stability. When DNA is damaged, p53 protects the genome by coordinating multiple DNA damage response mechanisms.51 The p53 protein activates the expression of DNA repair proteins DDB2 and XPC.52 The interaction of these proteins with effector proteins may lead to various cell fates, such as apoptosis, senescence or tumorigenesis.53,54

The gene encoding p21 (CDKN1A) is the first transcriptional target identified for p53.55 p21 is a potent inhibitor of binding to cyclin-dependent kinases (CDKs), which inhibits cell cycle proteins and further inhibits phosphorylation of Rb by the cyclin D1-CDK4, cyclin D2-CDK4 and cyclin E-CDK2 complexes.56–58 Hypophosphorylated Rb forms a complex with the E2F transcription factor, which inhibits the transcriptional activity of E2F and leads to G1 phase block.40,59 PTPRV, which encodes a transmembrane tyrosine phosphatase, and the phosphatase of regenerating liver-3 are both genes involved in p53-induced G1 phase block.60,61

In addition, p53 represses CDKs and cyclin B, which are required for entry into mitosis and are involved in G2/M phase block.62,63 p53 induces transcription of 14-3-3 sigma and represses the cell cycle protein-dependent kinase Cdc2.64 Gadd45 is a member of the growth arrest and DNA damage gene family. p53 regulates the transcription of Gadd45, disrupts the cyclin B1/Cdc2 complex, and further blocks the G2 phase.63,65 Reprimo is also involved in p53-induced cell cycle arrest in the G2 phase.66 These modulations of p53 reduce the risk of gene mutation and prevent the activation of oncogenes.

On the other hand, p53 can also induce apoptosis in cells with DNA damage.67 p53 causes apoptosis through transcriptional activation of the expression of the pro-apoptotic genes, such as Puma, Bax and Noxa.68–70 p53 is also thought to regulate mitochondrial apoptosis through a transcription-independent pathway.33 p53 binds physically to anti-apoptotic proteins (Bcl-2, Bcl-xL and Mcl-1), thereby indirectly inducing apoptosis.71 p53 directly activates the pro-apoptotic protein Bak or disrupts the Mcl-1 and Bak complex, releasing Bak and initiating apoptosis.37,72 In addition, p53-driven miR34a expression may sensitize cells to apoptotic stimuli by decreasing Bcl-2 levels.73,74 In the exogenous apoptotic pathway, p53 induces the expression of the death receptors Fas/Fas ligand and KILLER/DR5 located on the cell membrane, which activates caspase 8 and leads to apoptosis.75,76 p53 also drives the expression of various genes that may have pro-survival or pro-apoptotic functions,77,78 which also contribute to the maintenance of genomic stability.

Retrotransposons are replicated and inserted into new genomic sites by reverse transcription of RNA intermediates, which allows them to increase the copy number or gene mutations in the host genome.79 Disinhibition of retrotransposons has been reported to be closely associated with human tumorigenesis.80 p53 binds to the promoter region of the retrotransposon element LINE1 and prevents the expression of transposon sequences.81 When p53 is absent, cells overexpressing synthetic retrotransposon genes are able to avoid apoptosis.82 Genomic instability caused by deletion or mutation of p53 may accumulate more oncogenes and promote tumorigenesis, proliferation, metastasis and drug resistance. Functional inactivation of p53 not only contributes to genomic mutation and copy number increase, but also maintains the survival of cells carrying faulty genetic information.

Senescence

Senescence is a permanent cell cycle arrest. p53-mediated senescence is closely related to its tumor suppressive effects. DNA damage triggers senescence, a process often referred to as stress-induced premature senescence.83 Various internal or external stressors trigger the DNA damage response pathway, activating the p53 and/or p16INK4A pathways.84 p16INK4A inactivates Cdk4/6, phosphorylates Rb accumulation and inactivates E2F transcription, leading to cell cycle arrest or senescence.85 Alternatively, when UV-induced DNA damage occurs, ATM/ATR activates Chk1/Chk2 kinase, which further activates p53 and p21CIP1, leading to G1 arrest or senescence.86 In addition, p21CIP1 protein levels may lead to inhibition of CDK4/6 activity, resulting in G1 arrest or senescence.87 In addition, p53 directly induces senescence by stabilizing fibrinogen activator inhibitor-1, a marker of senescent cells.88 p53 also activates the transcription of genes that encode promyelocytic leukemia protein, leading to cellular senescence.89

Metabolic homeostasis

Tumor cells require large amounts of biological raw materials and energy to achieve their rapid and sustained growth. The Warburg effect,90 which was first proposed, states that tumor cells metabolize glucose differently than normal cells, as evidenced by enhanced glycolysis and increased lactate production.91 p53 regulation of the glycolytic pathway helps maintain the homeostasis of cellular metabolism and thus acts as a tumor suppressor. p53 can transcribe target genes required for oxidative phosphorylation, such as SCO2,92 or genes that inhibit glycolysis, such as TIGAR and Parkin.93,94 p53 binds to G6PDH, the rate-limiting enzyme of the pentose phosphate pathway, to further inhibit the activated pentose phosphate pathway in tumor cells.95,96 p53 inhibits glucose uptake and glycolysis by suppressing the expression and translocation of glucose transporter proteins such as GLUT1 and GLUT4.97 Glycolysis and gluconeogenesis can be considered reversible processes to some extent. p53 inhibition of glycolysis promotes the process of gluconeogenesis.98 Since tumor cells are highly dependent on glycolysis and the Warburg effect for proliferation and invasion, p53 inhibition of glycolysis tends to impede cancer cell growth.97,99,100

Cancer cells may indeed activate different metabolic pathways under different environmental conditions. Mutant p53 activates the Warburg effect by promoting the translocation of the GLUT1 to the plasma membrane, thereby enhancing tumor metabolism.101 Mutant 53 binds and activates PGC-1α, a major regulator of oxidative phosphorylation, enhancing mitochondrial function and promoting cancer metastasis.102,103 These studies suggest that mutant p53 may confer metabolic plasticity to cancer cells, thereby promote their adaptation to metabolic stress and increase their potential for proliferation and metastasis.

Since tumor cells need to accumulate or synthesize lipids to promote growth and proliferation,104 p53 promotes lipolysis leading to tumor suppression.46 The mevalonate pathway is responsible for the biosynthesis of cholesterol and nonsteroidal isoprenoids, and SREBP2 is a major transcriptional regulator of this pathway.105 p53 blocks the activation of SREBP2 by transcriptionally inducing the ABCA1 cholesterol transporter gene.105 p53 downregulates the expression of USP19 and SOAT1 to inhibit cholesterol esterification.106 p53 also promotes fatty acid oxidation by activating the expression of CPT1C, MCD and PANK1.107

Ammonia is a prevalent product of cellular metabolism. Tumor cells produce large amounts of ammonia during amino acid metabolism, and this ammonia can serve as a nitrogen source for tumor growth.108,109 p53 regulates ammonia content in tumor cells through the urea cycle. p53 regulates ammonia content in tumor cells by inhibiting the expression of three key enzyme genes in the urea cycle of tumor cells, CPS1, OTC and ARG1, which ultimately inhibits tumor growth.110

p53 is also involved in regulating the metabolism of tumor cells along with other metabolic signaling pathways. Increased levels of reactive oxygen species in tumor cells have a dual effect, both by promoting the acquisition of a tumor phenotype and by activating ROS-dependent death signals to kill tumor cells.111,112 The regulation of ROS by p53 also has a dual function. ROS act as an upstream signal to trigger the activation of p53, and p53 transcribes the expression of multiple antioxidant genes, such as GPX1 and manganese superoxide dismutase, to support tumor cell growth or death.113–115 ROS can also act as a downstream factor of p53 to drive tumor cell death through apoptosis and ferroptosis.45,116 p53 plays a dual role in inhibiting and promoting the tricarboxylic acid cycle and oxidative phosphorylation.46,117,118 p53 is also involved in regulating cellular redox reactions and mediating cancer cell death.46,119,120 In addition, p53 is involved in the regulation of lipid, amino acid and nucleotide metabolism.46,121,122

Ferroptosis

Ferroptosis is a form of regulated cell death initiated notably by severe lipid peroxidation.123–125 p53 was reported to inhibit cystine uptake and promote ferroptosis by transcriptional repression the expression of SLC7A11 which is a key component of the cystine-glutamate antiporter.45,126,127 p53 expression further enhances the ability of GPX4 to antagonize ferroptosis by increasing the biosynthesis of GSH.127 p53 also regulates SLC7A11 expression in a non-transcriptional manner. p53(3KR) is an acetylation-deficient mutant that fails to induce cell cycle arrest, apoptosis and senescence,128 but retains the ability to regulate SLC7A11 expression.45 Another mutant of p53(4KR) lost the ability to regulate SLC7A11 expression.126 This also suggests the importance of acetylation of p53 for the regulation of ferroptosis. H2Bub1 activates SLC7A11 expression. p53 inhibits the level of H2Bub1 by promoting nuclear translocation of the deubiquitinase USP7, which suppresses the expression of SLC7A11 and induces ferroptosis.129

p53 can also activate the expression of SAT1, a rate-limiting enzyme in polyamine catabolism, thereby inducing lipid peroxidation and ferroptosis upon ROS stress.130 SAT1-induced ferroptosis is involved in elevated expression levels of the lipoxygenase ALOX15.130 ALOX12 was also reported to be required for p53-mediated ferroptosis.131 Moreover, p53 promotes ferroptosis through modulation of GLS2, PTGS2, FDXR and noncoding RNAs.132 On the other hand, interaction of p53 with DPP4 promotes nuclear accumulation of DPP4 and blocks plasma-membrane-associated DPP4-dependent lipid peroxidation, thus limiting ferroptosis.133 The p53-p21 axis may contribute to the inhibition of cysteine deprivation-induced ferroptosis,134 whereas it has also been reported that p21 restricts the progression of ferroptosis in a p53-independent way.135

Tumor microenvironment

The status of p53 in tumor cells has a profound impact on the immune microenvironment. p53 regulates the release of cytokines and stimulates macrophage polarization toward the M1 phenotype to suppress tumorigenesis. Macrophages lacking p53 polarize toward M2 and enhance the proliferation of precancerous cells.136 p53 activation stimulates cellular anti-tumor responses,137,138 leading to interferon production, and there is a synergistic effect between cancer immunotherapy.139 Deletion or mutation of p53 in cancer affects the recruitment and activity of T cells, leading to immune evasion of cancer cells.47,140 Restoration of p53 expression enhanced the antitumor effect of anti-PD-1 monoclonal antibody on hepatocellular carcinoma cells and effectively induced reprogramming of the tumor microenvironment.141 TP53 mutations are associated with increased expression of PD-L1, which may be a predictor of response to PD-L1 targeted checkpoint inhibitors.142 Mutant TP53 contributes to the regulation of tumor cells into an immune microenvironment that is conducive to growth.143–146

Cancer stem cell self-renewal

The Rb/p53 signaling pathway regulates the proliferation and self-renewal process of neuroendocrine cells in the early stages of injury.116 Neuroendocrine cells return to a quiescent state after completing a limited proliferation.147 However, under conditions of Rb/p53 functional deficiency, neuroendocrine cells can acquire a sustained proliferative function and develop into small cell lung cancer.148,149 Activation of p53 in breast,150 prostate,151 epidermis,152 central nervous system153 and hematopoietic stem cells154–156 hinders stem cell self-renewal, but the exact mechanism remains to be confirmed.48 p53 has an essential role in regulating normal and malignant stem cell differentiation and self-renewal. Conversely, mutant p53 contributes to the maintenance of cancer stem cells.157 Mutant p53 enhances the proliferation of cancer stem cells by regulating WASP-interacting proteins.158 Mutant p53 also enhances the self-renewal of hematopoietic cells by upregulating FOXH1.159

The epithelial-mesenchymal transition is a form of reprogramming of cancer cells.160 Under pathological conditions, epithelial cells transform into mesenchymal cells, enhancing the invasive metastasis of cancer cells. p53 directly activates miR-200, miR-130 and miR-34 and inhibits the transcription factors Slug, Snail1 and Zeb1, which promote epithelial mesenchymal transformation.161–164 p53 deletion enhances self-renewal of lung cancer stem cells.165

Autophagy

Autophagy degrades intracellular macromolecules through the lysosomal pathway, thereby enabling intracellular energy supply and organelle renewal.166,167 p53 can directly activate damage-regulated autophagy regulators and induce autophagy.168,169 Autophagy is controlled by autophagy-related genes (Atg).170 Combined ChIP sequencing and RNA sequencing analysis revealed that p53 binds to many autophagy genes, including Atg2, Atg4, Atg7 and Atg10.171 This suggests that p53 induces autophagy in a transcription-dependent manner. Cathepsin D is a lysosomal aspartate protease and overexpression of cathepsin D activates autophagy.172,173 p53 binds to two DNA sites in the cathepsin D promoter region and regulates Cathepsin D expression.174,175 The upregulation of TGM2 expression by p53 enhances autophagy, thereby inhibiting oncogenic transformation and tumor formation in primary human mammary epithelial cells.176

p53 inhibits mTOR and enhances autophagy by activating AMP-responsive protein kinase.177–179 The p53 target genes Sestrin1 and Sestrin2 phosphorylate and activate AMPK and promote autophagy.178 p53 induces mitophagy by increasing the level of BNIP3.180 Interaction of beclin1 with Bcl-2 family anti-apoptotic proteins inhibits autophagy.181,182 p53 promotes the expression of BH3-only protein, which competitively binds to Bcl-2 family anti-apoptotic proteins, contributing to the restoration of beclin1 activity and promoting autophagy.181,183

p53 also functions as an inhibitor of autophagy. When p53 with deletion of nuclear localization sequence accumulates in the cytoplasm, it inhibits autophagy.184,185 HMGB1 and p53 regulate autophagy by mutually regulating their distribution in the nucleus and cytoplasm.186,187 In addition, autophagy regulates p53 activity. Atg7 inhibits p53 activation and p53 induced apoptosis.188

Other cellular processes

The signaling pathways involved in the regulation of p53 also include immune responses, non-coding RNAs and so on that exert tumor suppressive effects.49,87,189–192 In the process of tumor development, p53 suppresses tumor transformation,22 proliferation,193 metastasis194 and drug resistance195 through multifaceted regulation. p53 has an exceptionally flexible biological response that is altered by changes in cell type, cell differentiation status, stress conditions, and different signals in the environment.

Oncogenic effects of wild-type p53

Studies have confirmed that p53 is essential for suppressing cancer in humans. However, a study in 2019 showed that p53 could promote tumor growth by enhancing the metabolism of hepatocellular carcinoma cells117 (Fig. 3). p53 transcription activates Puma expression, which further initiates apoptosis.69 But certain levels of Puma protein interfere with normal mitochondrial function, leading to a shift in mitochondrial energy metabolism from oxidative phosphorylation to glycolysis.117 Another group knocked out MDM2 in hepatocyte-specific KRAS G12D mutant mice and observed p53 accumulation in mouse hepatocytes.196 These p53-activated mice exhibited increased inflammatory responses, hepatocyte apoptosis, and senescence-associated secretory phenotype, leading to the facilitation of a carcinogenic microenvironment196,197 (Fig. 3). Hepatic progenitor cells from p53-accumulating mice were injected into experimental mice growing tumors. The development of hepatocellular carcinoma and other related phenotypes no longer occurred after knockdown of TP53, suggesting that p53-accumulated mice do promote the development of hepatocellular carcinoma.196 Cellular activities regulated by p53 are integrated into tumor suppressive functions, but p53-induced regulation of certain elements may also provide a survival advantage for tumors (Fig. 3).Fig. 3 Pro-tumor effect of p53. In general, p53 is thought to have tumor suppressive effects, but in some cases, p53 promotes tumor growth. In hepatocellular carcinoma cells, p53 transcription activates the expression of Puma, which causes shift in mitochondrial energy metabolism from oxidative phosphorylation to glycolysis, thereby promoting tumorigenesis. In hepatocyte-specific KRASG12D cells knockout of MDM2 to activate p53. Accumulated p53 increased inflammatory responses, hepatocyte apoptosis, and senescence-associated secretory phenotypes that promote carcinogenesis

TP53 mutations in cancer

The TP53 gene is mutated in most tumor cells. Genome sequencing of different human cancer cells showed that 42% of cases carry TP53 mutations.198 The major type of mutation in TP53 is a missense mutation, a single amino acid substitution and the DNA binding domain (DBD) is the most common mutated region199,200 (Fig. 4a, b). p53 mutants are usually classified as structural mutants and DNA contact surface mutants. Structural mutants (R175H, R249S, G245S, Y220C) have reduced protein thermostability, resulting in proteins that do not fold properly at physiological temperatures and lose the ability to bind to DNA. Among them, R175H and C176Y affect the binding of protein to zinc ions. DNA contact surface mutants (R273H/C, R248W) are located in the DNA core binding region with mutations that prevent the binding of protein to DNA. R175, G245, R249, R282, R248 and R273 are the most common mutation sites and are therefore referred to as “hot spot” mutations of TP53201–204 (Fig. 4b). These mutants not only bind to wild-type p53 to produce dominant-negative (DN) effects but may also be converted to oncogenic proteins via gain-of-function (GOF).203,205,206 Thus, TP53 differs from many “classical” oncogenes, which are usually characterized by nonsense or shift mutations that result in truncated protein inactivation.207–210Fig. 4 TP53 mutations in cancer. a Frequency of somatic TP53 mutations associated with different types of cancer. b Frequency of missense mutations in TP53 (https://tp53.isb-cgc.org/). c Mutation frequency of TP53 in different tissues and organs

TP53 mutations are prevalent in tumors, but different tissues and organs have different TP53 mutation spectra3 (Fig. 4c). TP53 mutations were commonly found in the ovary (47.27%), colon and rectum (44.55%), lung (40.8%), pancreas (38.53%), stomach (36.78%), urethra (35.01%), liver (29.17%), breast (26.44%), prostate (22.52%), bone (16.19%), thyroid (11.13%), hematopoietic and lymphatic (10.13%) and kidney (8.75%) (https://cancer.sanger.ac.uk/cosmic). TP53 was mutated more frequently in esophageal carcinoma (93.77%), small cell lung cancer (79.06%), ovarian carcinoma (80.46%), colorectal carcinoma (74.45%) and gallbladder carcinoma (57.77%), and less frequently in thyroid carcinoma (3.13%), embryonal tumor (2.08%) and peripheral nervous system (1.25%). Different tumor subtypes of the same tissue and organ also have different TP53 mutation spectra. For example, the frequency of TP53 mutations in non-small cell lung cancer was 57.04%, which was lower than that in small cell lung cancer (79.06%) (https://www.cbioportal.org/). In addition, TP53 mutation spectra differed by race. The frequency of TP53 mutations in breast cancer is 42.9% in Asian and 30–35% in Caucasians.211

Mechanism of action of mutant p53

TP53 acts as a tumor suppressor gene and genome guardian, so cancer cell transformation is unlikely to occur in cells that maintain normal p53 function.212,213 TP53 mutations provide a permissive environment for tumorigenesis.214,215 TP53 mutations are a hallmark of an inherited cancer susceptibility syndrome known as Li-Fraumeni.216,217 The high frequency of TP53 mutations found in tumor cells19,218,219 may be the result of selection pressures that favor tumor cells to escape surveillance and be spared from death.220,221 Many mutant p53 proteins are more stable than wild-type p53 proteins and can accumulate in cells. Some mutant p53 proteins may have completely different functions than wild-type proteins,222 and this effect may be due to altered target gene profiles, mutant p53 secretome or inappropriate protein-protein interactions223 (Fig. 5).Fig. 5 The role of mutant p53 in cancer. Mutant p53 can result in loss-of-function of wild-type p53, dominant-negative repression of wild-type p53 by mutant p53, and gain-of-function with oncogenic properties. Mutant p53 affects various cellular responses, such as genomic instability, metabolic reprogramming, and tumor microenvironment, and promotes cancer cell proliferation, invasion, metastasis and drug resistance. WT wild-type

Loss of p53 transcriptional activity of mutant p53, and to some extent the DN effect are major drivers of the tumor phenotype (Fig. 5). The loss-of-function or DN effect of wild-type p53 enhanced the viability of tumor cells, and this effect was independent of missense mutations in TP53.193 The deletion of TP53 in gastric cells combined with an oncogenic diet confers a selective advantage to cancer cells.224 Analysis of more than 10,000 patient samples from 32 different cancers in The Cancer Genome Atlas revealed that more than 91% of mutant p53 was accompanied by deletion of TP53 alleles.225 Mutations in TP53 are associated with enhanced chromosomal instability,226,227 and are accompanied by amplification of oncogenes and deletion of suppressor genes.227,228 Significant upregulation of proteins associated with cell cycle progression was also observed in p53 mutant cancers, which may be due to loss of control of cell cycle checkpoints by TP53 deletion.225,229,230 Scott W. Lowe’s group used a mutation tracking system to reveal a pattern of TP53 inactivation leading to genomic alterations.231 Although TP53-deficient cells gain the potential for cancer cell transformation, TP53 deletion alone is not sufficient to cause cancer.231 TP53-deficient cells gain additional gene amplification in an ordered way that eventually spirals out of control and develops into cancer.231–234 Functional, DNA binding and transcriptional analyses against myeloid malignancy cell lines carrying TP53 missense mutations showed loss of p53 function, indicating that DN is the primary choice for TP53 missense mutations in myeloid malignancies.235

The activity of the p53 mutant GOF has been reported to be associated with cellular physiopathology and poor clinical outcomes in cancer patients236–246 (Fig. 5). Mutant p53 binds directly to TBK1, prevents TBK1 from forming a ternary complex with STING and IRF3, and ultimately inhibits the activation of the cGAS-STING pathway.223 Mutant p53 helps tumor tissue evade the killing effect of the immune system by inhibiting the anti-tumor immune response.223,247,248 However, in contrast, the evidence on the effects of p53 mutant GOF is much weaker compared to DN, and it may act modestly or only in certain specific situations.

Mutated TP53 not only lost its normal biological function, but also promoted cancer metastasis. Missense mutations in TP53 were associated with lymph node metastasis in prostate cancer patients.249 TP53 R175H and R273H mutations occurred in more metastatic tumors than in TP53 knockout mice.250,251 In mouse models of pancreatic cancer that specifically express oncogenic KRAS and mutant TP53, more than twice as many metastatic lesions were observed as in TP53 knockout mice.252 Lung adenocarcinoma mice carrying TP53 and KRAS mutations are highly aggressive and metastasize to multiple sites of intrathoracic and extrathoracic in a pattern similar to that of human lung cancer.253 Similarly, TP53 gene deletion induces an increase in systemic neutrophils, which drive systemic inflammation with breast cancer cell metastasis.194

Mutant p53 can lead to treatment resistance in cancer. Multidrug resistance protein 1 (MDR1, also known as P-glycoprotein), encoded by ATP-binding cassette subfamily B member 1, has been shown to be resistant to cytotoxicity and chemotherapy.254 In p53 mutant R248Q-expressing Hep3B cells, expression and activity of the multiple drug resistance gene, P-glycoprotein, are elevated mediating doxorubicin resistance.255 Acetylated mutant p53 interacts with p300 to promote transactivation of ephrin-B2 and enhances ATP-binding cassette subfamily G member 2 levels, thereby promoting chemoresistance.256 In R273H-expressing human squamous cell carcinoma cells, multidrug resistance to doxorubicin, methotrexate and apoptosis-inducing drugs was shown due to downregulation of procaspase-3 levels.257 Wild-type p53 inhibits LRPPRC expression via miR-34a, further reducing MDR1 expression. However, when TP53 is mutated, chemotherapy-induced inactivation of this pathway and the accumulation of LRPPRC and MDR1 promote drug resistance.195 Mutated p53 binds to the miR-223 promoter and reduces its transcriptional activity, and the introduction of exogenous miR-223 makes tumor cells carrying mutated TP53 sensitive to treatment.258

The structures of p53

The comprehensive function of p53 is closely related to its modular structure of typical signaling proteins.201 Human p53 is a multidomain protein that consists of 393 amino acids.259 It contains an N-terminal transactivation domain (TAD, residues 1–61), a proline-rich domain (PRD, residues 64–92), a DNA-binding domain (DBD, residues 96–292) linked to a tetramerization domain (TET, residues 324–356), and a C-terminal regulatory domain (CTD, residues 364–393)260,261 (Fig. 4b). More than 40% of the regions within p53 are intrinsically disordered, including the TAD, CTD, and the linker between DBD and TET.262 These disordered regions allow p53 to interact as a modular protein with a wide range of partner proteins. These structured and unstructured domains individually have unique properties and contribute to the overall functional diversity and complexity of p53. Due to the intrinsic flexibility of the intact protein, the high-resolution structure of full-length p53 remains unclear.

N-terminal region

The N-terminal region of p53 contains a highly acidic, intrinsically disordered TAD and a proline-rich region.263 TADs, including TAD1 (residues 1–40) and TAD2 (residues 40–61),264 can bind to transcription machinery components and transcriptional coactivators to promote transcriptional initiation and interact with negative regulators to suppress transcriptional activation. TAD can adopt an amphipathic α-helical conformation upon binding of partner proteins,259 which seems to be an essential binding mode, as seen in the structures of TAD bound to the negative regulator MDM2265/MDMX266 (Fig. 6a), transcription coactivator CBP267,268/p300269,270 (Fig. 6b), replication protein A,271 high-mobility group B1, HMGB1,272 Tfb1 subunits of yeast TFIIH273 and metastasis-associated protein S100A4.274 Notably, phosphorylated TAD2 exhibits an acidic string-like conformation when bound to subunit p62 of human TFIIH275 (Fig. 6c). Phosphorylation of TAD has been shown to serve as a switch to rapidly turn p53 function on and off but also as a mechanism for a graded p53 response.276,277 Overall, the conformational plasticity of the TAD, together with posttranslational modifications, makes p53 a highly efficient transcription factor.Fig. 6 TAD binds to partner proteins and regulates transcription. a MDM2/MDMX is the major negative regulator of p53, and the C-terminus of MDM2 has E3 ubiquitin ligase activity (Ub) that promotes p53 degradation. b Under cellular stress conditions, the acetyl group (Ac) is added to the lysine residue of p53-CTD, and p53 binds to the target DNA sequence and interacts with the coactivator CBP or p300 to jointly promote gene transcription. c DNA damage and other stresses induce p53 phosphorylation (P) and binding to TFIIH, which stabilizes p53 and promotes DNA binding and transcription. p53-TAD shown as cartoon. Partner proteins are shown as surfaces

The proline-rich region linking the TAD to DBD is required for p53 to induce cell cycle arrest and apoptosis.278,279 This region plays a role in signal transduction by binding to Src homology 3 domains.280 The PRD is also involved in interactions with focal adhesion kinase (FAK),281 peptidase D,282 ASPP family members,283 and the corepressor protein mSin3a.284 The PRD contains five PXXP motifs, some of which may adopt a polyproline helix-like structure.259 The exact structure and interaction mechanism of PRD are largely unknown.

DNA-binding domain

The structured DBD adopts a basic scaffold of an immunoglobulin-like β-sandwich, a loop-sheet-helix motif (loops L1, S2, and S2’, parts of the extended S10 and H2), and two large loops (L2 and L3) that are stabilized by a tetrahedrally coordinated zinc ion285 (Fig. 7a). The DBD is responsible for binding sequence-specific target DNA, which is central to the biological function of p53 as a transcription factor. In addition, the DBD is also capable of interactions with diverse proteins.Fig. 7 Structures of DBD, TET, CTD and full-length p53. a The structure of DBD in complex with a sequence-specific DNA (PDB: 1TSR). p53-DBD is shown as a cartoon, and the secondary structures are labeled. The interfacial residues are shown as sticks. DNA is shown as sticks and surfaces. b DNA recognition by the p53 tetramer (PDB: 3KMD). c ASPP2 (colored aquamarine). d iASPP (colored pale green). e 53BP1 (colored pink). f NMR structural model of the p53-DBD/BCL-xL complex. g Crystal structure of the p53-DBD/BCL-xL complex. BCL-xL is colored marine. h LTag (colored light blue). i E6/E6AP. E6 is colored light pink. E6AP is colored pale yellow. All p53-DBD molecules are shown as the surface. j Assembly of the p53 tetramerization domain (PDB: 1C26). k CTD sequence. The posttranscriptional modifications are shown as indicated. l A CTD peptide (colored light magenta) became a helical conformation when bound to Ca2+-loaded S100B(ββ) (colored pale cyan and pale green). m A CTD peptide dimethylated at K382 (p53K382me2) binds the tandem Tudor domain (TTD) of 53BP1 (colored yellow) in a U-shape conformation. n A p53 peptide acetylated at K381 and dimethylated at K382 (p53K381acK382me2) forms a helical conformation when interacting with 53BP1-TTD. o A p53K382ac peptide forms β sheet-like contacts with deacetylase Sir2-Af2 (colored light blue). p Structure of the p53/RNA polymerase II assembly. RNA polymerase II assembly is shown as surface. p53 is shown as cartoon. q Full-length p53 structure predicted by AlphaFold2. TAD colored pink, PRD colored green, DBD colored marine, Loop colored yellow, TET colored warm pink, and CTD colored cyan

DNA recognition

In response to a wide variety of stress signals, p53 regulates the transcription of many different genes involved in various pathways. p53 also acts as a pioneer transcription factor, binding to specific DNA sequences in the nucleosome to promote transcriptional activation in chromatin.286–288 Most p53 target genes contain a consensus response element (RE) composed of two decametric half-sites of RRRCWWGYYY (R = A, G; W = A, T; Y = C, T) separated by 0–13 base pairs.289–292 Some REs are cluster sites that have more than two half-sites. p53 also binds a set of noncanonical DNAs, such as cruciforms, left-handed DNA (Z-DNA), quadruplex and triplex DNA.293,294

Various structural studies have demonstrated the molecular mechanism of DNA recognition by p53 (Fig. 7a). Briefly, the residue Arg248 from the large loop L3 interacts with the minor groove.285 The loop-sheet-helix motif docks into the major groove and makes hydrogen bond contacts with bases via key residues Lys120, Cys277 and Arg280.285 Residues Ala276, Ser241 and Arg273 contribute to DNA backbone contacts. p53 binds to a full consensus DNA response element as a tetramer through a highly cooperative self-assembling mechanism (Fig. 7b). Two DBDs bind each decameric half-site as a symmetrical dimer (A-B), and two such dimers (A-B and C-D) constitute a tetramer on a full DNA response element via protein-protein and base stacking interactions.11,70,295–299

Upon DNA binding, the DBD and the DNA helix undergo structural changes. The binding of p53-DBD to the BAX response element causes DNA deformation, which is partially disordered around the spacer region, leading to unwinding and compression of the region to allow protein-protein interactions.70 In some p53/DNA structures, the central A-T doublet of each half-site shows noncanonical Hoogsteen base-pairing geometry instead of standard Watson-Crick base pairs.299,300 Some p53/DNA structures reveal that loop L1 of two p53 subunits adopts a conformational switch from an extended conformation where Lys120 interacts directly with DNA to a recessed conformation where there is no direct DNA contact.301 The conformational switch is related to the DNA-binding specificity of p53. Acetylation of loop L1 residue Lys120 expands the conformational space of loop L1 in the DNA-bound state and promotes sequence-dependent DNA-binding modes for p53.302

DBD-mediated protein-protein interactions

In addition to DNA recognition, the DBD mediates protein-protein interactions with multiple proteins. Interactions with these proteins influence various activities of p53. An increasing number of structures of the DBD/protein complex have been determined, providing fresh perspectives on the mechanisms of p53-DBD binding and functional diversity.

By using a yeast two-hybrid system, 53BP1 and 53BP2 (namely, the C-terminal fragment of ASPP2) were initially identified to bind to p53.303 They interact with p53-DBD through the L3 loop and L2 loop304–306 (Fig. 7c, e). 53BP1 plays multiple roles in DNA damage and repair and has been reported to enhance p53-mediated transcriptional activation of ASPP2. The inhibitory member iASPP belongs to the apoptosis-stimulating p53 protein (ASPP) family, which has opposite functions in regulating the apoptotic function of p53.307 Unlike ASPP2, iASPP preferentially binds p53-PRD283 and interacts with the DBD through the L1 loop, helix H2 and N-terminal loop308 (Fig. 7d). The L1 loop of p53 moves away from other DNA-binding modules upon binding iASPP, which disables Lys120 from making contact with a specific base.308 The different binding interfaces with the ASPP family provide insight into the opposing regulatory mechanism of p53.

Cytoplasmic p53 has been reported to regulate the mitochondrial apoptosis pathway by inhibiting antiapoptotic BCL-2 and BCL-xL. In a structural model of BCL-xL/p53 characterized by nuclear magnetic resonance (NMR) spectroscopy and determined using the HADDOCK docking method based on 1:1 stoichiometry, the BCL-xL binding surface of p53-DBD largely overlaps with the DNA-binding surface and encompasses helix H1 and the Zn2+-coordination site309 (Fig. 7f). However, the recently determined crystal structure of the p53/BCL-xL complex indicates that p53 binds BCL-xL with a 2:1 stoichiometry71 (Fig. 7g). Two p53-DBD molecules dimerize through the N-terminal loop and β9-β10 loop of one p53-DBD and the Zn2+-coordination site of the other p53-DBD, involving residues Tyr107 and His178, respectively. The resulting p53-DBD dimer forms a groove and interacts with one BCL-xL to form a ternary complex. The DNA-contacting residues Arg248 and Arg273 form direct hydrogen bonds with BCL-xL. The binding mode is distinct from other p53-DBD binding proteins.

The p53-DBD is also targeted by viral oncoproteins, such as the large T antigen (LTag) of simian virus 40 (SV40)310 (Fig. 7h) and human papillomavirus (HPV) oncoprotein E6311,312 (Fig. 7i). LTag promotes viral replication and cellular transformation. It occupies the entire DNA-binding surface of p53-DBD and interacts with a region of helix H1 that is involved in p53-DBD dimerization. The p53-binding site of HPV E6 substantially overlaps with the binding surface of iASPP, which has been reported to inhibit HPV E6-induced degradation of p53.308

Some of these proteins bind p53 at a surface overlapping with the DNA-binding site, such as 53BP1, ASPP2, Bcl-xL and LTag. Some partner proteins bind at a surface distal from the DNA-binding site, such as iASPP and HPV E6. Notably, the p53 hotspot mutant alleles at residues Arg248 and Arg273 not only make direct contact with DNA but are also involved in direct contact with ASPP, BCL-xL and LTag. Another hotspot residue, Arg282, is involved in iASPP binding. Thus, these hotspot mutants may have multiple hits on p53 activities.

Tetramerization domain

Full-length p53 reversibly forms tetramers through the TET. The structural analysis demonstrated that monomeric TET is a V-shaped structure composed of a β-strand and an α-helix linked by hinge residue Gly344313–315 (Fig. 7j). The primary dimer relies on eight backbone hydrogen bonds of the β-sheet and is also stabilized by hydrophobic interactions (Phe328, Leu330, Ile332, Phe338 and Phe341) as well as a salt bridge between Arg337 and Asp352.35 The dimer-dimer interactions are primarily mediated by hydrophobic contacts (Met340, Phe341, Leu344, Ala347, Leu348 and Leu350).35 R337C/H/P and L344P affect the formation and transcriptional activity of p53 tetramers and are involved in Li-Fraumeni Syndrome and Li-Fraumeni-Like Syndrome.316 The G334V mutant contributed to a beta-dominated structural transition leading to amyloid formation at physiological temperature.317 A highly conserved leucine-rich nuclear export signal (NES) within the TET is necessary for the subcellular localization of p53.318 Some proteins bind directly to TET, but no complex structure has yet been demonstrated.319

The C-terminal regulatory domain

Similar to the NTD, the CTD is also an intrinsically disordered region. This characteristic endows it with multiple regulatory functions in almost every aspect of p53, including DNA binding, cofactor recruitment, cellular localization, and protein stabilization.320 The CTD possesses many positively charged residues, which are highly conserved in mammals. Extensive posttranslational modifications of the CTD, including acetylation, methylation and phosphorylation, play an essential and interdependent role in its function and stability (Fig. 7k). The CTD adopts different conformations depending on the binding partners and posttranslational modifications201,321 (Fig. 7l–o).

Full-length p53

The highly intrinsic unfolded regions within p53 make it difficultt to determine the high-resolution structure of full-length p53. A 4.6 Å resolution structure of RNA polymerase II (Pol II) with full-length p53,322 has shown that the DBD targets the upstream DNA-binding site within Pol II, and the following TET is exposed on top of the DBD. The TAD distal to the DBD forms helices and binds Pol II’s jaw that contacts downstream DNA (Fig. 7p). This association introduces a conformational change in Pol II, providing insight into the p53-mediated regulation of gene expression.

How an intact p53 tetramer interacts with DNA and proteins is still largely unclear. A combination of NMR, electron microscopy, small-angle X-ray scattering, and FRET techniques indicates that the free p53 tetramer in solution forms an open cross-shaped structure with a pair of loosely coupled DBD.323,324 The oligomers close to form a compact complex upon binding a specific DNA response element. Chemical cross-linking and mass spectrometry methods are also employed to study the structural dynamics of full-length p53.325 A recent study has reported cryo-electron microscopy of p53-DBD and full-length p53 complexed with a nucleosome, in which the DBD binds as a tetramer to the DNA and peels the DNA from the histone surface.288 The N-terminal and C-terminal regions were not observed in the cryo-EM maps, but biochemical analysis suggests that the C-terminus of p53 may contain an additional DNA binding domain.288

The artificial intelligence system AlphaFold has accomplished the great challenge of protein amino acid sequence to structure, bringing great advances to the field of biology, especially structural biology.326–328 In 2021, AlphaFold2 released its predicted structure of the full-length p53 protein (https://alphafold.com/) (Fig. 7q).329 The predicted full-length p53 structure is shown as a monomer with the DBD and TET regions resembling the known structures of individual structural domains. Nevertheless, it does not provide more information on how the disordered regions fold and how p53 assembles into a tetramer. In addition, the most important feature of p53 is missense mutations leading to its altered or lost function. AlphaFold2 is currently unable to correctly predict the structural impact of missense mutations.330 Furthermore, the p53 protein functions by binding to various ligands such as DNA, small molecules, metal ions or other proteins. We still lack structural information about this interaction to aid in drug development against p53 and recognition of protein complexes.331–333 Following technological revolution, we expect that artificial intelligence will provide more valuable information in the future.

Regardless, structural studies on full-length p53 in complex with different DNA targets, full-length partner proteins, and even higher-order complexes are needed. This structural biology information will not only help to understand the role of p53 in cellular life activities, but these structures may also help to design drugs that target p53.

Structure-based p53 targeting

Structural and biochemical analyses have provided insight into the function of p53. However, many important questions regarding the structure‒function and specific regulation of p53 remain to be determined. In recent years, with the development of NMR, protein crystallography and cryo-electron microscopy techniques, much structural information has been obtained about the binding of p53 to ligands. From this critical information, structure-based design strategies can be applied to optimize the structure and thus improve activity and selectivity.

MDM2/MDMX-p53, a central hub for p53 activation

MDM2/MDMX is the major negative regulator of p53.334 In the MDM2-p53 negative feedback regulatory loop, wild-type p53 activates the transcription of MDM2, while the N-terminal of MDM2 binds to p53-TAD and represses the transcriptional activity of p53.265 In addition, the C-terminus of MDM2 has the enzymatic activity of E3 ubiquitin ligase, which promotes the nuclear export and degradation of p53.335,336 MDMX (or MDM4), a homolog of MDM2, is structurally similar to MDM2, but it lacks ubiquitin ligase activity and can enhance the ubiquitination activity of MDM2 by forming a dimer with MDM2.337,338 Overexpression or activation of MDM2/MDM4 is present in many human tumors, leading to p53 inactivation.334,339,340 Many antitumor drugs targeting MDM2/MDMX-p53 interactions have been developed in recent years (Fig. 8, Table 1).Fig. 8 Structure of MDM2/X with small molecules. a Overlay of the crystal structures of MDM2/p53-TAD (white, sky blue), MDMX/p53-TAD (greencyan, pink) and the three residues of p53-TAD (F19, W23, L26) are shown as sticks. b MDM2 is shown as a surface. c MDMX is shown as surface. d MDM2/RG7112 (PDB: 4IPF). e MDM2/RG7388 (PDB: 4JRG). f MDM2/AMG 232 (PDB: 4OAS). g MDM2/MI-77301 (PDB: 5TRF). h MDM2/NVP-CGM097 (PDB: 4ZYF). Water molecules are red spheres, and hydrogen bonds are black lines. The interacting amino acid residues are shown as sticks (colored gray)

Table 1 MDM2/X inhibitor in clinical trails

Inhibitors	Chemical class (first report time)	Chemical structure	Affinity	Population	Identifier /status/phase	
RG7112	Imidazoline

(2013)

		Kd = 2.9 nM	Hematologic neoplasms, advanced solid tumors, PV or ET	NCT00623870 Completed I

NCT00559533 Completed I

NCT01677780 Completed I

NCT01164033 Completed I

NCT01605526 Completed I

NCT01143740 Completed I

NCT01635296 Completed I

	
RG7388	Imidazoline

(2013)

		Kd = 0.15 nM	AML, ALL, ET or PV, FL, MM, DLBCL, solid tumors	NCT03287245 Terminated II

NCT02545283 Terminated III

NCT03362723 Completed I

NCT02828930 Completed I

NCT02633059 Active, not recruiting I/II

NCT03850535 Terminated I/II

NCT02407080 Completed I

NCT03135262 Terminated I/II

NCT02624986 Terminated I/II

NCT04029688 Recruiting I/II

NCT02670044 Completed I

NCT03566485 Terminated I/II

NCT04589845 Recruiting II

NCT03555149 Active, not recruiting I/II

NCT03158389 Recruiting I/II

	
AMG232	Piperidone

(2014)

		Kd = 0.045 nM	AML, MM, solid tumors	NCT04640532 Recruiting I/II

NCT04835584 Recruiting I/II

NCT04502394 Recruiting I/II

NCT05027867 Recruiting II

NCT04485260 Recruiting I/II

NCT03787602 Recruiting I/II

NCT04878003 Recruiting II

NCT04669067 Recruiting I/II

NCT04113616 Recruiting I/II

NCT03669965 Active, not recruiting I

NCT03217266 Active, not recruiting I

NCT03662126 Recruiting II/III

NCT04190550 Recruiting I

NCT03031730 Recruiting I

NCT03107780 Suspended I

NCT03041688 Suspended I

	
SAR405838	Spirooxindole

(2014)

		Ki = 0.88 nM	Neoplasm malignant	NCT01636479 Completed I

NCT01985191 Completed I

	
NVP-CGM097	Dihydroisoquinoline (2015)		Ki = 1.3 nM	Advanced solid tumors	NCT01760525 Completed I	
HDM201	Imidazopyrrolidinone

(2016)

		In the picomole range	AML, MDS, sarcoma, solid tumors	NCT05180695 Recruiting I/II

NCT04496999 Recruiting I

NCT03714958 Recruiting I

NCT02343172 Completed I

NCT02143635 Completed I

NCT03940352 Recruiting I

NCT03760445 Withdrawn I/II

NCT02601378 Terminated I

NCT05447663 Not yet recruiting I/II

NCT05155709 Recruiting I/II

NCT04097821 Suspended I/II

NCT04116541 Recruiting I

NCT02890069 Completed I

	
MK-8242	Purine carboxylic acid-derived inhibitor (2016)		IC50 0.07 μM	AML, solid tumors	NCT01451437 Terminated I

NCT01463696 Terminated I

	
DS-3032	Dispiropyrrolidine (2017)		IC50 17.7 ± 5.1 nM	AML, MDS, MM, lymphoma, advanced solid tumor	NCT02579824 Terminated I

NCT03634228 Completed I/II

NCT03671564 Completed I

NCT03552029 Terminated I

NCT02319369 Terminated I

NCT01877382 Completed I

	
APG-115	Spirooxindole

(2017)

		Ki 60 ± 22 nM	AML, CMML, MDS, T-PLL, lymphoma, sarcoma, advanced solid tumor	NCT02935907 Completed I

NCT04496349 Recruiting II

NCT04785196 Recruiting I/II

NCT04358393 Recruiting I/II

NCT03611868 Recruiting I/II

NCT03781986 Recruiting I/II

NCT04275518 Recruiting I

	
BI-907828	Unknow (2020)	–	IC50 58.52 pM	Liposarcoma, solid tumors	NCT05372367 Recruiting I

NCT05376800 Recruiting I

NCT05512377 Not yet recruiting II

NCT05218499 Recruiting II/III

NCT03964233 Recruiting I

NCT03449381 Recruiting I

	
ALRN-6924	Stapled peptide (2018)	–	MDMX Kd 57 nM

MDM2 Kd 10.9 nM

	AML, MDS, lymphoma, solid tumor	NCT02909972 Completed I

NCT03725436 Recruiting I

NCT03654716 Recruiting I

NCT02264613 Completed I/II

NCT04022876 Active, not recruiting I

	
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CMML chronic myelomonocytic leukemia, DLBCL diffuse large B-cell lymphoma, ET essential thrombocythemia, FL follicular lymphoma, MDS myelodysplastic syndrome, MM multiple myeloma, PV polycythemia vera, T-PLL T-prolymphocytic leukemia

MDM2-p53 inhibitor

The cocrystal structure of p53-TAD with MDM2 shows that Phe19, Trp23 and Leu26 on the α-helix of p53 penetrate deeply into the hydrophobic cleft of MDM2 (Fig. 8a, b), with Leu22 providing additional van der Waals forces.265 These structural features of the p53/MDM2 complex provide a basis for finding inhibitors that block the interaction between these two proteins.

RG7112

Based on the structural features of p53/MDM2, researchers synthesized imidazole-like MDM2 antagonists, among which RG7112 is the first small-molecule inhibitor of MDM2 to enter the clinic. The crystal structure showed that the 4-chlorophenyl ring occupied the Trp23 and Leu26 pockets, while the ethoxy group was prominently located in the Phe19 pocket341 (Fig. 8d). RG7112 had a Kd = 2.9 nM. It effectively blocks p53-MDM2 binding and promotes cancer cell cycle arrest and apoptosis.342 However, the ability of RG7112 to induce apoptosis in cancer cells varies widely. The best responses were observed in MDM2 gene-amplified osteosarcoma cell lines and xenografts.341,343

RG7388

The MDM2 inhibitor RG7388, which was subsequently designed and synthesized, is a class of pyrrolidine derivatives.344 RG7388, Kd = 0.15 nM, induces dose-dependent apoptosis in wild-type p53 cancer cells.342 Structurally, the 4-chlorophenyl ring, 3-chlorophenyl group and neopentyl group mimic p53 occupying the Phe19, Trp23 and Leu26 pockets. In addition, the 3-chlorophenyl group forms a π-π stacking interaction with the His96 residue on MDM2, and the pyrrolidine Cα carbonyl group forms another hydrogen bond with His96344 (Fig. 8e). RG7388 activates p53 to inhibit hematological tumors345 and solid tumors,346,347 but long-term administration may lead to p53 mutations and drug resistance.348,349

AM232

AMG32, Kd = 0.045 nM, is a piperidone analog that potently inhibits the MDM2-p53 interaction.342 Structural analysis revealed that the “cleft” of Gly58 may provide additional assistance for the small molecule to bind MDM2.350 The crystal structure shows that the isopropyl group, C6 aryl group and C5 aryl group occupy the three major binding pockets of p53, namely, Phe19, Trp23 and Leu26, respectively. Meanwhile, the imidazole group of His96 formed π-π stacking interactions with the C5 aryl group and formed hydrogen bonds with carboxylate.342 In addition, the isopropyl group extends into the “cleft” of Gly58, forming CH·O-type interactions with Gly58 and enhancing contacts with nearby hydrophobic residues350 (Fig. 8f). In tumor cells with high MDM2 expression, AMG232 enhances p53 activity and inhibits tumor growth.351 AMG232, in combination with immune checkpoint drugs, also enhances T-cell-mediated tumor killing.352 However, high doses of AMG232 may trigger gastrointestinal side effects, neutropenia and leukopenia, which requires further study.353

SAR405838

SAR405838 (MI77301), Ki = 0.88 nM, is an optimized spiro-oxide compound that blocks the MDM2-p53 interaction and prevents p53 degradation.354 SAR405838 mimics the three key amino acid residues of p53 and forms hydrogen bonds with the His96 residue of MDM2 at different chemical groups, generating π-π stacking, as seen in other MDM2 inhibitors. The structural differences are that SAR405838 mediates the refolding of the MDM2 N-terminus (residues 10–18) and interacts extensively with Val14 and Thr16. Moreover, the hydroxy-cyclohexyl group forms a hydrogen bond with Lys94354 (Fig. 8g). These structural features allow SAR405838 to achieve a tight binding and high specificity for MDM2. SAR405838 activates the p53 pathway, increases the expression of PUMA and P21, and induces complete tumor regression in SJSA-1 osteosarcoma xenograft mice.354 The safety of SAR405838 alone355 or in combination with MEK inhibitors356 has been established, but the drug activity is limited, and TP53 mutations may occur with long-term administration.357

NVP-CGM097

NVP-CGM097, Ki = 1.3 nM, is a novel dihydroisoquinoline-like MDM2 inhibitor obtained by virtual screening and structural optimization.358 The cocrystal structure revealed that in addition to the three key amino acids that mimic the interaction between p53 and MDM2, the isopropyl ether group also forms water-mediated hydrogen bonds with Tyr100, Gln24 and Phe55. NVP-CGM097 induced a conformational change in Phe55; thus, Phe55 formed a π-π stacking interaction with the dihydroisoquinolone core (Fig. 8h). NVP-CGM097 exhibits high selectivity for wild-type p53 and shows potent antiproliferative ability in colorectal cancer and osteosarcoma cells with wild-type p53.358 NVP-CGM097, combined with MEK inhibitors, activates the MAPK signaling pathway and attenuates acute myelogenous leukemia (AML) cell load.359 When combined with BET or Cdk4/6 inhibitors, NVP-CGM097 induces cell death in neuroblastoma or ER-positive breast cancer cells.360,361

MDM2/MDMX-p53 inhibitor

The main features of the MDM2-p53 interaction are preserved in the MDMX-p53 structure, but the central hydrophobic cleft of p53 peptide binding in MDMX is smaller and differently shaped than that of MDM2 (Fig. 8a–c). Therefore, many small molecule drugs targeting MDM2 do not bind MDMX well.

ALRN-6924

Currently, there are no inhibitors that act on MDMX alone, but one stapled peptide, ALRN-6924, binds both MDM2 (Kd = 10.9 nM) and MDMX (Kd = 57 nM).362 In AML cells, ALRN-6924 induces cell cycle arrest and apoptosis and significantly prolongs the survival of AML model mice.362 ALRN-6924 is well tolerated in phase I clinical trials in patients with solid tumors and lymphomas carrying wild-type p53.363 However, molecular simulations reveal that ATSP-7041, an analog of ALRN-6924, may bind to the p53 coactivator p300 and isolate free p300, thus reducing the transcriptional activity of p53.364 This mechanism needs further investigation.

Other MDM2 inhibitors

Other MDM2 inhibitors currently in clinical trials include HDM201,365,366 MK-8242,367–369 BI-907828,370 APG-115,371–373 and milademetan (DS-3032b)374 (Table 1). Although the specific interaction sites are unknown, they all induce cell death in a variety of tumor cells, particularly in patients with MDM2 amplification and intact p53 expression. APG-115 was the first MDM2 inhibitor to enter the clinic in China and was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration. APG-115 interrupts the p53-MDM2 interaction, increases the abundance of MDM2 in T cells, and plays a critical biological role in maintaining T-cell stability, survival, and antitumor immunity.371

In addition, researchers designed Proteolysis-targeting chimera (PROTAC) degraders based on MDM2 inhibitors.375 WB156, consisting of a nutlin derivative linked to the CRBN ligand lenalidomide, effectively depleted MDM2 and activated wild-type p53, thereby inducing apoptosis.376,377 The rapid degradation of MDM2 by MD-224 resulted in complete tumor regression in leukemia cells carrying wild-type p53.378

Overall, the design and development of drugs targeting MDM2/MDMX-p53 is a hot spot and priority in the field of oncology drug research worldwide. However, the specificity of MDM2/MDMX-p53 protein interactions poses a great difficulty in the development of small molecule inhibitors. Although some MDM2 inhibitors have entered clinical trials, there are currently no marketed drugs, and it is hoped that structure-based guidance will lead to new breakthroughs for MDM2-p53 inhibitors.

Tackling the p53 mutation

Under normal conditions, wild-type p53 suppresses tumor development through transcriptional regulation and protein-protein interactions. However, in many situations, missense mutant p53 is expressed at high levels in tumor cells, partly due to the inability of mutant p53 to induce gene expression of MDM2,379 which supports the reactivation of mutant p53 as a therapeutic option.5 Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380 p53 mutants mainly affect the thermostability of p53 protein, structural stability (structural mutants such as 175, 220, 245 and 249) or p53-DNA contact (DNA contact mutants such as 248 and 273). Therefore, a number of small molecule compounds, peptide or antibody drugs targeting p53 mutants have been developed to recover the native conformation or normal function of the p53 protein.381–385

Broad-spectrum mutant p53 rescue compounds

Employing library screens, structure-based design and other methods, drugs or compounds were discovered to have effects on the thermostability, specific DNA binding capacity or transcriptional activity of p53 mutant proteins. Some of them were initially identified as p53 mutant activators, but as research progressed, it was discovered that they could also exert antitumor activity independent of p53 status (Tables 2–3).Table 2 Drugs targeting mutant p53

Compounds	Discovery method (Report time)	Chemical structure	p53 targets	Rescue potency	Method: detailed interactions	Identifier/phase/status	Refs	
Broad-spectrum mutant p53 rescue compounds	
CP-31398	Screening a chemical library

(1999)

		Null, WT and mutant p53	Thermostabilized, transcriptional activity	NMR:

Does not bind p53

	–	454–456	
PRIMA	Screening a chemical library

(2002)

		Null, WT and mutant p53	Restore conformation and transcriptional activity	X-ray:

Binds to cysteine

	–	386	
APR-246	Methylated form of PRIMA-1		Null, WT and mutant p53	Restore conformation and transcriptional activity	X-ray:

Binds to cysteine

	NCT03931291 Completed II

NCT04214860 Completed I

NCT04383938 Completed I/II

NCT02999893 Terminated I/II

NCT04419389 Suspended I/II

NCT03588078 Unknown I/II

NCT03745716 Completed III

NCT03268382 Completed II

NCT03391050 Terminated I/II

NCT03072043 Completed I/II

NCT02098343 Completed Ib/II

NCT00900614 Completed I

NCT04990778 Withdrawn II

	425	
STIMA-1	Cell-based screening (2008)		Null, WT, and mutant p53	Transcriptional activity	Docking:

L1/S3 pocket, C124

	–	458	
MIRA-1	Cell-based screening (2005)		WT and mutant p53	Restore conformation and transcriptional activity	Docking

L1/S3 pocket, C124

	–	459–461	
Stictic Acid	Screening a chemical library

(2013)

		Mutant p53	Thermostabilized, transcriptional activity	Docking:

L1/S3 pocket, C124

	–	424	
ATO	Cell-based screening (2021)	As2O3	Structural mutants	Thermostabilized, transcriptional activity	X-ray:

C124, C135, C141, M133

	NCT04489706 Recruiting –

NCT04695223 Recruiting II

NCT03381781 Unknown II

NCT03855371 Recruiting I

NCT04869475 Recruiting II

NCT03377725 Unknown III

NCT01428128 Completed II

	431	
PAT	Cell-based screening (2022)	C8H4K2O12Sb2	Temperature-sensitive mutants	Thermostabilized, transcriptional activity	X-ray:

C124, C135, C141, M133

	NCT04906031 Recruiting II	432	
ZMC1	Silico screen

(2012)

		Mutant p53	Restore conformation, Zinc ion delivery and transcriptional activity	-:

Delivered zinc bound to C238, C242 and C176

	–	441	
COTI-2	Structure-based design

(2016)

		WT and mutant p53	Restore conformation and transcriptional activity	–	NCT02433626 Unknown I	186	
UCI-LC0023	Virtual screen (2022)		Mutant p53	Restore conformation and transcriptional activity	Docking:

L1/S3 pocket

	–	462	
Allele-specific mutant p53 rescue compounds	
PhiKan083	Structure-based in silico screening (2008)		Y220C/S

Kd = 140 ± 73 μM

	Thermostabilized, structural stability	X-ray: The ethyl group bound to sulfhydryl group of C220, N-methyl methanamine forms a hydrogen bond with D228, hydrophobic interaction: F109, V147, L145 L257.	–	467,474	
PhiKan5196	Screening halogen-enriched fragment library (2012)		Y220C

Kd = 9.7 μM

	Structural stability	X-ray: An iodine atom forms halogen bond with L145, the phenol group forms water molecule-mediated hydrogen bonds with V47 and D228, benzamine moiety forms a hydrogen bond with C220, hydrophobic interactions: P153, P222.	–	468	
PK7088 (PK7242)	Cell-based

techniques (2013)

		Y220C

Kd, ~140 μM

	Structural stability	X-ray: The flip of the C220 side chain increases the depth of the cavity, and the pyrazole ring penetrates deep into the pocket, while forming water molecule-mediated hydrogen bonds with L145, D228, hydrogen bonds with T230.	–	469	
Compound9	Fragment screening or structure-based design (2015)		Y220C

Kd = 21 μM

	Structural stability	X-ray: The pyrrole moiety binds to the cavity of the C220 side chain flip. Iodine forms a halogen bond with L145, while forms hydrogen bonds with T150 and structural water molecule hydrogen bonds (V147, D228).	–	470	
Compound6	Structure-based optimization (2016)		Y220C

Kd = 37.2 μM

	Structural stability	X-ray: The CF3 group interacts with L145 and W146, C220.	–	471	
PK11007	Fragment screening

(2016)

		Y220C

IC50: 2.3 to 42.2 μM

	Thermostabilized, structural stability	X-ray: Covalent Modification C182, C277		477,478	
MB710	Fragment screening (2018)		Y220C

Kd = 4 μM

	Thermostabilized, structural stability	X-ray: Structural water molecule hydrogen bonds (Val147 and Asp228) and hydrophobic interactions of the N-ethyl group with P151, P152, P153 T155.		472	
L5	Structure-based desjgn (2018)		Y220C	Zinc ion delivery	Docking: Cavity of p53-Y220C	–	475	
PK9318	In silico and fragment-based screening (2019)		Y220C

Kd = 2.6 μM

	Structural stability	X-ray: The secondary amine forms hydrogen bonds with D228. There are interactions the sulfur atom and C220, other hydrophobic interactions: T150, P153, P222, P223.		473	
LI	Structure-based design

(2019)

		Y220C	p53 aggregates and

Zinc ion delivery

	Native mass spectrometry: A p53 mutant binds two LI

Delivered zinc bound to C238, C242 and C176

	–	499	
LH	Structure-based design

(2019)

		Y220C	Zinc ion delivery	Native mass spectrometry: Does not bind p53

Delivered zinc bound to C238, C242 and C176

	–	499	
PC14586	(2020)	–	Y220C

Kd ~ 2.5 nM

	Structural stability	-	NCT04585750 Recruiting I/II	479	
Targeting p53 aggregation compounds	
ReAcp53	Sequence-based design

(2016)

	H-RRRRRRRRRRPILTRITLE-OH	p53 aggregates	Thermostabilized, transcriptional activity	Computational Analysis:

p53 (251–258)

	–	490	
ADH-6	Screening an oligopyridylamide library

(2021)

		p53 aggregates	Thermostabilized, transcriptional activity	NMR:

P53-DBD

	–	496	
Peptide and antibody drugs	
Drugs	Discovery method
(Report time)	Chemical structure	p53 targets	Rescue potency	Method:
Detailed interactions	Identifier/phase/status	Refs	
Peptide 46	p53 C-terminus

(1997)

	GSRAHSSHLKSKKGQST

SRHKK

	Mutant p53	Restore conformation and transcriptional activity	Pull-Down: P53-DBD and CTD	–	548

549

	
CDB3	Designed based on 53BP2 (2002)	REDEDEIEW-NH2	Structural mutants	Restore conformation and transcriptional activity	NMR:

P53-DBD

	–	507,510	
P28	Azurin-derived peptides (2009)	LSTAADMQGVVTDGMASGLDKDYLKPDD	WT and mutant p53	Inhibits p53 degradation	Structural simulations: P53 Loop L1, L7, L8	NCT01975116 Completed I

NCT00914914 Completed I

	512	
pCAPs	Phage display technology (2016)	Peptide	Mutant p53	Restore conformation and transcriptional activity	–	–	511	
Nb139	VIB Nanobody Service Facility (2014)	Antibody	WT and mutant p53	–	X-ray:

T32, A34, W54, P101

	–	527	
Nb3	VIB Nanobody Service Facility (2014)	Antibody	R175H, R282W	Inhibits transcriptional activity	X-ray:

T32, A34, W54, P101

	–	527	
H2-scDb	Screening and design optimization (2021)	Antibody	R175H

Kd = 86 nM

	T-cell immune response kills mutated p53 cells	X-ray:

175H

	–	530	
WT wild-type

Table 3 Scope of rescue drugs for mutant p53

Drugs	p53-DNA contact	Restore the p53 structure	Refs	
PRIMA/APR-246	R248Q, R273H	R175H	386,410	
ATO	–	Structural mutants: R175H, G245S, R249S, R282W and so on.	431	
PAT	–	Temperature-sensitive mutants: V272M, P278A, Q136P and so on.	432	
ZMC1	–	R175H	441	
UCI-LC0023	–	R175H	462	
PhiKan083

PhiKan5196

PK7088 (PK7242)

Compound9

Compound6

PK11007

MB710

L5

PK9318

LI

LH

PC14586

	–	Y220C	467–478	
ReAcp53	R248Q	R175H	490	
ADH-6	R248W	–	496	
Peptide 46	R273H	–	549	
CDB3	R273H	R175H, G245S, R249S	507,510	
pCAPs	R273H	R175H, R280H and so on.	511	

PRIMA-1 and APR-246

PRIMA-1 and APR-246 are prodrugs that are converted into the bioactive compound methylene quinuclidinone (MQ). PRIMA-1 was obtained by screening a library of compounds.386 PRIMA-1 restores the wild-type conformation and DNA contact of p53 mutants, and induces transcription of the downstream target genes BAX, P21 and PUMA.386–388 After PRIMA-1 treatment of SKOV-His-175 cells, a 46% increase in folded p53 protein was observed using the p53 conformation-specific monoclonal antibody PAb1620.386 Further studies revealed that APR-246 (PRIMA-1Met, eprenetapopt), a methylated derivative of PRIMA-1,389 has stronger antitumor activity and fewer toxic side effects than PRIMA-1, and inhibits the growth of p53 mutant tumors of various origins in combination with other anticancer drugs.390–396 Tumor cell lines carrying TP53, TP53 mutations, or TP53 deletions responded to APR-246 treatment.397–400 However, growing evidence suggests that APR-246 exerts its effects through a multitude of pathways independent of p53,401–404 such as downregulating glutathione concentrations in tumor cells,405,406 regulating oxidation-reduction homeostasis407–409 in tumor cells to trigger ferroptosis,410–412 and inducing endoplasmic reticulum stress413 or unfolded protein responses.414

Clinical and preclinical data showed that the combination of APR-246 and azacytidine (AZA) showed synergistic activity in patients with myelodysplastic syndromes (MDS), AML and solid tumors carrying TP53 mutations with an acceptable safety and tolerability profile.415–420 Food and Drug Administration and European Medicines Agency have granted APR-246 orphan drug status and FTD for the treatment of MDS carrying the TP53 mutation. Aprea Therapeutics recently announced preliminary data from its Phase III clinical trial. In a cohort of 154 intention-to-treat patients, the complete remission rate for APR-246 in combination with AZA was 33.3%, compared to 22.4% in the AZA alone group. Although the complete remission rate was higher with the combination, it did not reach statistical significance (https://www.aprea.com). Data from another clinical study could explain this phenomenon. Decitabine alone (a hypomethylating agent, similar to AZA) was able to produce a very high response rate (100%) in patients with AML or MDS carrying a TP53 mutation.421 This suggests that the therapeutic effect of the hypomethylating agent may be dominant in myeloid malignancies carrying TP53 mutations.

MQ can covalently bind to cysteine to restore the function and conformation of mutant p53. MQ is a very active Michael receptor that preferentially and reversibly binds to the soft nucleophile cysteine thiol of p53.422 Theoretically, all cysteines exposed on the surface of p53 are potential modification sites of Michael addition reaction285,423 (Fig. 9a). Computational docking indicated that Cys124, located in the center of the L1/S3 pocket of the p53 core region, may be the site of the MQ modification.424 In 2021, Degtjarik and colleagues investigated the mechanism of MQ reactivation of mutant p53 based on structure.425 Based on the DNA contact surface mutant R273H/R273C and the structural mutant R282W, six cysteines, Cys124, Cys182, Cys229, Cys273, Cys275 and Cys277, were identified to bind to MQ. Among them, the formation of new hydrogen bonds between MQ-Cys277 and DNA stabilizes the protein‒DNA interface, while MQ-Cys124 and MQ-Cys229 stabilize the local conformation and support the p53 dimer interface (Fig. 9b). MQ-Cys182, MQ-Cys275 and MQ-Cys273 are only observed in the structures absent from DNA, and seem to be incompatible with DNA binding. These conjugates form intramolecular interactions or intermolecular interactions with neighboring p53 molecules, stabilizing a p53 dimer different from that in p53-DNA tetrameric complexes. Therefore, MQ shows great diversity in reacting with p53 cysteines, while it worth considering whether each conjugate is beneficial for p53 rescue. Theoretically, MQ can bind to any exposed cysteine and GSH can also bind covalently to MQ,411 which may be one of the reasons for the antitumor activity of MQ.Fig. 9 Compounds targeting cysteine in p53-DBD. a The amino acid sequence and structure of p53-DBD, cysteine is highlighted and labeled, p53 tetramers are labeled as (a–d), respectively and cysteines are shown as sticks. b MQ bound to C124, C229 and C277 in p53-R282W-DNA tetramers. The MQ conjugates are in stick representation (green). c Structure of p53-bound arsenic and zinc ions. d Structure of p53-bound antimony and zinc ions. The interacting amino acid residues are shown as sticks

ATO

Arsenic trioxide (ATO) is a traditional Chinese medicine that leads to complete remission in patients with acute promyelocytic leukemia (APL).426 The specific fusion protein PML-RARα is present in more than 98% of APL patients. One of the mechanisms by which ATO treats APL is its ability to bind directly to the cysteine in the zinc finger structure of the fusion protein, mediating the ubiquitinated degradation of PML-RARα.427 Subsequently, a series of reports showed that ATO induced apoptosis in tumor cells carrying TP53 mutations.428–430

Lu Min’s team found that ATO could help stabilize the structural mutation of p53 (R175H) and restore the cancer suppressive activity of p53.431 The crystal structure showed that the DNA-binding domains of Cys124, Cys135, Cys141 and Met133 formed an As-binding pocket, with direct interaction of arsenic with Cys124, Cys135 and Cys141 and van der Waals forces between the side chain of Met133 and the arsenic atom (Fig. 9c). Most structural p53 mutants were rescued to varying degrees by ATO, but mutations in the DNA contact surface (R248Q, R273H) were not observed. ATO increased the thermostability of structural mutant p53 by 0.9–6.5 °C, restored the protein folding state close to wild-type, and increased transcriptional activity by several fold to 44-fold. Studies on hematologic tumors showed that ATO significantly prolonged the median survival time in mice; and studies on solid tumors showed that ATO-treated mice had only 10–20% of the tumor volume of the control group.431

Potassium antimony tartrate (PAT)

Subsequently, the Lu Min’s team screened compounds for temperature-sensitive p53 mutant proteins, using thermostability as a criterion for rescue. Potassium antimony tartrate (PAT) was identified as binding to the p53 V272M mutant (Kd = 9.09 μM) in a non-covalent manner, increasing its thermostability by 3.6 °C and remarkably restoring protein folding and transcriptional activity.432 PAT is an antiparasitic agent that has been used as a treatment for leishmaniasis,433,434 and has since been found to have antitumor activity.435,436 PAT is similar to ATO in that both can induce apoptosis in APL cells.437,438 PAT and ATO bind to mutant p53 at similar sites (Fig. 9d), but differ in two aspects, with PAT non-covalently binding mutant p53 and preferentially rescuing temperature-sensitive mutants (a subtype of structural mutants), whereas ATO covalently binding mutant p53 and apparently rescuing more structural p53 mutants.432 Notably, the ATO and PAT studies comprehensively and experimentally compared the set of representative mutant p53-rescuing compounds. PAT exhibited specific p53 V272M antitumor activity in both cellular and xenograft mouse models. Further testing identified 65 of p53 mutants that could be rescued by PAT, but all were non-hotspot mutations.432 A clinical trial of antimony for the treatment of MDS/AML with TP53 mutations is currently underway.

ZMC1

Zn2+ is crucial for DNA recognition by p53. Zn2+ can help stabilize the interaction between p53 and DNA by tetrahedral coordination with the imidazole group of H179 and the thiol groups of Cys238, Cys242 and Cys176298 (Fig. 9c, d). Conversely, the lack of Zn2+ affects the correct folding and DNA recognition of the p53-DBD protein.439 Therefore, helping zinc ions to bind in the correct position may be an effective strategy to target p53.

R175H is one of the p53 hotspot mutations and is classified as a Zn2+-binding mutation. The binding affinity of DBD-R175H to Zn2+ was significantly reduced compared to that of wild type.440,441 On the basis of this hotspot mutation, NSC319726, also known as ZMC1, was identified from 48129 compounds.441 ZMC1 helped coordinate zinc ions at appropriate sites to restore the structure and function of the R175 mutant442 and significantly inhibited tumor growth in mice carrying the R175H mutation.441 ZMCI treatment increased the folded R175 mutant protein by twofold.442 ZMC1 acts as an ionophore,443 transferring zinc ions from the extracellular space to the cytoplasm, maintaining the cytoplasmic zinc ion concentration within an appropriate range and thus reactivating the p53 mutant.444–446 In addition, ZMC1 can chelate redox-active copper,447 increase intracellular reactive oxygen levels and decrease glutathione concentrations to exert antitumor effects.441,444

ZMC1 acts as an ionophore,443 transferring zinc ions from the extracellular space to the cytoplasm, maintaining the cytoplasmic zinc ion concentration within an appropriate range and thus reactivating the p53 mutant.444–446 In addition, ZMC1 can chelate redox-active copper,447 increase intracellular reactive oxygen levels and decrease glutathione concentrations to exert antitumor effects.441,444

Other compounds

Salim et al. identified a thiosemicarbazideb compound COTI-2 that showed inhibitory activity in a variety of tumors by using a computational platform.448 COTI-2 inhibits tumor growth in a p53-dependent and p53-independent manner, ultimately leading to cell cycle arrest and apoptosis.448–450 COTI-2 was reported to restore DNA-binding properties to the p53-mutant protein,449,451–453 whereas it is obscure whether COTI-2 can physically bind p53. COTI-2 is currently in phase I clinical trials for the treatment of gynecologic malignancies or head and neck squamous cell carcinomas.

There are also small molecule drugs that have not been structurally studied but may interact with the cysteine residues of p53-DBD and restore the wild-type conformational and transcriptional function of p53. CP-31398 was screened from a library of >100,000 compounds originally identified to rescue the mutant p53.454–456 However, subsequent studies have shown that CP-31398 does not interact with p53-DBD or full-length p53, but rather acts as an intercalator and may interact with p53 during biosynthesis. CP-31398 inhibited ubiquitination and degradation of p53457 and activated BAX independently of p53 to promote apoptosis of tumor cells.455 Molecular docking structures revealed that STIMA-1,458 MIRA-1459–461 stictic acid424 and UCI-LC0023462 could bind in the L1/S3 pocket of p53-DBD, probably to the thiol group of Cys124 in this transiently opened pocket.424

Some of these broad-spectrum mutant p53 rescue compounds have been reported to bind p53-DBD cysteine, helping restore the correct folding and thermostability of mutant p53. Complex structures show that MQ can bind to six of the ten cysteines,425 while ATO431 and PAT432 bind at a pocket formed by Cys124, Cys135, Cys141 and Met133. p53 has ten cysteines in its DBD (Fig. 9a). Theoretically, these cysteines are all potential sites for modification. Amino acids exposed on the surface of p53-DBD, Cys182, Cys229 and Cys277, are the most susceptible sites for modification. Cys182 and Cys229 are located on the p53 dimer contact surface and modification of these two sites may cause non-functional artificial dimers.463 Cys277 is located on the DNA contact surface and modification of this site may result in spatial site blocking that inhibits p53 binding to DNA.463 Cys176, Cys238 and Cys242 are relatively unlikely to be modified, as they involve the coordination of a zinc atom.298 Besides, Cys124, Cys135, Cys141 and Cys275 are located in the p53-DBD core region, which is exposed when the protein is not fully folded or conformationally altered, and may also be the site of modification. Specific targeting of these sites may be more helpful in restoring the structure and function of mutant p53.

Allele-specific mutant p53 rescue compounds

Y220C

The Y220C mutation in p53 is a relatively specific mutation. Y220 is far from the site where p53 binds to DNA, while the tyrosine mutation between S7/S8 becomes cysteine, forming a hydrophobic cavity on the p53 surface.464,465 Therefore, targeting the hydrophobic pocket of Y220C becomes an ideal drug target, helping p53 to restore normal folding without interfering with p53 binding to DNA.466 Several small molecules have been shown to bind to the hydrophobic pocket of Y220C and restore p53 function467–478 (Tables 2–3, Fig. 10a–i).Fig. 10 Structure of the p53 mutant Y220C with small molecules. a p53-WT surface (PDB: 3KMD). b p53-Y220C surface (PDB: 2VUK). c p53-Y220C/Phikan083 (PDB: 2VUK). d p53-Y220C/Phikan5196 (PDB: 4AGQ). e p53-Y220C/PK7242 (PDB: 3ZME). f p53-Y220C/Compound9 (PDB: 5AOJ). g p53-Y220C/Compound6 (PDB: 5G4O). h p53-Y220C/MB710 (PDB: 5O1I). i p53-Y220C/PK9318 (PDB: 6GGB). Water molecules are red spheres, and hydrogen bonds are black lines. The interacting amino acid residues are shown as sticks (colored greencyan)

C14586 is the first orally bioavailable mutant p53 protein-selective reactivator that selectively binds to the cleft produced by the p53 Y220C mutant protein, thereby restoring wild-type p53 protein structure and tumor suppressor function.479 Preclinical trials have shown that continuous oral administration leads to complete tumor regression in 80% of mice.479 An ongoing clinical phase 1/2 study will evaluate the safety, tolerability and antitumor activity of C14586 in adult patients with advanced or metastatic solid tumors with the Y220C mutation.480

The hot spot mutation Y220C is a particularly suitable target site for structure-based drug design. The mutant p53 temperature sensitivity can be repaired by small molecule drugs, and the cavity that appears due to the mutation is also a good target for small molecules. Structure-based drug design and optimization may lead to new strategies for patients with tumors carrying the p53-Y220C mutation.

Targeting p53 aggregation

p53 is a temperature-sensitive protein. Once mutated, its structural stability is compromised, exposing adhesion sequences encased in the hydrophobic core of p53, which drives the formation of p53 aggregates,481 thereby depriving p53 of its DNA recognition function and proapoptotic capacity482,483 (Tables 2–3, Fig. 11). Amyloid aggregates caused by TP53 mutations have been found in biopsy specimens from ovarian and breast cancers.484,485Fig. 11 Targeting p53 aggregation. p53-DBD has an amyloid-forming segment, LTIITLE, that forms Mutant p53 aggregates. ReAcp53, ADH-6 and LI inhibit p53 aggregation and restore the conformation and function of p53

ReACp53

The formation of p53 aggregates is considered to be an amyloid lesion, where two β-sheet layers stack in parallel to form a tight complementary spatial zipper, forming amyloid fibrils mainly through hydrogen bonding interactions between the main and side chains of the β-sheet layer.486,487 Several research groups have reported similar sequence positions as highly adherent fragments of p53 (251–258, ILTIITLE) (Fig. 11). p53 mutations result in reduced p53 stability and expose the highly adherent fragment that drives p53 aggregation, which is effectively inhibited by the I254R mutation.457,488,489 Soragni et al. designed a cell-penetrating peptide (named ReACp53) that inhibits amyloid aggregation of the mutant p53 protein and restores the transcriptional function of p53 and its ability to induce mitochondrial apoptosis.490 ReACp53 treatment increased the nuclear localization of mutant p53 by 70–100% and approximately doubled the transcriptional activity.490

Molecular dynamics simulations were used to study the binding characteristics of the ReACp53 peptide to the R175H mutant p53-DBD.491 The results show that ReACp53 has hydrophobic interactions with residues Leu188 and Leu201 and forms salt bridges or hydrogen bonds with residues Asp186, Glu198, Asp204, Glu 221 and Glu 224, which prevent the aggregation-prone region (residues 182–213) from being exposed. In addition, the complex formed by the ReACp53 peptide and the R175H mutant p53-DBD has the same positive net charge as wild-type p53. The aggregation of p53 was inhibited by electrostatic repulsion.491 ReACp53 also inhibits the growth of various tumors characterized by p53 mutations.490,492–494

ReACp53 inhibits the aggregation of mutant p53 to rescue p53 function, but it is clear that its non-p53 targets are also present in cancer cells. In p53-silenced cells, the response of ReACp53 was not abolished, and addition of this peptide to p53-silenced two-dimensional cultured cancer cells resulted in rapid apoptosis.495 Thus, although ReACp53 was designed as a mutant p53 rescue compound, its exact mechanism of action and targeting in tumors and whether it acts primarily by targeting p53 need to be further elucidated.

ADH-6

ADH-6, Kd = 366 nM, is a cationic tripyridylamide obtained by screening the oligopyridylamide library.496 Previous studies have reported that these α-helix-like mimics can mimic the secondary structure of proteins and effectively regulate amyloid aggregation497,498 (Fig. 11). Using NMR spectroscopy, ADH-6 was shown to bind not only p53-prone aggregation sites but also multiple regions of p53-DBD, including sheet 1, 3, 4, 6, 7 and helix 2. Subsequently, researchers also found that ADH-6 dissociated p53 mutant aggregates and selectively induced apoptosis in multiple p53 aggregation-prone mutated cancer cells (R248W, R248Q, R175H, R273H, Y220C and R280K). In addition, the unfolded state of mutant p53 was reduced by 24–50% after ADH-6 treatment of cells, and the expression of downstream target genes p21, Noxa and BAX was significantly increased.496

LI/LH

Miller et al. designed two bifunctional ligands (LI/LH) based on other compounds that bind amyloid proteins.499 LI and LH have the same structural features except for an iodine substituent at the ortho position. The iodine atoms may form halogen bonds that bind to exposed hydrophobic amino acid residues and regulate the aggregation of p53 (Fig. 11). LI and LH acted as metallochaperones binding to zinc ions, which increased the intracellular zinc ion level and improved the binding ability of zinc ions to mutant p53, thus regulating mutant p53 aggregation. LI and LH also increased the expression of Noxa and p21 by 1.5 to 4.3-fold. Meanwhile, transmission electron microscopy observation confirmed that mutant p53 could significantly inhibit the formation of aggregates when cocultured with LI.499

HDAC6/Hsp90 inhibitors

Mutant p53 aggregates not only induced wild-type p53 aggregates but also coaggregated with p63 and p73495,500 (Fig. 11). The p53 aggregates led to upregulation of Hsp70 and Hsp9098 (Fig. 11). Hsp70 inhibited MDM2-mediated degradation of mutant p53 ubiquitination and led to transient exposure of p53 adhesion sequences, increasing the formation of p53 aggregates.501 The interaction between Hsp90 and mutant p53 prevented the ubiquitinated degradation of mutant p53 protein.502 Thus, disruption of the HDAC6/Hsp90 complex by HDAC inhibitors503 or Hsp90 inhibitors504 induces degradation of the p53 mutant.

Peptide and antibody drugs targeting protein interactions

Peptide drugs and antibody drugs are characterized by high specificity and good safety profiles. With the maturation of biotechnology, an increasing number of peptide and antibody therapeutics are beginning to emerge that can bind to mutated p53 and restore the function of the p53 mutant (Tables 2–3). However, although peptide drugs can enter cells to restore p53 function, it is difficult to maintain stability and function after entering the human body.505,506

CDB3

A nine amino acid peptide, CDB3, was designed based on the p53 binding protein 53BP2 region (490–498).507 The NMR structure showed that CDB3 interacts with multiple sites in the DBD region, concentrated between loop 1, helix 2 and sheet 8, located at the edge of the DNA-binding site and partially overlapping with the DNA-binding site.507 Further experiments revealed that CDB3 could bind to G245S and R249S structural mutants,508 restore conformational folding,509 improve the affinity of the β-sheet I195T mutant to DNA, and restore the transcriptional activation function of p53 (R175H, R237H). Upon binding of CDB3 to mutant p53, the p53 protein is activated, and target genes compete for the position of binding CDB3, which in turn is released back into the cell and continues to target other mutants.507,510

pCAPs

A series of p53 conformation-activating peptides, or pCAPs, were identified using phage display technology. Despite the absence of clear structural information, pCAPs were shown to bind to misfolded p53 mutants, forcing p53 conformational recovery and activating transcription of p53 downstream target genes. Significantly reduced mouse tumor size in mouse xenograft models of breast, ovarian and colon cancer.511

p28

The amphipathic penetrating peptide p28 contains twenty-eight amino acids from Pseudomonas aeruginosa.512–514 It preferentially enters cancer cells and inhibits their proliferation by stabilizing the expression of p53.515 p28 forms a complex with the DBD of p53, and structural simulations show that the main binding sites of p28 are in the nonmutagenic loop L1 (amino acids 112–124) and the mutagenic loop L7/L8 regions (Y220C, P223L).516 p28 inhibits the interaction between the E3 ligase COP1 and p53,517 improves the posttranslational stability of p53, and increases p53 protein expression in various p53 wild-type or mutated tumor cell lines.518,519 These results provide foundational evidence that p28 performs well in phase 1 clinical trials in patients with various p53 wild-type or mutant tumors.520–522

Nb3 and Nb139

Nanobodies containing only a heavy chain variable region (VHH) but still retain antigen specificity and high affinity523 have proven their value in cancer therapy and diagnosis in recent years.524–526 Two p53-binding nanobodies, Nb3 and Nb139, were obtained by immunization and panning procedures.527 Nb3 binds to the “structural mutations” R175H and R282W, and Nb139 binds to both wild-type and mutant p53, inhibiting the transcriptional capacity of p53. The cocrystal structure shows that the three complementary determining regions (CDRs) of Nb139 interact with p53-DBD by forming backbone or side chain hydrogen bonds and van der Waals forces (Fig. 12a). Compared with the wild-type p53 structure, the Nb139/p53-DBD complex maintains the structural and DNA-binding properties of p53, which provides an innovative approach to study p53.527Fig. 12 Antibody drugs against p53. a Structure of the Nb139/p53-DBD complex. p53-DBD shown as cartoon/surface (colored pink). Nb139 shown as cartoon (colored marine). b Mechanism of action and structure of the bispecific antibody H2-scDb. H2-scDb is a bispecific antibody that recognizes the p53R175H mutant peptide presented on the cell surface by HLA-A and binds to the T-cell receptor, activating T cells and releasing cytokines to kill tumor cells. The interacting amino acid residues are shown as sticks. Hydrogen bonds as black lines

H2-scDb

Mutant p53 is hydrolyzed intracellularly to produce a peptide known as a mutation-associated neoantigen that can be presented on the cell surface after forming a complex (pHLA) with human leukocyte antigen (HLA) proteins.528,529 In two patients with metastatic epithelial carcinoma carrying the p53R175H mutation, Malekzadeh et al. identified the neoantigen as the HMTEVVRHC peptide, which can be recognized and formed into a complex by HLA*02:01530 (Fig. 12b). To exploit this tumor-specific surface antigen, the researchers screened the antibody fragment library and optimized the design to identify a TCR-mimetic antibody in the form of a single-chain double antibody (scDb) with Kd = 86 nM.529 The structure revealed that the p53R175H peptide occupies the binding cleft between α1 and α2 of HLA-A*02:01. The His175 amino acid residue in the p53R175H peptide fragment plays a significant role in direct contact with H2-Fab. The imidazole side chain of His175 forms hydrogen bonds with Asp54 (CDR-H2) and Tyr94 (CDR-L3) and forms a π-π stacking interaction with Tyr52 (CDR-H2) (Fig. 12b). Functionally, H2-scDb bound specifically to the p53R175H/HLA complex and efficiently induced T-cell immune responses. In multiple myeloma xenograft mice carrying p53R175H, H2-scDb effectively regressed tumors.529

Second-site suppressor mutation

Mutant p53 usually affects the binding of p53 to DNA or the conformation of p53. Second site suppressor mutations could help correct the conformation of mutant p53, improve the stability of p53-DNA binding, and provide a theoretical basis for the reactivation of mutant p53 (Table 4).531–545Table 4 Second-site suppressor mutation

Mutation	Second-site suppressor mutation	Mechanism	Reference	
G245S	H178Y	Contributes to tetramer formation and restores transcriptional activity.	533	
N239Y	Restores p53 stability to wild-type levels and improves DNA binding.	531,542	
T123P	Improves structural stability and restores transcriptional activity.	537	
S240N	Improves structural stability and restores transcriptional activity.	537	
R249S	H168R	Restore DNA contact and transcriptional activity.	531,532	
R249S	T123A + H168R	Improves structural stability and restores transcriptional activity.	532,537	
V143A	N268D	Stabilized the global folding of p53.	531,534,537	
V143A	M133L + V203A + N239Y + N268D	Improves thermal and structural stability	534	
N131Y	N239Y	Restored p53 function and inhibited tumor growth.	535	
R273C	S240R	Restore protein-DNA interactions.	536,543	
R273C	T284R	Restore protein-DNA interactions.	345	
R273H	T284R	Restore protein-DNA interactions.	536,543	
R273H	N263Y	Improves structural stability.	540	
R273H	N200Q + D208T	Improves structural stability.	540	
R273H	N235K + N239Y	Improves structural stability.	540	
R273H	S240R	Improves structural stability.	540	
Y220C	A138G	Improves structural stability.	540	
Y220C	L137R	Improves structural stability.	540	
R248Q	H115N	Improves structural stability and restores transcriptional activity.	541	
V157F	N235K + N239Y	Improves thermal and structural stability.	545	

Crystal structures show that the second-site suppressor mutations usually cause only small local structural changes, whereas do not alter the overall structure of the p53 protein.534,536,545,546 These second-site suppressor mutations act through two types of mechanisms: supplying a new DNA-contacting amino acids when rescuing DNA-contacting mutants, or increasing thermostability when rescue structural mutants.537,547 These mutants provide the basis for designing drugs that restore the transcriptional inactivation and instability of p53 caused by mutations.

Other therapies

The TET and CTD have essential roles in the proper folding and functional regulation of p53. There are no drugs that specifically target these two structural domains. A synthetic peptide (361–382) extracted from the p53-CTD region (361–382, peptide 46) can interact with the DBD and CTD regions of p53,548 and the addition of different concentrations of peptide 46 restores the DNA binding ability of p53 mutants (R273H, R248W, R175H, R249S, V143A).549 The fusion of the p53 protein with the N-terminal spider silk domain contributes to the stability of the p53 protein.550 The therapeutic effects and specific mechanisms targeting these two structural domains need further exploration.

Researchers have also developed innovative therapies that target mRNA for protein degradation. For example, a specific deoxyribozyme (DZ-249A) has been designed to target the mutation site of TP53 to degrade the mRNA of mutant TP53, thereby reducing the expression of the mutant p53 protein.551,552 Combination therapy of multiple mechanisms is also a promising strategy; for instance, the combination of MDM2 and BCL-2 inhibitors can effectively induce apoptosis.553,554 Moreover, gene therapy and immunotherapy are also new options for targeting p53.

Therapeutic strategy for truncated p53

Nonsense mutations cause proteins to terminate or end translation earlier than expected, generating truncated proteins. A total of 8.19% of TP53 mutant tumors were detected to carry nonsense mutations and were cleared by the nonsense-mediated mRNA decay (NMD) machinery during transcription555,556 (Fig. 1a). Currently, there are two approaches to rescue truncated p53.557 One is to restore production of full-length p53 protein by drug-induced read-through of the premature termination codon. For instance, G418 and NB124 can stably promote the expression of full-length p53 protein.558,559 The other is the inhibition of NMD.560,561 However, NMD is a potent cellular surveillance mechanism562 and non-specific inhibition of NMD may do more harm than good.

Therapeutic strategy for p53 isoforms

Fourteen isoforms of p53 have been identified: p53, p53β, p53γ, Δ40p53, Δ40p53β, Δ40p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ160p53, Δ160p53β, Δ160p53γ, Δp53, and p53ψ.563–568 It was shown that Δ133p53 activates the anti-apoptotic BCL-2 protein and antagonizes p53-induced apoptosis.563 p53Ψ cannot bind to DNA or transcriptionally activate p53 target genes. However, it induces the expression of epithelial-mesenchymal transition markers and enhances the viability and invasiveness of cancer cells.565 Overexpression of Δ133p53α facilitates the long-term propagation of primary epithelial cells in vitro.569 These evidences suggest that some p53 isoforms are in marked contradiction to the function of wild-type full-length p53, exhibit oncogenic effects, and support cancer cell proliferation and invasion. Therefore, rescue therapy may not be appropriate for these p53 isoforms, and targeted degradation may be a better strategy to remove their oncogenic effects, such as PROTAC,570 ATTEC,571 AUTAC,572 and LYTAC.573

Conclusion

The TP53 gene is the most frequently mutated gene in humans. In the 40 years since the discovery of p53, new insights have been made into the gene regulatory mechanisms and tumor suppression pathways of p53. We have learned about an elaborate and complex tumor suppression network, but have not yet discovered its accurate and complete picture. Based on the relationship between the structure and function of p53 and cancer development, many anticancer drugs targeting p53 have been developed. However, there are no approved drugs to date.

Summary points

Among the molecules developed to target p53, two main mechanistic approaches have been implemented. One is to target wild-type p53 and inhibit the p53/MDM2 complex to prevent its degradation. To date, eleven MDM2 inhibitors are in clinical trials. However, long-term administration of an MDM2 inhibitor may induce acquired resistance related to TP53 mutations and increased MDMX expression.574,575 There is still a lack of MDM2/MDMX dual-target or specific MDMX inhibitors. Moreover, the accumulation of p53 in normal tissues may produce greater toxic effects.353

The second is to target p53 mutants. Many therapeutic approaches aim to rescue the function of mutated p53 through small molecule compounds. The development of p53 mutant-rescuing drugs has been hampered by false trials that have proven not to be reproducible in other labs or to function by p53-unrelated pathways. Some drugs were initially identified as p53 mutant activators, but it remains puzzling whether they actually rely on p53 for their action. For example, CP-31398 was initially thought to maintain the wild-type conformation of the mutant p53,454 but was shown to be unable to bind p53 in a different lab.455 Dr. Soragni states on her website that “we don’t really know what the mechanism is for ReACp53 to kill cancer cells” (http://alice.mbi.ucla.edu/reacp53.html). This may be because most experiments to rescue mutant p53 drugs are performed in cells, and the lack of information on the direct interaction of compounds with proteins leads to our incomplete understanding of the mechanism of drug action. Most of the currently reported drugs that activate p53 mutants have p53-independent antitumor effects. It is undeniable that these drugs do act to rescue mutant p53 function, but it may be ambiguous which is more effective, whether it is mutant p53-dependent, mutant p53-independent, or both. The field of targeting mutant p53 remains a shimmering light after the dawn, and we see hope, but there is still a long road of discovery to go.

The availability of structural data on p53 mutants and their complexes with drugs, combined with data on the functional rescue of the mutants, has helped to understand the rescue mechanism and optimize drug design. For example, a special class of p53 structural mutant, Y220C, leads to a hydrophobic cavity in p53 protein structure.467 Small molecules are designed to target this cavity to stabilize the protein structure. ATO431 and PAT432 bind to an allosteric site exposed within the p53 mutant protein and help stabilize the local structure. They are likely to be effective for structural mutants or temperature-sensitive mutants, but not DNA contact mutants. Those mutations at the DNA contact surface tend to benefit from small molecules that have the ability to restore protein-DNA binding. The structures of MQ with p53 mutants R282W, R273H and R273C show that the binding of MQ with Cys277 supports the p53-DNA interface by complementing additional interactions, while MQ interaction modes exhibit large diversity by binding to some other cystines.425 In addition, structural analysis illustrates the basis of a TCR-like antibody H2-Fab specifically targeting the p53R175H peptide-HLA interaction.529 Nevertheless, structural information about p53 mutants and their complexes is still insufficient, so we need more structural insights to help target p53 mutants for rational drug design.

Challenges and perspectives

There are significant challenges in the development of drugs targeting p53. The lack of an established mechanism for protein reactivation and the lack of pockets (except in the case of Y220C) are the two main reasons. It is relatively easy to inhibit protein function by simply using compounds to occupy their active sites, but elusive as to how compound binding leads to reactivation of protein function. In addition, resistance to TP53 mutations, the off-target effects of the drug, and the possible toxic side effects of p53 accumulation in normal tissues, all make p53 difficult to drug. Currently, the structures of full-length p53 in complex with different DNA targets and full-length partner proteins remain unavailable. Certain p53 mutants cannot be expressed, and their structures are not available, which limits structure-based drug design. In recent years, there have been great advances in cryo-electron microscopy, and artificial intelligence. With these technological advances, we have reason to believe that the structural study of p53 will make more progress in the near future, which will provide a structural basis for the development of p53-targeted drugs.

For p53-targeted therapy, several other factors also need to be considered. First, TP53 mutations are heterogeneous and not all mutations are equal. Hence a one-drug-fits-all approach may not be feasible for targeting TP53 mutations.12,576,577 Therefore, different p53-targeting drugs may be required for different p53 mutants. Second, p53-targeted therapy alone may not be sufficient to treat cancer. Combination therapy, such as simultaneous blockade of the MDM2-p53 pathway and p53-BCL-2 pathway, may have a synthetic lethal mechanism. Third, there are some other new therapeutic directions that may be explored, such as targeting p53 mRNA, targeting disordered structural domains, targeting mutant protein for degradation, and genome editing using CRISPR-Cas9. CRISPR-Cas9 based gene editing technology has been applied to cancer treatment.578,579 With the advancement of CRISPR-Cas9 technology, the correction of TP53 mutations using CRISPR-Cas9 may become an effective cancer treatment option in the future.

For decades, there has been a lack of effective progress in the development of drugs targeting p53, and p53 was once considered to be an undruggable target. As technology advances, many undruggable targets are becoming druggable, such as KRAS.580,581 We have reason to believe that drugs targeting p53 will also make progress. Given the prevalence of TP53 mutations in human cancers, drugs targeting p53 may bring a breakthrough in cancer therapy.

Acknowledgements

This work was financially supported by the Natural Science Foundation of China (No. 81570537, 81974074, 82172654, 82273496 and 31900880), Hunan Provincial Science and Technology Department (2018RS3026 and 2021RC4012) and Central South University Innovation-Driven Research Programme (2023CXQD077).

Author contributions

All authors were involved in the design of the review, and in writing the manuscript. All authors have read and approved the manuscript.

Competing interests

The authors declare no competing interests.
==== Refs
References

1. Kastenhuber ER Lowe SW Putting p53 in context Cell 2017 170 1062 1078 10.1016/j.cell.2017.08.028 28886379
Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017).28886379 10.1016/j.cell.2017.08.028
2. Levine AJ p53: 800 million years of evolution and 40 years of discovery Nat. Rev. Cancer 2020 20 471 480 10.1038/s41568-020-0262-1 32404993
Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471–480 (2020).32404993 10.1038/s41568-020-0262-1
3. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 578, 82–93 (2020).
4. Lawrence MS Discovery and saturation analysis of cancer genes across 21 tumour types Nature 2014 505 495 501 10.1038/nature12912 24390350
Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).24390350 10.1038/nature12912
5. Bykov VJN Eriksson SE Bianchi J Wiman KG Targeting mutant p53 for efficient cancer therapy Nat. Rev. Cancer. 2018 18 89 102 10.1038/nrc.2017.109 29242642
Bykov, V. J. N., Eriksson, S. E., Bianchi, J. & Wiman, K. G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer. 18, 89–102 (2018).29242642 10.1038/nrc.2017.109
6. Sullivan KD Galbraith MD Andrysik Z Espinosa JM Mechanisms of transcriptional regulation by p53 Cell Death Differ. 2018 25 133 143 10.1038/cdd.2017.174 29125602
Sullivan, K. D., Galbraith, M. D., Andrysik, Z. & Espinosa, J. M. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 25, 133–143 (2018).29125602 10.1038/cdd.2017.174
7. Sager R Tumor suppressor genes: the puzzle and the promise Science 1989 246 1406 1412 10.1126/science.2574499 2574499
Sager, R. Tumor suppressor genes: the puzzle and the promise. Science 246, 1406–1412 (1989).2574499 10.1126/science.2574499
8. Muller PAJ Vousden KH p53 mutations in cancer Nat. Cell Biol. 2013 15 2 8 10.1038/ncb2641 23263379
Muller, P. A. J. & Vousden, K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2–8 (2013).23263379 10.1038/ncb2641
9. Meek DW Tumour suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer 2009 9 714 723 10.1038/nrc2716 19730431
Meek, D. W. Tumour suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer 9, 714–723 (2009).19730431 10.1038/nrc2716
10. Wong KB Hot-spot mutants of p53 core domain evince characteristic local structural changes Proc. Natl. Acad. Sci. USA 1999 96 8438 8442 10.1073/pnas.96.15.8438 10411893
Wong, K. B. et al. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96, 8438–8442 (1999).10411893 10.1073/pnas.96.15.8438
11. Kitayner M Structural basis of DNA recognition by p53 tetramers Mol. Cell 2006 22 741 753 10.1016/j.molcel.2006.05.015 16793544
Kitayner, M. et al. Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22, 741–753 (2006).16793544 10.1016/j.molcel.2006.05.015
12. Joerger AC Fersht AR Structural biology of the tumor suppressor p53 and cancer-associated mutants Adv. Cancer Res. 2007 97 1 23 10.1016/S0065-230X(06)97001-8 17419939
Joerger, A. C. & Fersht, A. R. Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv. Cancer Res. 97, 1–23 (2007).17419939 10.1016/S0065-230X(06)97001-8
13. Loh SN Arsenic and an old place: rescuing p53 mutants in cancer Cancer Cell 2021 39 140 142 10.1016/j.ccell.2021.01.012 33561393
Loh, S. N. Arsenic and an old place: rescuing p53 mutants in cancer. Cancer Cell 39, 140–142 (2021).33561393 10.1016/j.ccell.2021.01.012
14. Linzer DI Levine AJ Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells Cell 1979 17 43 52 10.1016/0092-8674(79)90293-9 222475
Linzer, D. I. & Levine, A. J. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43–52 (1979).222475 10.1016/0092-8674(79)90293-9
15. Lane DP Crawford LV T antigen is bound to a host protein in SV40-transformed cells Nature 1979 278 261 263 10.1038/278261a0 218111
Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261–263 (1979).218111 10.1038/278261a0
16. Parada LF Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation Nature 1984 312 649 651 10.1038/312649a0 6390217
Parada, L. F. et al. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312, 649–651 (1984).6390217 10.1038/312649a0
17. Eliyahu D Michalovitz D Oren M Overproduction of p53 antigen makes established cells highly tumorigenic Nature 1985 316 158 160 10.1038/316158a0 3892307
Eliyahu, D., Michalovitz, D. & Oren, M. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316, 158–160 (1985).3892307 10.1038/316158a0
18. Lane DP Benchimol S p53: oncogene or anti-oncogene? Genes Dev. 1990 4 1 8 10.1101/gad.4.1.1 2137806
Lane, D. P. & Benchimol, S. p53: oncogene or anti-oncogene? Genes Dev. 4, 1–8 (1990).2137806 10.1101/gad.4.1.1
19. Nigro JM Mutations in the p53 gene occur in diverse human tumour types Nature 1989 342 705 708 10.1038/342705a0 2531845
Nigro, J. M. et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705–708 (1989).2531845 10.1038/342705a0
20. Cunningham J Expression of p53 and 17p allelic loss in colorectal carcinoma Cancer Res 1992 52 1974 1980 1551126
Cunningham, J. et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 52, 1974–1980 (1992).1551126
21. Hinds P Finlay C Levine AJ Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation J. Virol. 1989 63 739 746 10.1128/jvi.63.2.739-746.1989 2642977
Hinds, P., Finlay, C. & Levine, A. J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63, 739–746 (1989).2642977 10.1128/jvi.63.2.739-746.1989
22. Eliyahu D Meth A fibrosarcoma cells express two transforming mutant p53 species Oncogene 1988 3 313 321 3060794
Eliyahu, D. et al. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3, 313–321 (1988).3060794
23. Donehower LA Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 1992 356 215 221 10.1038/356215a0 1552940
Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992).1552940 10.1038/356215a0
24. Olivero CE p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis Mol. Cell. 2020 77 761 774 10.1016/j.molcel.2019.12.014 31973890
Olivero, C. E. et al. p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis. Mol. Cell. 77, 761–774 (2020).31973890 10.1016/j.molcel.2019.12.014
25. Yonish-Rouach E The role of p53 as a transcription factor in the induction of apoptosis Behring Inst. Mitt. 1996 97 60 71
Yonish-Rouach, E. et al. The role of p53 as a transcription factor in the induction of apoptosis. Behring Inst. Mitt. 97, 60–71 (1996).
26. Wei C-L A global map of p53 transcription-factor binding sites in the human genome Cell 2006 124 207 219 10.1016/j.cell.2005.10.043 16413492
Wei, C.-L. et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207–219 (2006).16413492 10.1016/j.cell.2005.10.043
27. Bieging KT Mello SS Attardi LD Unravelling mechanisms of p53-mediated tumour suppression Nat. Rev. Cancer 2014 14 359 370 10.1038/nrc3711 24739573
Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359–370 (2014).24739573 10.1038/nrc3711
28. Lakin N Jackson S Regulation of p53 in response to DNA damage Oncogene 1999 18 7644 7655 10.1038/sj.onc.1203015 10618704
Lakin, N. & Jackson, S. Regulation of p53 in response to DNA damage. Oncogene 18, 7644–7655 (1999).10618704 10.1038/sj.onc.1203015
29. Gu B Zhu W Surf the post-translational modification network of p53 regulation Int. J. Biol. Sci. 2012 8 672 684 10.7150/ijbs.4283 22606048
Gu, B. & Zhu, W. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 8, 672–684 (2012).22606048 10.7150/ijbs.4283
30. DeHart C Chahal J Flint S Perlman D Extensive post-translational modification of active and inactivated forms of endogenous p53 Mol. Cell Proteom. 2014 13 1 17 10.1074/mcp.M113.030254
DeHart, C., Chahal, J., Flint, S. & Perlman, D. Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol. Cell Proteom. 13, 1–17 (2014).10.1074/mcp.M113.030254
31. Chen L Liu S Tao Y Regulating tumor suppressor genes: post-translational modifications Signal Transduct. Target Ther. 2020 5 90 10.1038/s41392-020-0196-9 32532965
Chen, L., Liu, S. & Tao, Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct. Target Ther. 5, 90 (2020).32532965 10.1038/s41392-020-0196-9
32. Kruse J-P Gu W SnapShot: p53 posttranslational modifications Cell 2008 133 930 30 10.1016/j.cell.2008.05.020 18510935
Kruse, J.-P. & Gu, W. SnapShot: p53 posttranslational modifications. Cell 133, 930–30 (2008).18510935 10.1016/j.cell.2008.05.020
33. Aubrey B How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018 25 104 113 10.1038/cdd.2017.169 29149101
Aubrey, B. et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 25, 104–113 (2018).29149101 10.1038/cdd.2017.169
34. Vaddavalli P Schumacher B The p53 network: cellular and systemic DNA damage responses in cancer and aging Trends Genet 2022 38 598 612 10.1016/j.tig.2022.02.010 35346511
Vaddavalli, P. & Schumacher, B. The p53 network: cellular and systemic DNA damage responses in cancer and aging. Trends Genet 38, 598–612 (2022).35346511 10.1016/j.tig.2022.02.010
35. Ma M p53 positively regulates the proliferation of hepatic progenitor cells promoted by laminin-521 Signal Transduct. Target Ther. 2022 7 290 10.1038/s41392-022-01107-7 36042225
Ma, M. et al. p53 positively regulates the proliferation of hepatic progenitor cells promoted by laminin-521. Signal Transduct. Target Ther. 7, 290 (2022).36042225 10.1038/s41392-022-01107-7
36. Mihara M p53 has a direct apoptogenic role at the mitochondria Mol. Cell. 2003 11 577 590 10.1016/S1097-2765(03)00050-9 12667443
Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell. 11, 577–590 (2003).12667443 10.1016/S1097-2765(03)00050-9
37. Chipuk JE Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis Science 2004 303 1010 1014 10.1126/science.1092734 14963330
Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010–1014 (2004).14963330 10.1126/science.1092734
38. Miyashita T Reed JC Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 1995 80 293 299 10.1016/0092-8674(95)90412-3 7834749
Miyashita, T. & Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293–299 (1995).7834749 10.1016/0092-8674(95)90412-3
39. Seoane J Le H-V Massagué J Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage Nature 2002 419 729 734 10.1038/nature01119 12384701
Seoane, J., Le, H.-V. & Massagué, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002).12384701 10.1038/nature01119
40. Engeland K Cell cycle regulation: p53-p21-RB signaling Cell Death Differ. 2022 29 946 960 10.1038/s41418-022-00988-z 35361964
Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29, 946–960 (2022).35361964 10.1038/s41418-022-00988-z
41. Hafner A Bulyk M Jambhekar A Lahav G The multiple mechanisms that regulate p53 activity and cell fate Nat. Rev. Mol. Cell Biol. 2019 20 199 210 10.1038/s41580-019-0110-x 30824861
Hafner, A., Bulyk, M., Jambhekar, A. & Lahav, G. The multiple mechanisms that regulate p53 activity and cell fate. Nat. Rev. Mol. Cell Biol. 20, 199–210 (2019).30824861 10.1038/s41580-019-0110-x
42. Sherr CJ McCormick F The RB and p53 pathways in cancer Cancer Cell 2002 2 103 112 10.1016/S1535-6108(02)00102-2 12204530
Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103–112 (2002).12204530 10.1016/S1535-6108(02)00102-2
43. Sancar A DNA repair in humans Annu. Rev. Genet. 1995 29 69 105 10.1146/annurev.ge.29.120195.000441 8825469
Sancar, A. DNA repair in humans. Annu. Rev. Genet. 29, 69–105 (1995).8825469 10.1146/annurev.ge.29.120195.000441
44. Sancar A Lindsey-Boltz LA Unsal-Kaçmaz K Linn S Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annu. Rev. Biochem. 2004 73 39 85 10.1146/annurev.biochem.73.011303.073723 15189136
Sancar, A., Lindsey-Boltz, L. A., Unsal-Kaçmaz, K. & Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39–85 (2004).15189136 10.1146/annurev.biochem.73.011303.073723
45. Jiang L Ferroptosis as a p53-mediated activity during tumour suppression Nature 2015 520 57 62 10.1038/nature14344 25799988
Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).25799988 10.1038/nature14344
46. Liu Y Gu W The complexity of p53-mediated metabolic regulation in tumor suppression Semin. Cancer Biol. 2021 85 4 32 10.1016/j.semcancer.2021.03.010 33785447
Liu, Y. & Gu, W. The complexity of p53-mediated metabolic regulation in tumor suppression. Semin. Cancer Biol. 85, 4–32 (2021).33785447 10.1016/j.semcancer.2021.03.010
47. Blagih J Buck MD Vousden KH p53, cancer and the immune response J. Cell Sci. 2020 133 jcs237453 10.1242/jcs.237453 32144194
Blagih, J., Buck, M. D. & Vousden, K. H. p53, cancer and the immune response. J. Cell Sci. 133, jcs237453 (2020).32144194 10.1242/jcs.237453
48. Spike BT Wahl GM p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome Genes Cancer 2011 2 404 419 10.1177/1947601911410224 21779509
Spike, B. T. & Wahl, G. M. p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. Genes Cancer 2, 404–419 (2011).21779509 10.1177/1947601911410224
49. White E Autophagy and p53 Cold Spring Harb. Perspect. Med. 2016 6 a026120 10.1101/cshperspect.a026120 27037419
White, E. Autophagy and p53. Cold Spring Harb. Perspect. Med. 6, a026120 (2016).27037419 10.1101/cshperspect.a026120
50. Mrakovcic M Fröhlich L p53-mediated molecular control of autophagy in tumor cells Biomolecules 2018 8 14 10.3390/biom8020014 29561758
Mrakovcic, M. & Fröhlich, L. p53-mediated molecular control of autophagy in tumor cells. Biomolecules 8, 14 (2018).29561758 10.3390/biom8020014
51. Williams AB Schumacher B p53 in the DNA-damage-repair process Cold Spring Harb. Perspect. Med. 2016 6 a026070 10.1101/cshperspect.a026070 27048304
Williams, A. B. & Schumacher, B. p53 in the DNA-damage-repair process. Cold Spring Harb. Perspect. Med. 6, a026070 (2016).27048304 10.1101/cshperspect.a026070
52. Adimoolam S Ford JM p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene Proc. Natl. Acad. Sci. USA 2002 99 12985 12990 10.1073/pnas.202485699 12242345
Adimoolam, S. & Ford, J. M. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc. Natl. Acad. Sci. USA 99, 12985–12990 (2002).12242345 10.1073/pnas.202485699
53. Zebian A XPC multifaceted roles beyond DNA damage repair: p53-dependent and p53-independent functions of XPC in cell fate decisions Mutat. Res. Rev. Mutat. Res. 2022 789 108400 10.1016/j.mrrev.2021.108400 35690409
Zebian, A. et al. XPC multifaceted roles beyond DNA damage repair: p53-dependent and p53-independent functions of XPC in cell fate decisions. Mutat. Res. Rev. Mutat. Res. 789, 108400 (2022).35690409 10.1016/j.mrrev.2021.108400
54. Sugasawa K Regulation of damage recognition in mammalian global genomic nucleotide excision repair Mutat. Res. 2010 685 29 37 10.1016/j.mrfmmm.2009.08.004 19682467
Sugasawa, K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat. Res. 685, 29–37 (2010).19682467 10.1016/j.mrfmmm.2009.08.004
55. el-Deiry WS WAF1, a potential mediator of p53 tumor suppression Cell 1993 75 817 825 10.1016/0092-8674(93)90500-P 8242752
el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993).8242752 10.1016/0092-8674(93)90500-P
56. Narasimha AM Cyclin D activates the Rb tumor suppressor by mono-phosphorylation Elife 2014 3 e02872 10.7554/eLife.02872 24876129
Narasimha, A. M. et al. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife 3, e02872 (2014).24876129 10.7554/eLife.02872
57. Prall OW Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2 J. Biol. Chem. 1997 272 10882 10894 10.1074/jbc.272.16.10882 9099745
Prall, O. W. et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272, 10882–10894 (1997).9099745 10.1074/jbc.272.16.10882
58. Harper JW The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 1993 75 805 816 10.1016/0092-8674(93)90499-G 8242751
Harper, J. W. et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816 (1993).8242751 10.1016/0092-8674(93)90499-G
59. Stevaux O Dyson NJ A revised picture of the E2F transcriptional network and RB function Curr. Opin. Cell Biol. 2002 14 684 691 10.1016/S0955-0674(02)00388-5 12473340
Stevaux, O. & Dyson, N. J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14, 684–691 (2002).12473340 10.1016/S0955-0674(02)00388-5
60. Basak S The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation Mol. Cell. 2008 30 303 314 10.1016/j.molcel.2008.04.002 18471976
Basak, S. et al. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol. Cell. 30, 303–314 (2008).18471976 10.1016/j.molcel.2008.04.002
61. Doumont G Martoriati A Marine J-C PTPRV is a key mediator of p53-induced cell cycle exit Cell Cycle 2005 4 1703 1705 10.4161/cc.4.12.2207 16258284
Doumont, G., Martoriati, A. & Marine, J.-C. PTPRV is a key mediator of p53-induced cell cycle exit. Cell Cycle 4, 1703–1705 (2005).16258284 10.4161/cc.4.12.2207
62. Fischer M Quaas M Steiner L Engeland K The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes Nucleic Acids Res 2016 44 164 174 10.1093/nar/gkv927 26384566
Fischer, M., Quaas, M., Steiner, L. & Engeland, K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res 44, 164–174 (2016).26384566 10.1093/nar/gkv927
63. Taylor WR Stark GR Regulation of the G2/M transition by p53 Oncogene 2001 20 1803 1815 10.1038/sj.onc.1204252 11313928
Taylor, W. R. & Stark, G. R. Regulation of the G2/M transition by p53. Oncogene 20, 1803–1815 (2001).11313928 10.1038/sj.onc.1204252
64. Hermeking H 14-3-3sigma is a p53-regulated inhibitor of G2/M progression Mol. Cell. 1997 1 3 11 10.1016/S1097-2765(00)80002-7 9659898
Hermeking, H. et al. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1, 3–11 (1997).9659898 10.1016/S1097-2765(00)80002-7
65. Wang XW GADD45 induction of a G2/M cell cycle checkpoint Proc. Natl. Acad. Sci. USA 1999 96 3706 3711 10.1073/pnas.96.7.3706 10097101
Wang, X. W. et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc. Natl. Acad. Sci. USA 96, 3706–3711 (1999).10097101 10.1073/pnas.96.7.3706
66. Ohki R Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase J. Biol. Chem. 2000 275 22627 22630 10.1074/jbc.C000235200 10930422
Ohki, R. et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J. Biol. Chem. 275, 22627–22630 (2000).10930422 10.1074/jbc.C000235200
67. Eischen CM Genome Stability Requires p53 Cold Spring Harb. Perspect. Med. 2016 6 a026096 10.1101/cshperspect.a026096 27252396
Eischen, C. M. Genome Stability Requires p53. Cold Spring Harb. Perspect. Med. 6, a026096 (2016).27252396 10.1101/cshperspect.a026096
68. Oda E Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis Science 2000 288 1053 1058 10.1126/science.288.5468.1053 10807576
Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053–1058 (2000).10807576 10.1126/science.288.5468.1053
69. Nakano K Vousden KH PUMA, a novel proapoptotic gene, is induced by p53 Mol. Cell. 2001 7 683 694 10.1016/S1097-2765(01)00214-3 11463392
Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell. 7, 683–694 (2001).11463392 10.1016/S1097-2765(01)00214-3
70. Chen Y Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion Nucleic Acids Res 2013 41 8368 8376 10.1093/nar/gkt584 23836939
Chen, Y. et al. Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Res 41, 8368–8376 (2013).23836939 10.1093/nar/gkt584
71. Wei H Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis Nat. Commun. 2021 12 2280 10.1038/s41467-021-22655-6 33863900
Wei, H. et al. Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nat. Commun. 12, 2280 (2021).33863900 10.1038/s41467-021-22655-6
72. Leu JIJ Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex Nat. Cell Biol. 2004 6 443 450 10.1038/ncb1123 15077116
Leu, J. I. J. et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6, 443–450 (2004).15077116 10.1038/ncb1123
73. Bommer GT p53-mediated activation of miRNA34 candidate tumor-suppressor genes Curr. Biol. 2007 17 1298 1307 10.1016/j.cub.2007.06.068 17656095
Bommer, G. T. et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17, 1298–1307 (2007).17656095 10.1016/j.cub.2007.06.068
74. Tarasov V Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest Cell Cycle 2007 6 1586 1593 10.4161/cc.6.13.4436 17554199
Tarasov, V. et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6, 1586–1593 (2007).17554199 10.4161/cc.6.13.4436
75. Wu GS Kim K el-Deiry WS KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death Adv. Exp. Med. Biol. 2000 465 143 151 10.1007/0-306-46817-4_13 10810622
Wu, G. S., Kim, K. & el-Deiry, W. S. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv. Exp. Med. Biol. 465, 143–151 (2000).10810622 10.1007/0-306-46817-4_13
76. Maecker HL Koumenis C Giaccia AJ p53 promotes selection for Fas-mediated apoptotic resistance Cancer Res 2000 60 4638 4644 10969818
Maecker, H. L., Koumenis, C. & Giaccia, A. J. p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res 60, 4638–4644 (2000).10969818
77. Müller M p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs J. Exp. Med 1998 188 2033 2045 10.1084/jem.188.11.2033 9841917
Müller, M. et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med 188, 2033–2045 (1998).9841917 10.1084/jem.188.11.2033
78. Allen MA Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms Elife 2014 3 e02200 10.7554/eLife.02200 24867637
Allen, M. A. et al. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife 3, e02200 (2014).24867637 10.7554/eLife.02200
79. Cordaux R Batzer MA The impact of retrotransposons on human genome evolution Nat. Rev. Genet. 2009 10 691 703 10.1038/nrg2640 19763152
Cordaux, R. & Batzer, M. A. The impact of retrotransposons on human genome evolution. Nat. Rev. Genet. 10, 691–703 (2009).19763152 10.1038/nrg2640
80. Tiwari B Jones AE Abrams JM Transposons, p53 and Genome Security Trends Genet 2018 34 846 855 10.1016/j.tig.2018.08.003 30195581
Tiwari, B., Jones, A. E. & Abrams, J. M. Transposons, p53 and Genome Security. Trends Genet 34, 846–855 (2018).30195581 10.1016/j.tig.2018.08.003
81. Harris CR p53 responsive elements in human retrotransposons Oncogene 2009 28 3857 3865 10.1038/onc.2009.246 19718052
Harris, C. R. et al. p53 responsive elements in human retrotransposons. Oncogene 28, 3857–3865 (2009).19718052 10.1038/onc.2009.246
82. Haoudi A Semmes OJ Mason JM Cannon RE Retrotransposition-Competent Human LINE-1 Induces Apoptosis in Cancer Cells With Intact p53 J. Biomed. Biotechnol. 2004 2004 185 194 15467158
Haoudi, A., Semmes, O. J., Mason, J. M. & Cannon, R. E. Retrotransposition-Competent Human LINE-1 Induces Apoptosis in Cancer Cells With Intact p53. J. Biomed. Biotechnol. 2004, 185–194 (2004).15467158
83. Zuckerman V Tumour suppression by p53: the importance of apoptosis and cellular senescence J. Pathol. 2009 219 3 15 10.1002/path.2584 19562738
Zuckerman, V. et al. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J. Pathol. 219, 3–15 (2009).19562738 10.1002/path.2584
84. Schmitt CA A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy Cell 2002 109 335 346 10.1016/S0092-8674(02)00734-1 12015983
Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002).12015983 10.1016/S0092-8674(02)00734-1
85. Mijit M Role of p53 in the regulation of cellular senescence Biomolecules 2020 10 420 10.3390/biom10030420 32182711
Mijit, M. et al. Role of p53 in the regulation of cellular senescence. Biomolecules 10, 420 (2020).32182711 10.3390/biom10030420
86. Abuetabh Y DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities Exp. Mol. Med. 2022 54 1658 1669 10.1038/s12276-022-00863-4 36207426
Abuetabh, Y. et al. DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. Exp. Mol. Med. 54, 1658–1669 (2022).36207426 10.1038/s12276-022-00863-4
87. Capuozzo M p53: from fundamental biology to clinical applications in cancer Biology 2022 11 1325 10.3390/biology11091325 36138802
Capuozzo, M. et al. p53: from fundamental biology to clinical applications in cancer. Biology 11, 1325 (2022).36138802 10.3390/biology11091325
88. Kortlever RM Higgins PJ Bernards R Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence Nat. Cell Biol. 2006 8 877 884 10.1038/ncb1448 16862142
Kortlever, R. M., Higgins, P. J. & Bernards, R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8, 877–884 (2006).16862142 10.1038/ncb1448
89. Pearson M PML regulates p53 acetylation and premature senescence induced by oncogenic Ras Nature 2000 406 207 210 10.1038/35018127 10910364
Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207–210 (2000).10910364 10.1038/35018127
90. Warburg O Wind F Negelein E The metabolism of tumors in the body J. Gen. Physiol. 1927 8 519 530 10.1085/jgp.8.6.519 19872213
Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).19872213 10.1085/jgp.8.6.519
91. Devic S Warburg effect—a consequence or the cause of carcinogenesis? J. Cancer 2016 7 817 822 10.7150/jca.14274 27162540
Devic, S. Warburg effect—a consequence or the cause of carcinogenesis? J. Cancer 7, 817–822 (2016).27162540 10.7150/jca.14274
92. Matoba S p53 regulates mitochondrial respiration Science 2006 312 1650 1653 10.1126/science.1126863 16728594
Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650–1653 (2006).16728594 10.1126/science.1126863
93. Bensaad K TIGAR, a p53-inducible regulator of glycolysis and apoptosis Cell 2006 126 107 120 10.1016/j.cell.2006.05.036 16839880
Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120 (2006).16839880 10.1016/j.cell.2006.05.036
94. Zhang C Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect Proc. Natl. Acad. Sci. USA 2011 108 16259 16264 10.1073/pnas.1113884108 21930938
Zhang, C. et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl. Acad. Sci. USA 108, 16259–16264 (2011).21930938 10.1073/pnas.1113884108
95. Jiang P p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase Nat. Cell Biol. 2011 13 310 316 10.1038/ncb2172 21336310
Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13, 310–316 (2011).21336310 10.1038/ncb2172
96. Li Q Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer Nat. Commun. 2020 11 1456 10.1038/s41467-020-15308-7 32193458
Li, Q. et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat. Commun. 11, 1456 (2020).32193458 10.1038/s41467-020-15308-7
97. Schwartzenberg-Bar-Yoseph F Armoni M Karnieli E The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression Cancer Res 2004 64 2627 2633 10.1158/0008-5472.CAN-03-0846 15059920
Schwartzenberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64, 2627–2633 (2004).15059920 10.1158/0008-5472.CAN-03-0846
98. Boidot R Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors Cancer Res 2012 72 939 948 10.1158/0008-5472.CAN-11-2474 22184616
Boidot, R. et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res 72, 939–948 (2012).22184616 10.1158/0008-5472.CAN-11-2474
99. Ward PS Thompson CB Metabolic reprogramming: a cancer hallmark even warburg did not anticipate Cancer Cell 2012 21 297 308 10.1016/j.ccr.2012.02.014 22439925
Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297–308 (2012).22439925 10.1016/j.ccr.2012.02.014
100. Zawacka-Pankau J Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer J. Biol. Chem. 2011 286 41600 41615 10.1074/jbc.M111.240812 21862591
Zawacka-Pankau, J. et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J. Biol. Chem. 286, 41600–41615 (2011).21862591 10.1074/jbc.M111.240812
101. Zhang C Tumour-associated mutant p53 drives the Warburg effect Nat. Commun. 2013 4 2935 10.1038/ncomms3935 24343302
Zhang, C. et al. Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 4, 2935 (2013).24343302 10.1038/ncomms3935
102. Basu S Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α Genes Dev. 2018 32 230 243 10.1101/gad.309062.117 29463573
Basu, S. et al. Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. Genes Dev. 32, 230–243 (2018).29463573 10.1101/gad.309062.117
103. Wang P-Y Increased oxidative metabolism in the Li-Fraumeni syndrome N. Engl. J. Med. 2013 368 1027 1032 10.1056/NEJMoa1214091 23484829
Wang, P.-Y. et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N. Engl. J. Med. 368, 1027–1032 (2013).23484829 10.1056/NEJMoa1214091
104. Snaebjornsson MT Janaki-Raman S Schulze A Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer Cell Metab. 2020 31 62 76 10.1016/j.cmet.2019.11.010 31813823
Snaebjornsson, M. T., Janaki-Raman, S. & Schulze, A. Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metab. 31, 62–76 (2020).31813823 10.1016/j.cmet.2019.11.010
105. Moon S-H p53 represses the mevalonate pathway to mediate tumor suppression Cell 2019 176 564 580 10.1016/j.cell.2018.11.011 30580964
Moon, S.-H. et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell 176, 564–580 (2019).30580964 10.1016/j.cell.2018.11.011
106. Zhu, Y. et al. P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology, (2022).
107. Kruiswijk F Labuschagne CF Vousden KH p53 in survival, death and metabolic health: a lifeguard with a licence to kill Nat. Rev. Mol. Cell Biol. 2015 16 393 405 10.1038/nrm4007 26122615
Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16, 393–405 (2015).26122615 10.1038/nrm4007
108. Spinelli JB Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass Science 2017 358 941 946 10.1126/science.aam9305 29025995
Spinelli, J. B. et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science 358, 941–946 (2017).29025995 10.1126/science.aam9305
109. Zhang T Metformin inhibits the urea cycle and reduces putrescine generation in colorectal cancer cell lines Molecules 2021 26 1990 10.3390/molecules26071990 33915902
Zhang, T. et al. Metformin inhibits the urea cycle and reduces putrescine generation in colorectal cancer cell lines. Molecules 26, 1990 (2021).33915902 10.3390/molecules26071990
110. Li L p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis Nature 2019 567 253 256 10.1038/s41586-019-0996-7 30842655
Li, L. et al. p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis. Nature 567, 253–256 (2019).30842655 10.1038/s41586-019-0996-7
111. Cheung EC Vousden KH The role of ROS in tumour development and progression Nat. Rev. Cancer 2022 22 280 297 10.1038/s41568-021-00435-0 35102280
Cheung, E. C. & Vousden, K. H. The role of ROS in tumour development and progression. Nat. Rev. Cancer 22, 280–297 (2022).35102280 10.1038/s41568-021-00435-0
112. Liu B Chen Y St Clair DK ROS and p53: a versatile partnership Free Radic. Biol. Med. 2008 44 1529 1535 10.1016/j.freeradbiomed.2008.01.011 18275858
Liu, B., Chen, Y. & St Clair, D. K. ROS and p53: a versatile partnership. Free Radic. Biol. Med. 44, 1529–1535 (2008).18275858 10.1016/j.freeradbiomed.2008.01.011
113. Hussain SP p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis Cancer Res 2004 64 2350 2356 10.1158/0008-5472.CAN-2287-2 15059885
Hussain, S. P. et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 64, 2350–2356 (2004).15059885 10.1158/0008-5472.CAN-2287-2
114. Sablina AA The antioxidant function of the p53 tumor suppressor Nat. Med. 2005 11 1306 1313 10.1038/nm1320 16286925
Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11, 1306–1313 (2005).16286925 10.1038/nm1320
115. Humpton TJ Vousden KH Regulation of cellular metabolism and hypoxia by p53 Cold Spring Harb. Perspect. Med 2016 6 a026146 10.1101/cshperspect.a026146 27371670
Humpton, T. J. & Vousden, K. H. Regulation of cellular metabolism and hypoxia by p53. Cold Spring Harb. Perspect. Med 6, a026146 (2016).27371670 10.1101/cshperspect.a026146
116. Liu G Chen X The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis Oncogene 2002 21 7195 7204 10.1038/sj.onc.1205862 12370809
Liu, G. & Chen, X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21, 7195–7204 (2002).12370809 10.1038/sj.onc.1205862
117. Kim J Wild-Type p53 Promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation Cancer Cell. 2019 35 191 203 10.1016/j.ccell.2018.12.012 30712844
Kim, J. et al. Wild-Type p53 Promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation. Cancer Cell. 35, 191–203 (2019).30712844 10.1016/j.ccell.2018.12.012
118. Suzuki S Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species Proc. Natl. Acad. Sci. USA 2010 107 7461 7466 10.1073/pnas.1002459107 20351271
Suzuki, S. et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA 107, 7461–7466 (2010).20351271 10.1073/pnas.1002459107
119. Gallo O Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma Am. J. Pathol. 2003 163 723 732 10.1016/S0002-9440(10)63699-1 12875991
Gallo, O. et al. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am. J. Pathol. 163, 723–732 (2003).12875991 10.1016/S0002-9440(10)63699-1
120. Italiano D Lena AM Melino G Candi E Identification of NCF2/p67phox as a novel p53 target gene Cell Cycle 2012 11 4589 4596 10.4161/cc.22853 23187810
Italiano, D., Lena, A. M., Melino, G. & Candi, E. Identification of NCF2/p67phox as a novel p53 target gene. Cell Cycle 11, 4589–4596 (2012).23187810 10.4161/cc.22853
121. Faraonio R p53 suppresses the Nrf2-dependent transcription of antioxidant response genes J. Biol. Chem. 2006 281 39776 39784 10.1074/jbc.M605707200 17077087
Faraonio, R. et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J. Biol. Chem. 281, 39776–39784 (2006).17077087 10.1074/jbc.M605707200
122. Reddy BA Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization Mol. Cell. 2014 53 458 470 10.1016/j.molcel.2013.12.017 24462112
Reddy, B. A. et al. Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization. Mol. Cell. 53, 458–470 (2014).24462112 10.1016/j.molcel.2013.12.017
123. Stockwell BR Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications Cell 2022 185 2401 2421 10.1016/j.cell.2022.06.003 35803244
Stockwell, B. R. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401–2421 (2022).35803244 10.1016/j.cell.2022.06.003
124. Yan H-F Ferroptosis: mechanisms and links with diseases Signal Transduct. Target Ther. 2021 6 49 10.1038/s41392-020-00428-9 33536413
Yan, H.-F. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct. Target Ther. 6, 49 (2021).33536413 10.1038/s41392-020-00428-9
125. Dixon SJ Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 1072 10.1016/j.cell.2012.03.042 22632970
Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).22632970 10.1016/j.cell.2012.03.042
126. Wang S-J Acetylation is crucial for p53-mediated ferroptosis and tumor suppression Cell Rep. 2016 17 366 373 10.1016/j.celrep.2016.09.022 27705786
Wang, S.-J. et al. Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 17, 366–373 (2016).27705786 10.1016/j.celrep.2016.09.022
127. Liu Y Gu W p53 in ferroptosis regulation: the new weapon for the old guardian Cell Death Differ. 2022 29 895 910 10.1038/s41418-022-00943-y 35087226
Liu, Y. & Gu, W. p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death Differ. 29, 895–910 (2022).35087226 10.1038/s41418-022-00943-y
128. Li T Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence Cell 2012 149 1269 1283 10.1016/j.cell.2012.04.026 22682249
Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269–1283 (2012).22682249 10.1016/j.cell.2012.04.026
129. Wang Y Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53 EMBO Rep. 2019 20 e47563 10.15252/embr.201847563 31267712
Wang, Y. et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 20, e47563 (2019).31267712 10.15252/embr.201847563
130. Ou Y Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses Proc. Natl Acad. Sci. USA 2016 113 E6806 E6812 10.1073/pnas.1607152113 27698118
Ou, Y. et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl Acad. Sci. USA 113, E6806–E6812 (2016).27698118 10.1073/pnas.1607152113
131. Chu B ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway Nat. Cell Biol. 2019 21 579 591 10.1038/s41556-019-0305-6 30962574
Chu, B. et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat. Cell Biol. 21, 579–591 (2019).30962574 10.1038/s41556-019-0305-6
132. Liu J The regulation of ferroptosis by tumor suppressor p53 and its pathway Int. J. Mol. Sci. 2020 21 8387 10.3390/ijms21218387 33182266
Liu, J. et al. The regulation of ferroptosis by tumor suppressor p53 and its pathway. Int. J. Mol. Sci. 21, 8387 (2020).33182266 10.3390/ijms21218387
133. Xie Y The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity Cell Rep. 2017 20 1692 1704 10.1016/j.celrep.2017.07.055 28813679
Xie, Y. et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 20, 1692–1704 (2017).28813679 10.1016/j.celrep.2017.07.055
134. Tarangelo A p53 suppresses metabolic stress-induced ferroptosis in cancer cells Cell Rep. 2018 22 569 575 10.1016/j.celrep.2017.12.077 29346757
Tarangelo, A. et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 22, 569–575 (2018).29346757 10.1016/j.celrep.2017.12.077
135. Venkatesh D Stockwell BR Prives C p21 can be a barrier to ferroptosis independent of p53 Aging 2020 12 17800 17814 10.18632/aging.103961 32979260
Venkatesh, D., Stockwell, B. R. & Prives, C. p21 can be a barrier to ferroptosis independent of p53. Aging 12, 17800–17814 (2020).32979260 10.18632/aging.103961
136. Lujambio A Non-cell-autonomous tumor suppression by p53 Cell 2013 153 449 460 10.1016/j.cell.2013.03.020 23562644
Lujambio, A. et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449–460 (2013).23562644 10.1016/j.cell.2013.03.020
137. Menendez D p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus J. Clin. Invest 2019 129 4875 4884 10.1172/JCI128626 31430261
Menendez, D. et al. p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. J. Clin. Invest 129, 4875–4884 (2019).31430261 10.1172/JCI128626
138. Guo G Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity Cancer Res 2017 77 2292 2305 10.1158/0008-5472.CAN-16-2832 28280037
Guo, G. et al. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res 77, 2292–2305 (2017).28280037 10.1158/0008-5472.CAN-16-2832
139. Zhou X Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity Cancer Disco. 2021 11 3090 3105 10.1158/2159-8290.CD-20-1741
Zhou, X. et al. Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity. Cancer Disco. 11, 3090–3105 (2021).10.1158/2159-8290.CD-20-1741
140. Wang B Niu D Lai L Ren EC p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1 Nat. Commun. 2013 4 2359 10.1038/ncomms3359 23965983
Wang, B., Niu, D., Lai, L. & Ren, E. C. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat. Commun. 4, 2359 (2013).23965983 10.1038/ncomms3359
141. Xiao Y Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy Nat. Commun. 2022 13 758 10.1038/s41467-022-28279-8 35140208
Xiao, Y. et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat. Commun. 13, 758 (2022).35140208 10.1038/s41467-022-28279-8
142. Dong Z-Y Potential predictive value of and mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma Clin. Cancer Res 2017 23 3012 3024 10.1158/1078-0432.CCR-16-2554 28039262
Dong, Z.-Y. et al. Potential predictive value of and mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res 23, 3012–3024 (2017).28039262 10.1158/1078-0432.CCR-16-2554
143. Ubertini V Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist Oncogene 2015 34 2493 2504 10.1038/onc.2014.191 24998848
Ubertini, V. et al. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. Oncogene 34, 2493–2504 (2015).24998848 10.1038/onc.2014.191
144. Cooks T Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246 Nat. Commun. 2018 9 771 10.1038/s41467-018-03224-w 29472616
Cooks, T. et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018).29472616 10.1038/s41467-018-03224-w
145. Cooks T Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer Cancer Cell 2013 23 634 646 10.1016/j.ccr.2013.03.022 23680148
Cooks, T. et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634–646 (2013).23680148 10.1016/j.ccr.2013.03.022
146. Di Minin G Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP Mol. Cell 2014 56 617 629 10.1016/j.molcel.2014.10.013 25454946
Di Minin, G. et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol. Cell 56, 617–629 (2014).25454946 10.1016/j.molcel.2014.10.013
147. Song H Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis Proc. Natl Acad. Sci. USA 2012 109 17531 17536 10.1073/pnas.1207238109 23047698
Song, H. et al. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc. Natl Acad. Sci. USA 109, 17531–17536 (2012).23047698 10.1073/pnas.1207238109
148. Ouadah Y Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and Notch Cell 2019 179 403 416 10.1016/j.cell.2019.09.010 31585080
Ouadah, Y. et al. Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and Notch. Cell 179, 403–416 (2019).31585080 10.1016/j.cell.2019.09.010
149. George J Comprehensive genomic profiles of small cell lung cancer Nature 2015 524 47 53 10.1038/nature14664 26168399
George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).26168399 10.1038/nature14664
150. Cicalese A The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells Cell 2009 138 1083 1095 10.1016/j.cell.2009.06.048 19766563
Cicalese, A. et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138, 1083–1095 (2009).19766563 10.1016/j.cell.2009.06.048
151. Zhou Z Flesken-Nikitin A Nikitin AY Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts Cancer Res 2007 67 5683 5690 10.1158/0008-5472.CAN-07-0768 17553900
Zhou, Z., Flesken-Nikitin, A. & Nikitin, A. Y. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res. 67, 5683–5690 (2007).17553900 10.1158/0008-5472.CAN-07-0768
152. Flores I Blasco MA A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres PLoS One 2009 4 e4934 10.1371/journal.pone.0004934 19295915
Flores, I. & Blasco, M. A. A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres. PLoS One 4, e4934 (2009).19295915 10.1371/journal.pone.0004934
153. Zheng H p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation Nature 2008 455 1129 1133 10.1038/nature07443 18948956
Zheng, H. et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129–1133 (2008).18948956 10.1038/nature07443
154. Liu Y p53 regulates hematopoietic stem cell quiescence Cell Stem Cell 2009 4 37 48 10.1016/j.stem.2008.11.006 19128791
Liu, Y. et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4, 37–48 (2009).19128791 10.1016/j.stem.2008.11.006
155. Cheng T Hematopoietic stem cell quiescence maintained by p21cip1/waf1 Science 2000 287 1804 1808 10.1126/science.287.5459.1804 10710306
Cheng, T. et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287, 1804–1808 (2000).10710306 10.1126/science.287.5459.1804
156. van Os R A Limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning Stem Cells 2007 25 836 843 10.1634/stemcells.2006-0631 17170062
van Os, R. et al. A Limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells 25, 836–843 (2007).17170062 10.1634/stemcells.2006-0631
157. Shetzer Y Molchadsky A Rotter V Oncogenic mutant p53 gain of function nourishes the vicious cycle of tumor development and cancer stem-cell formation Cold Spring Harb. Perspect. Med. 2016 6 a026203 10.1101/cshperspect.a026203 27235476
Shetzer, Y., Molchadsky, A., & Rotter, V. Oncogenic mutant p53 gain of function nourishes the vicious cycle of tumor development and cancer stem-cell formation. Cold Spring Harb. Perspect. Med. 6, a026203 (2016).27235476 10.1101/cshperspect.a026203
158. Escoll M Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ Oncogene 2017 36 3515 3527 10.1038/onc.2016.518 28166194
Escoll, M. et al. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene 36, 3515–3527 (2017).28166194 10.1038/onc.2016.518
159. Loizou E A gain-of-function p53-Mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1 Cancer Disco. 2019 9 962 979 10.1158/2159-8290.CD-18-1391
Loizou, E. et al. A gain-of-function p53-Mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1. Cancer Disco. 9, 962–979 (2019).10.1158/2159-8290.CD-18-1391
160. Dongre A Weinberg RA New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer Nat. Rev. Mol. Cell Biol. 2019 20 69 84 10.1038/s41580-018-0080-4 30459476
Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019).30459476 10.1038/s41580-018-0080-4
161. Wang S-P p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug Nat. Cell Biol. 2009 11 694 704 10.1038/ncb1875 19448627
Wang, S.-P. et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 11, 694–704 (2009).19448627 10.1038/ncb1875
162. Kim NH A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition J. Cell Biol. 2011 195 417 433 10.1083/jcb.201103097 22024162
Kim, N. H. et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 195, 417–433 (2011).22024162 10.1083/jcb.201103097
163. Dong P Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis Oncogene 2013 32 3286 3295 10.1038/onc.2012.334 22847613
Dong, P. et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32, 3286–3295 (2013).22847613 10.1038/onc.2012.334
164. Chang C-J p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs Nat. Cell Biol. 2011 13 317 323 10.1038/ncb2173 21336307
Chang, C.-J. et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 13, 317–323 (2011).21336307 10.1038/ncb2173
165. Wang J Autophagy augments the self-renewal of lung cancer stem cells by the degradation of ubiquitinated p53 Cell Death Dis. 2021 12 98 10.1038/s41419-021-03392-6 33468994
Wang, J. et al. Autophagy augments the self-renewal of lung cancer stem cells by the degradation of ubiquitinated p53. Cell Death Dis. 12, 98 (2021).33468994 10.1038/s41419-021-03392-6
166. Klionsky DJ Autophagy in major human diseases EMBO J. 2021 40 e108863 10.15252/embj.2021108863 34459017
Klionsky, D. J. et al. Autophagy in major human diseases. EMBO J. 40, e108863 (2021).34459017 10.15252/embj.2021108863
167. Abida WM Gu W p53-Dependent and p53-independent activation of autophagy by ARF Cancer Res. 2008 68 352 357 10.1158/0008-5472.CAN-07-2069 18199527
Abida, W. M. & Gu, W. p53-Dependent and p53-independent activation of autophagy by ARF. Cancer Res. 68, 352–357 (2008).18199527 10.1158/0008-5472.CAN-07-2069
168. Crighton D DRAM, a p53-induced modulator of autophagy, is critical for apoptosis Cell 2006 126 121 134 10.1016/j.cell.2006.05.034 16839881
Crighton, D. et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126, 121–134 (2006).16839881 10.1016/j.cell.2006.05.034
169. Mrschtik M Ryan KM Another DRAM involved in autophagy and cell death Autophagy 2016 12 603 605 10.1080/15548627.2015.1137412 27046253
Mrschtik, M. & Ryan, K. M. Another DRAM involved in autophagy and cell death. Autophagy 12, 603–605 (2016).27046253 10.1080/15548627.2015.1137412
170. Levine B Kroemer G Biological functions of autophagy genes: a disease perspective Cell 2019 176 11 42 10.1016/j.cell.2018.09.048 30633901
Levine, B. & Kroemer, G. Biological functions of autophagy genes: a disease perspective. Cell 176, 11–42 (2019).30633901 10.1016/j.cell.2018.09.048
171. Kenzelmann Broz D Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses Genes Dev. 2013 27 1016 1031 10.1101/gad.212282.112 23651856
Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev. 27, 1016–1031 (2013).23651856 10.1101/gad.212282.112
172. Zheng W Inhibition of Cathepsin D (CTSD) enhances radiosensitivity of glioblastoma cells by attenuating autophagy Mol. Carcinog. 2020 59 651 660 10.1002/mc.23194 32253787
Zheng, W. et al. Inhibition of Cathepsin D (CTSD) enhances radiosensitivity of glioblastoma cells by attenuating autophagy. Mol. Carcinog. 59, 651–660 (2020).32253787 10.1002/mc.23194
173. Liu Y-J The noncanonical role of the protease cathepsin D as a cofilin phosphatase Cell Res. 2021 31 801 813 10.1038/s41422-020-00454-w 33514914
Liu, Y.-J. et al. The noncanonical role of the protease cathepsin D as a cofilin phosphatase. Cell Res. 31, 801–813 (2021).33514914 10.1038/s41422-020-00454-w
174. Wu GS Saftig P Peters C El-Deiry WS Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity Oncogene 1998 16 2177 2183 10.1038/sj.onc.1201755 9619826
Wu, G. S., Saftig, P., Peters, C. & El-Deiry, W. S. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16, 2177–2183 (1998).9619826 10.1038/sj.onc.1201755
175. Ikeguchi M Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma J. Clin. Pathol. 2002 55 121 126 10.1136/jcp.55.2.121 11865007
Ikeguchi, M. et al. Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma. J. Clin. Pathol. 55, 121–126 (2002).11865007 10.1136/jcp.55.2.121
176. Yeo SY Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation Elife 2016 5 e07101 10.7554/eLife.07101 26956429
Yeo, S. Y. et al. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation. Elife 5, e07101 (2016).26956429 10.7554/eLife.07101
177. Kim J Kundu M Viollet B Guan K-L AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 Nat. Cell Biol. 2011 13 132 141 10.1038/ncb2152 21258367
Kim, J., Kundu, M., Viollet, B. & Guan, K.-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132–141 (2011).21258367 10.1038/ncb2152
178. Budanov AV Karin M p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling Cell 2008 134 451 460 10.1016/j.cell.2008.06.028 18692468
Budanov, A. V. & Karin, M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451–460 (2008).18692468 10.1016/j.cell.2008.06.028
179. Kon N mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression Genes Dev. 2021 35 59 64 10.1101/gad.340919.120 33303641
Kon, N. et al. mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression. Genes Dev. 35, 59–64 (2021).33303641 10.1101/gad.340919.120
180. Chang HW p53/BNIP3-dependent mitophagy limits glycolytic shift in radioresistant cancer Oncogene 2019 38 3729 3742 10.1038/s41388-019-0697-6 30664690
Chang, H. W. et al. p53/BNIP3-dependent mitophagy limits glycolytic shift in radioresistant cancer. Oncogene 38, 3729–3742 (2019).30664690 10.1038/s41388-019-0697-6
181. Fernández ÁF Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice Nature 2018 558 136 140 10.1038/s41586-018-0162-7 29849149
Fernández, Á. F. et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature 558, 136–140 (2018).29849149 10.1038/s41586-018-0162-7
182. Lee EF Structural insights into BCL2 pro-survival protein interactions with the key autophagy regulator BECN1 following phosphorylation by STK4/MST1 Autophagy 2019 15 785 795 10.1080/15548627.2018.1564557 30626284
Lee, E. F. et al. Structural insights into BCL2 pro-survival protein interactions with the key autophagy regulator BECN1 following phosphorylation by STK4/MST1. Autophagy 15, 785–795 (2019).30626284 10.1080/15548627.2018.1564557
183. Feng W Huang S Wu H Zhang M Molecular basis of Bcl-xL’s target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1 J. Mol. Biol. 2007 372 223 235 10.1016/j.jmb.2007.06.069 17659302
Feng, W., Huang, S., Wu, H. & Zhang, M. Molecular basis of Bcl-xL’s target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1. J. Mol. Biol. 372, 223–235 (2007).17659302 10.1016/j.jmb.2007.06.069
184. Zheng R The status of p53 in cancer cells affects the role of autophagy in tumor radiosensitisation J. BUON 2014 19 336 341 24965389
Zheng, R. et al. The status of p53 in cancer cells affects the role of autophagy in tumor radiosensitisation. J. BUON 19, 336–341 (2014).24965389
185. Maiuri MC Autophagy regulation by p53 Curr. Opin. Cell Biol. 2010 22 181 185 10.1016/j.ceb.2009.12.001 20044243
Maiuri, M. C. et al. Autophagy regulation by p53. Curr. Opin. Cell Biol. 22, 181–185 (2010).20044243 10.1016/j.ceb.2009.12.001
186. Livesey KM p53/HMGB1 complexes regulate autophagy and apoptosis Cancer Res 2012 72 1996 2005 10.1158/0008-5472.CAN-11-2291 22345153
Livesey, K. M. et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 72, 1996–2005 (2012).22345153 10.1158/0008-5472.CAN-11-2291
187. Livesey KM Direct molecular interactions between HMGB1 and TP53 in colorectal cancer Autophagy 2012 8 846 848 10.4161/auto.19891 22647615
Livesey, K. M. et al. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 8, 846–848 (2012).22647615 10.4161/auto.19891
188. Yang Y Autophagy promotes mammalian survival by suppressing oxidative stress and p53 Genes Dev. 2020 34 688 p700 10.1101/gad.335570.119 32193353
Yang, Y. et al. Autophagy promotes mammalian survival by suppressing oxidative stress and p53. Genes Dev. 34, 688–p700 (2020).32193353 10.1101/gad.335570.119
189. Agupitan AD P53: a guardian of immunity becomes its saboteur through mutation Int. J. Mol. Sci. 2020 21 3452 10.3390/ijms21103452 32414156
Agupitan, A. D. et al. P53: a guardian of immunity becomes its saboteur through mutation. Int. J. Mol. Sci. 21, 3452 (2020).32414156 10.3390/ijms21103452
190. Levine A P53 and the immune response: 40 years of exploration-a plan for the future Int. J. Mol. Sci. 2020 21 541 10.3390/ijms21020541 31952115
Levine, A. P53 and the immune response: 40 years of exploration-a plan for the future. Int. J. Mol. Sci. 21, 541 (2020).31952115 10.3390/ijms21020541
191. Min E-Y The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines Int. J. Oncol. 2014 45 47 56 10.3892/ijo.2014.2426 24807532
Min, E.-Y. et al. The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines. Int. J. Oncol. 45, 47–56 (2014).24807532 10.3892/ijo.2014.2426
192. Winkler L Functional elements of the cis-regulatory lincRNA-p21 Cell Rep. 2022 39 110687 10.1016/j.celrep.2022.110687 35443176
Winkler, L. et al. Functional elements of the cis-regulatory lincRNA-p21. Cell Rep. 39, 110687 (2022).35443176 10.1016/j.celrep.2022.110687
193. Giacomelli AO Mutational processes shape the landscape of TP53 mutations in human cancer Nat. Genet. 2018 50 1381 1387 10.1038/s41588-018-0204-y 30224644
Giacomelli, A. O. et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet. 50, 1381–1387 (2018).30224644 10.1038/s41588-018-0204-y
194. Wellenstein MD Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis Nature 2019 572 538 542 10.1038/s41586-019-1450-6 31367040
Wellenstein, M. D. et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572, 538–542 (2019).31367040 10.1038/s41586-019-1450-6
195. Yang Y Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer Cell Death Differ. 2022 29 2177 2189 10.1038/s41418-022-01007-x 35484333
Yang, Y. et al. Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. Cell Death Differ. 29, 2177–2189 (2022).35484333 10.1038/s41418-022-01007-x
196. Makino Y Constitutive activation of the tumor suppressor p53 in hepatocytes paradoxically promotes non-cell autonomous liver carcinogenesis Cancer Res 2022 82 2860 2873 10.1158/0008-5472.CAN-21-4390 35696550
Makino, Y. et al. Constitutive activation of the tumor suppressor p53 in hepatocytes paradoxically promotes non-cell autonomous liver carcinogenesis. Cancer Res 82, 2860–2873 (2022).35696550 10.1158/0008-5472.CAN-21-4390
197. Hamarsheh SA Groß O Brummer T Zeiser R Immune modulatory effects of oncogenic KRAS in cancer Nat. Commun. 2020 11 5439 10.1038/s41467-020-19288-6 33116132
Hamarsheh, S. A., Groß, O., Brummer, T. & Zeiser, R. Immune modulatory effects of oncogenic KRAS in cancer. Nat. Commun. 11, 5439 (2020).33116132 10.1038/s41467-020-19288-6
198. Kandoth C Mutational landscape and significance across 12 major cancer types Nature 2013 502 333 339 10.1038/nature12634 24132290
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).24132290 10.1038/nature12634
199. de Andrade KC Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study Lancet Oncol. 2021 22 1787 1798 10.1016/S1470-2045(21)00580-5 34780712
de Andrade, K. C. et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 22, 1787–1798 (2021).34780712 10.1016/S1470-2045(21)00580-5
200. Freed-Pastor WA Prives C Mutant p53: one name, many proteins Genes Dev. 2012 26 1268 1286 10.1101/gad.190678.112 22713868
Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012).22713868 10.1101/gad.190678.112
201. Joerger AC Fersht AR The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches Annu. Rev. Biochem. 2016 85 375 404 10.1146/annurev-biochem-060815-014710 27145840
Joerger, A. C. & Fersht, A. R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu. Rev. Biochem. 85, 375–404 (2016).27145840 10.1146/annurev-biochem-060815-014710
202. Duffy MJ Synnott NC O’Grady S Crown J Targeting p53 for the treatment of cancer Semin. Cancer Biol. 2022 79 58 67 10.1016/j.semcancer.2020.07.005 32741700
Duffy, M. J., Synnott, N. C., O’Grady, S. & Crown, J. Targeting p53 for the treatment of cancer. Semin. Cancer Biol. 79, 58–67 (2022).32741700 10.1016/j.semcancer.2020.07.005
203. Baugh EH Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018 25 154 160 10.1038/cdd.2017.180 29099487
Baugh, E. H. et al. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 25, 154–160 (2018).29099487 10.1038/cdd.2017.180
204. Bullock AN Henckel J Fersht AR Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy Oncogene 2000 19 1245 1256 10.1038/sj.onc.1203434 10713666
Bullock, A. N., Henckel, J. & Fersht, A. R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245–1256 (2000).10713666 10.1038/sj.onc.1203434
205. Mantovani F Collavin L Del Sal G Mutant p53 as a guardian of the cancer cell Cell Death Differ. 2019 26 199 212 10.1038/s41418-018-0246-9 30538286
Mantovani, F., Collavin, L. & Del Sal, G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 26, 199–212 (2019).30538286 10.1038/s41418-018-0246-9
206. Yue X Mutant p53 in cancer: accumulation, gain-of-function, and therapy J. Mol. Biol. 2017 429 1595 1606 10.1016/j.jmb.2017.03.030 28390900
Yue, X. et al. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J. Mol. Biol. 429, 1595–1606 (2017).28390900 10.1016/j.jmb.2017.03.030
207. Hainaut P Pfeifer GP Somatic TP53 mutations in the era of genome sequencing Cold Spring Harb. Perspect. Med. 2016 6 a026179 10.1101/cshperspect.a026179 27503997
Hainaut, P. & Pfeifer, G. P. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb. Perspect. Med. 6, a026179 (2016).27503997 10.1101/cshperspect.a026179
208. Petitjean A Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database Hum. Mutat. 2007 28 622 629 10.1002/humu.20495 17311302
Petitjean, A. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622–629 (2007).17311302 10.1002/humu.20495
209. Petitjean A TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 2007 26 2157 2165 10.1038/sj.onc.1210302 17401424
Petitjean, A. et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157–2165 (2007).17401424 10.1038/sj.onc.1210302
210. Olivier M The IARC TP53 database: new online mutation analysis and recommendations to users Hum. Mutat. 2002 19 607 614 10.1002/humu.10081 12007217
Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607–614 (2002).12007217 10.1002/humu.10081
211. Pan J-W The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences Nat. Commun. 2020 11 6433 10.1038/s41467-020-20173-5 33353943
Pan, J.-W. et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat. Commun. 11, 6433 (2020).33353943 10.1038/s41467-020-20173-5
212. Matozaki T p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells Cancer Res 1992 52 4335 4341 1322785
Matozaki, T. et al. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 52, 4335–4341 (1992).1322785
213. Isaacs WB Carter BS Ewing CM Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles Cancer Res 1991 51 4716 4720 1873816
Isaacs, W. B., Carter, B. S. & Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51, 4716–4720 (1991).1873816
214. Menon AG Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis Proc. Natl. Acad. Sci. USA 1990 87 5435 5439 10.1073/pnas.87.14.5435 2142531
Menon, A. G. et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA 87, 5435–5439 (1990).2142531 10.1073/pnas.87.14.5435
215. Maxwell KN Inherited TP53 variants and risk of prostate cancer Eur. Urol. 2022 81 243 250 10.1016/j.eururo.2021.10.036 34863587
Maxwell, K. N. et al. Inherited TP53 variants and risk of prostate cancer. Eur. Urol. 81, 243–250 (2022).34863587 10.1016/j.eururo.2021.10.036
216. Malkin D Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 1990 250 1233 1238 10.1126/science.1978757 1978757
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).1978757 10.1126/science.1978757
217. McBride K Li-Fraumeni syndrome: cancer risk assessment and clinical management Nat. Rev. Clin. Oncol. 2014 11 260 271 10.1038/nrclinonc.2014.41 24642672
McBride, K. et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat. Rev. Clin. Oncol. 11, 260–271 (2014).24642672 10.1038/nrclinonc.2014.41
218. Baker SJ Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas Science 1989 244 217 221 10.1126/science.2649981 2649981
Baker, S. J. et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217–221 (1989).2649981 10.1126/science.2649981
219. Kashkin KN Fleĭshman EV Chumakov PM Perevoshchikov AG Genetic alterations in the region of the p53 gene on human chromosome 17 in colorectal cancer Genetika 1998 34 1049 1055 9777351
Kashkin, K. N., Fleĭshman, E. V., Chumakov, P. M. & Perevoshchikov, A. G. Genetic alterations in the region of the p53 gene on human chromosome 17 in colorectal cancer. Genetika 34, 1049–1055 (1998).9777351
220. Cooper MJ p53 mutations in bladder carcinoma cell lines Oncol. Res. 1994 6 569 579 7787250
Cooper, M. J. et al. p53 mutations in bladder carcinoma cell lines. Oncol. Res. 6, 569–579 (1994).7787250
221. Goh AM Coffill CR Lane DP The role of mutant p53 in human cancer J. Pathol. 2011 223 116 126 10.1002/path.2784 21125670
Goh, A. M., Coffill, C. R. & Lane, D. P. The role of mutant p53 in human cancer. J. Pathol. 223, 116–126 (2011).21125670 10.1002/path.2784
222. Dittmer D Gain of function mutations in p53 Nat. Genet. 1993 4 42 46 10.1038/ng0593-42 8099841
Dittmer, D. et al. Gain of function mutations in p53. Nat. Genet. 4, 42–46 (1993).8099841 10.1038/ng0593-42
223. Ghosh M Mutant p53 suppresses innate immune signaling to promote tumorigenesis Cancer Cell. 2021 39 494 508 10.1016/j.ccell.2021.01.003 33545063
Ghosh, M. et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 39, 494–508 (2021).33545063 10.1016/j.ccell.2021.01.003
224. Sethi NS Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model Nat. Genet. 2020 52 219 230 10.1038/s41588-019-0574-9 32025000
Sethi, N. S. et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat. Genet. 52, 219–230 (2020).32025000 10.1038/s41588-019-0574-9
225. Donehower LA Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas Cell Rep. 2019 28 3010 10.1016/j.celrep.2019.08.061 31509758
Donehower, L. A. et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 28, 3010 (2019).31509758 10.1016/j.celrep.2019.08.061
226. Hanel W Moll UM Links between mutant p53 and genomic instability J. Cell. Biochem. 2012 113 433 439 10.1002/jcb.23400 22006292
Hanel, W. & Moll, U. M. Links between mutant p53 and genomic instability. J. Cell. Biochem. 113, 433–439 (2012).22006292 10.1002/jcb.23400
227. Lengauer C Kinzler KW Vogelstein B Genetic instabilities in human cancers Nature 1998 396 643 649 10.1038/25292 9872311
Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643–649 (1998).9872311 10.1038/25292
228. Livingstone LR Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 Cell 1992 70 923 935 10.1016/0092-8674(92)90243-6 1356076
Livingstone, L. R. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923–935 (1992).1356076 10.1016/0092-8674(92)90243-6
229. Negrini S Gorgoulis VG Halazonetis TD Genomic instability-an evolving hallmark of cancer Nat. Rev. Mol. Cell Biol. 2010 11 220 228 10.1038/nrm2858 20177397
Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228 (2010).20177397 10.1038/nrm2858
230. Tomasini R Mak TW Melino G The impact of p53 and p73 on aneuploidy and cancer Trends Cell Biol. 2008 18 244 252 10.1016/j.tcb.2008.03.003 18406616
Tomasini, R., Mak, T. W. & Melino, G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 18, 244–252 (2008).18406616 10.1016/j.tcb.2008.03.003
231. Baslan T Ordered and deterministic cancer genome evolution after p53 loss Nature 2022 608 795 802 10.1038/s41586-022-05082-5 35978189
Baslan, T. et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature 608, 795–802 (2022).35978189 10.1038/s41586-022-05082-5
232. Chan-Seng-Yue M Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution Nat. Genet. 2020 52 231 240 10.1038/s41588-019-0566-9 31932696
Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231–240 (2020).31932696 10.1038/s41588-019-0566-9
233. Mueller S Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes Nature 2018 554 62 68 10.1038/nature25459 29364867
Mueller, S. et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554, 62–68 (2018).29364867 10.1038/nature25459
234. Maddipati R Levels regulate metastatic heterogeneity in pancreatic adenocarcinoma Cancer Disco. 2022 12 542 561 10.1158/2159-8290.CD-20-1826
Maddipati, R. et al. Levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Disco. 12, 542–561 (2022).10.1158/2159-8290.CD-20-1826
235. Boettcher S A dominant-negative effect drives selection of missense mutations in myeloid malignancies Science 2019 365 599 604 10.1126/science.aax3649 31395785
Boettcher, S. et al. A dominant-negative effect drives selection of missense mutations in myeloid malignancies. Science 365, 599–604 (2019).31395785 10.1126/science.aax3649
236. Zhu J Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth Nature 2015 525 206 211 10.1038/nature15251 26331536
Zhu, J. et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206–211 (2015).26331536 10.1038/nature15251
237. Xiong S Differential gain-of-function activity of three p53 hotspot mutants in vivo Cancer Res 2022 82 1926 1936 10.1158/0008-5472.CAN-21-3376 35320355
Xiong, S. et al. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Cancer Res 82, 1926–1936 (2022).35320355 10.1158/0008-5472.CAN-21-3376
238. Song H Hollstein M Xu Y p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM Nat. Cell Biol. 2007 9 573 580 10.1038/ncb1571 17417627
Song, H., Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9, 573–580 (2007).17417627 10.1038/ncb1571
239. Restle A Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants Nucleic Acids Res 2008 36 5362 5375 10.1093/nar/gkn503 18697815
Restle, A. et al. Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. Nucleic Acids Res 36, 5362–5375 (2008).18697815 10.1093/nar/gkn503
240. Dong P Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway Mol. Cancer 2009 8 103 10.1186/1476-4598-8-103 19917135
Dong, P. et al. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol. Cancer 8, 103 (2009).19917135 10.1186/1476-4598-8-103
241. Powell E Piwnica-Worms D Piwnica-Worms H Contribution of p53 to metastasis Cancer Disco. 2014 4 405 414 10.1158/2159-8290.CD-13-0136
Powell, E., Piwnica-Worms, D. & Piwnica-Worms, H. Contribution of p53 to metastasis. Cancer Disco. 4, 405–414 (2014).10.1158/2159-8290.CD-13-0136
242. Brosh R Rotter V When mutants gain new powers: news from the mutant p53 field Nat. Rev. Cancer 2009 9 701 713 10.1038/nrc2693 19693097
Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701–713 (2009).19693097 10.1038/nrc2693
243. Oren M Kotler E p53 mutations promote proteasomal activity Nat. Cell Biol. 2016 18 833 835 10.1038/ncb3392 27463250
Oren, M. & Kotler, E. p53 mutations promote proteasomal activity. Nat. Cell Biol. 18, 833–835 (2016).27463250 10.1038/ncb3392
244. van Oijen M Slootweg P Gain-of-function mutations in the tumor suppressor gene p53 Clin. Cancer Res. 2000 6 2138 2145 10873062
van Oijen, M. & Slootweg, P. Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res. 6, 2138–2145 (2000).10873062
245. Halevy O Michalovitz D Oren M Different tumor-derived p53 mutants exhibit distinct biological activities Science 1990 250 113 116 10.1126/science.2218501 2218501
Halevy, O., Michalovitz, D. & Oren, M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250, 113–116 (1990).2218501 10.1126/science.2218501
246. Redman-Rivera LN Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes Nat. Commun. 2021 12 5184 10.1038/s41467-021-25359-z 34465782
Redman-Rivera, L. N. et al. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nat. Commun. 12, 5184 (2021).34465782 10.1038/s41467-021-25359-z
247. Jiang Z Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer Transl. Oncol. 2018 11 1171 1187 10.1016/j.tranon.2018.07.012 30059832
Jiang, Z. et al. Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer. Transl. Oncol. 11, 1171–1187 (2018).30059832 10.1016/j.tranon.2018.07.012
248. Lyu H Correlate the mutation and the mutation with immune signatures in head and neck squamous cell cancer Comput Struct. Biotechnol. J. 2019 17 1020 1030 10.1016/j.csbj.2019.07.009 31428295
Lyu, H. et al. Correlate the mutation and the mutation with immune signatures in head and neck squamous cell cancer. Comput Struct. Biotechnol. J. 17, 1020–1030 (2019).31428295 10.1016/j.csbj.2019.07.009
249. Eastham JA Association of p53 mutations with metastatic prostate cancer Clin. Cancer Res 1995 1 1111 1118 9815901
Eastham, J. A. et al. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res. 1, 1111–1118 (1995).9815901
250. Lang GA Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome Cell 2004 119 861 872 10.1016/j.cell.2004.11.006 15607981
Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861–872 (2004).15607981 10.1016/j.cell.2004.11.006
251. Olive KP Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome Cell 2004 119 847 860 10.1016/j.cell.2004.11.004 15607980
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860 (2004).15607980 10.1016/j.cell.2004.11.004
252. Kim MP Oncogenic recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis Cancer Disco. 2021 11 2094 2111 10.1158/2159-8290.CD-20-1228
Kim, M. P. et al. Oncogenic recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Disco. 11, 2094–2111 (2021).10.1158/2159-8290.CD-20-1228
253. Zheng S A genetic mouse model for metastatic lung cancer with gender differences in survival Oncogene 2007 26 6896 6904 10.1038/sj.onc.1210493 17486075
Zheng, S. et al. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 26, 6896–6904 (2007).17486075 10.1038/sj.onc.1210493
254. Robey RW Revisiting the role of ABC transporters in multidrug-resistant cancer Nat. Rev. Cancer 2018 18 452 464 10.1038/s41568-018-0005-8 29643473
Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452–464 (2018).29643473 10.1038/s41568-018-0005-8
255. Chan K-T Lung ML Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line Cancer Chemother. Pharmacol. 2004 53 519 526 10.1007/s00280-004-0767-4 15004724
Chan, K.-T. & Lung, M. L. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother. Pharmacol. 53, 519–526 (2004).15004724 10.1007/s00280-004-0767-4
256. Alam SK DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53 Cell Death Differ. 2016 23 707 722 10.1038/cdd.2015.133 26494468
Alam, S. K. et al. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 23, 707–722 (2016).26494468 10.1038/cdd.2015.133
257. Wong RPC p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther. 2007 6 1054 1061 10.1158/1535-7163.MCT-06-0336 17363498
Wong, R. P. C. et al. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol. Cancer Ther. 6, 1054–1061 (2007).17363498 10.1158/1535-7163.MCT-06-0336
258. Masciarelli S Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells Oncogene 2014 33 1601 1608 10.1038/onc.2013.106 23584479
Masciarelli, S. et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 33, 1601–1608 (2014).23584479 10.1038/onc.2013.106
259. Joerger AC Fersht AR Structural biology of the tumor suppressor p53 Annu. Rev. Biochem. 2008 77 557 582 10.1146/annurev.biochem.77.060806.091238 18410249
Joerger, A. C. & Fersht, A. R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557–582 (2008).18410249 10.1146/annurev.biochem.77.060806.091238
260. Chillemi G Structural evolution and dynamics of the p53 proteins Cold Spring Harb. Perspect. Med. 2017 7 a028308 10.1101/cshperspect.a028308 27091942
Chillemi, G. et al. Structural evolution and dynamics of the p53 proteins. Cold Spring Harb. Perspect. Med. 7, a028308 (2017).27091942 10.1101/cshperspect.a028308
261. Joerger AC Fersht AR The tumor suppressor p53: from structures to drug discovery Cold Spring Harb. Perspect. Biol. 2010 2 a000919 10.1101/cshperspect.a000919 20516128
Joerger, A. C. & Fersht, A. R. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb. Perspect. Biol. 2, a000919 (2010).20516128 10.1101/cshperspect.a000919
262. Bell S p53 contains large unstructured regions in its native state J. Mol. Biol. 2002 322 917 927 10.1016/S0022-2836(02)00848-3 12367518
Bell, S. et al. p53 contains large unstructured regions in its native state. J. Mol. Biol. 322, 917–927 (2002).12367518 10.1016/S0022-2836(02)00848-3
263. Krois AS Dyson HJ Wright PE Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain Proc. Natl. Acad. Sci. USA 2018 115 E11302 E11310 10.1073/pnas.1814051115 30420502
Krois, A. S., Dyson, H. J. & Wright, P. E. Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain. Proc. Natl. Acad. Sci. USA 115, E11302–E11310 (2018).30420502 10.1073/pnas.1814051115
264. Walker KK Levine AJ Identification of a novel p53 functional domain that is necessary for efficient growth suppression Proc. Natl Acad. Sci. USA 1996 93 15335 15340 10.1073/pnas.93.26.15335 8986812
Walker, K. K. & Levine, A. J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl Acad. Sci. USA 93, 15335–15340 (1996).8986812 10.1073/pnas.93.26.15335
265. Kussie PH Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996 274 948 953 10.1126/science.274.5289.948 8875929
Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948–953 (1996).8875929 10.1126/science.274.5289.948
266. Popowicz GM Molecular basis for the inhibition of p53 by Mdmx Cell Cycle 2007 6 2386 2392 10.4161/cc.6.19.4740 17938582
Popowicz, G. M. et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6, 2386–2392 (2007).17938582 10.4161/cc.6.19.4740
267. Lee CW Martinez-Yamout MA Dyson HJ Wright PE Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein Biochemistry 2010 49 9964 9971 10.1021/bi1012996 20961098
Lee, C. W., Martinez-Yamout, M. A., Dyson, H. J. & Wright, P. E. Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry 49, 9964–9971 (2010).20961098 10.1021/bi1012996
268. Krois AS Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein Proc. Natl Acad. Sci. USA 2016 113 E1853 E1862 10.1073/pnas.1602487113 26976603
Krois, A. S. et al. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein. Proc. Natl Acad. Sci. USA 113, E1853–E1862 (2016).26976603 10.1073/pnas.1602487113
269. Feng H Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation Structure 2009 17 202 210 10.1016/j.str.2008.12.009 19217391
Feng, H. et al. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 17, 202–210 (2009).19217391 10.1016/j.str.2008.12.009
270. Miller Jenkins LM Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex Biochemistry 2015 54 2001 2010 10.1021/acs.biochem.5b00044 25753752
Miller Jenkins, L. M. et al. Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex. Biochemistry 54, 2001–2010 (2015).25753752 10.1021/acs.biochem.5b00044
271. Bochkareva E Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A Proc. Natl. Acad. Sci. USA 2005 102 15412 15417 10.1073/pnas.0504614102 16234232
Bochkareva, E. et al. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl. Acad. Sci. USA 102, 15412–15417 (2005).16234232 10.1073/pnas.0504614102
272. Rowell JP HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail Structure 2012 20 2014 2024 10.1016/j.str.2012.09.004 23063560
Rowell, J. P. et al. HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail. Structure 20, 2014–2024 (2012).23063560 10.1016/j.str.2012.09.004
273. Di Lello P Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53 Mol. Cell. 2006 22 731 740 10.1016/j.molcel.2006.05.007 16793543
Di Lello, P. et al. Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell. 22, 731–740 (2006).16793543 10.1016/j.molcel.2006.05.007
274. Ecsédi P Structure determination of the transactivation domain of p53 in complex with S100A4 using Annexin A2 as a crystallization chaperone Structure 2020 28 943 953 10.1016/j.str.2020.05.001 32442400
Ecsédi, P. et al. Structure determination of the transactivation domain of p53 in complex with S100A4 using Annexin A2 as a crystallization chaperone. Structure 28, 943–953 (2020).32442400 10.1016/j.str.2020.05.001
275. Okuda M Nishimura Y Extended string binding mode of the phosphorylated transactivation domain of tumor suppressor p53 J. Am. Chem. Soc. 2014 136 14143 14152 10.1021/ja506351f 25216154
Okuda, M. & Nishimura, Y. Extended string binding mode of the phosphorylated transactivation domain of tumor suppressor p53. J. Am. Chem. Soc. 136, 14143–14152 (2014).25216154 10.1021/ja506351f
276. Lee CW Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation Proc. Natl Acad. Sci. USA 2010 107 19290 19295 10.1073/pnas.1013078107 20962272
Lee, C. W. et al. Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proc. Natl Acad. Sci. USA 107, 19290–19295 (2010).20962272 10.1073/pnas.1013078107
277. Raj N Attardi LD The transactivation domains of the p53 protein Cold Spring Harb. Perspect. Med 2017 7 a026047 10.1101/cshperspect.a026047 27864306
Raj, N. & Attardi, L. D. The transactivation domains of the p53 protein. Cold Spring Harb. Perspect. Med 7, a026047 (2017).27864306 10.1101/cshperspect.a026047
278. Dumont P The codon 72 polymorphic variants of p53 have markedly different apoptotic potential Nat. Genet. 2003 33 357 365 10.1038/ng1093 12567188
Dumont, P. et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357–365 (2003).12567188 10.1038/ng1093
279. Ruaro EM A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1 Proc. Natl. Acad. Sci. USA 1997 94 4675 4680 10.1073/pnas.94.9.4675 9114050
Ruaro, E. M. et al. A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1. Proc. Natl. Acad. Sci. USA 94, 4675–4680 (1997).9114050 10.1073/pnas.94.9.4675
280. Jiang M p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress Oncogene 2001 20 5449 5458 10.1038/sj.onc.1204705 11571642
Jiang, M. et al. p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress. Oncogene 20, 5449–5458 (2001).11571642 10.1038/sj.onc.1204705
281. Golubovskaya VM The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning Biochem. J. 2008 411 151 160 10.1042/BJ20071657 18215142
Golubovskaya, V. M. et al. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning. Biochem. J. 411, 151–160 (2008).18215142 10.1042/BJ20071657
282. Yang L Li Y Bhattacharya A Zhang Y PEPD is a pivotal regulator of p53 tumor suppressor Nat. Commun. 2017 8 2052 10.1038/s41467-017-02097-9 29233996
Yang, L., Li, Y., Bhattacharya, A. & Zhang, Y. PEPD is a pivotal regulator of p53 tumor suppressor. Nat. Commun. 8, 2052 (2017).29233996 10.1038/s41467-017-02097-9
283. Bergamaschi D iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53 Nat. Genet. 2006 38 1133 1141 10.1038/ng1879 16964264
Bergamaschi, D. et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 38, 1133–1141 (2006).16964264 10.1038/ng1879
284. Zilfou JT The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation Mol. Cell. Biol. 2001 21 3974 3985 10.1128/MCB.21.12.3974-3985.2001 11359905
Zilfou, J. T. et al. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell. Biol. 21, 3974–3985 (2001).11359905 10.1128/MCB.21.12.3974-3985.2001
285. Cho Y Gorina S Jeffrey PD Pavletich NP Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations Science 1994 265 346 355 10.1126/science.8023157 8023157
Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346–355 (1994).8023157 10.1126/science.8023157
286. Iwafuchi-Doi M Zaret KS Pioneer transcription factors in cell reprogramming Genes Dev. 2014 28 2679 2692 10.1101/gad.253443.114 25512556
Iwafuchi-Doi, M. & Zaret, K. S. Pioneer transcription factors in cell reprogramming. Genes Dev. 28, 2679–2692 (2014).25512556 10.1101/gad.253443.114
287. Clarke CL Graham JD Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes PLoS One 2012 7 e35859 10.1371/journal.pone.0035859 22545144
Clarke, C. L. & Graham, J. D. Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One 7, e35859 (2012).22545144 10.1371/journal.pone.0035859
288. Nishimura M Takizawa Y Nozawa K Kurumizaka H Structural basis for p53 binding to its nucleosomal target DNA sequence PNAS Nexus 2022 1 pgac177 10.1093/pnasnexus/pgac177 36714865
Nishimura, M., Takizawa, Y., Nozawa, K. & Kurumizaka, H. Structural basis for p53 binding to its nucleosomal target DNA sequence. PNAS Nexus 1, pgac177 (2022).36714865 10.1093/pnasnexus/pgac177
289. el-Deiry WS Definition of a consensus binding site for p53 Nat. Genet. 1992 1 45 49 10.1038/ng0492-45 1301998
el-Deiry, W. S. et al. Definition of a consensus binding site for p53. Nat. Genet. 1, 45–49 (1992).1301998 10.1038/ng0492-45
290. Funk WD A transcriptionally active DNA-binding site for human p53 protein complexes Mol. Cell. Biol. 1992 12 2866 2871 1588974
Funk, W. D. et al. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866–2871 (1992).1588974
291. Friedman PN Chen X Bargonetti J Prives C The p53 protein is an unusually shaped tetramer that binds directly to DNA Proc. Natl. Acad. Sci. USA 1993 90 3319 3323 10.1073/pnas.90.8.3319 8475074
Friedman, P. N., Chen, X., Bargonetti, J. & Prives, C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 90, 3319–3323 (1993).8475074 10.1073/pnas.90.8.3319
292. Riley T Sontag E Chen P Levine A Transcriptional control of human p53-regulated genes Nat. Rev. Mol. Cell Biol. 2008 9 402 412 10.1038/nrm2395 18431400
Riley, T., Sontag, E., Chen, P. & Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402–412 (2008).18431400 10.1038/nrm2395
293. Brázda V Coufal J Recognition of local DNA structures by p53 protein Int. J. Mol. Sci. 2017 18 375 10.3390/ijms18020375 28208646
Brázda, V. & Coufal, J. Recognition of local DNA structures by p53 protein. Int. J. Mol. Sci. 18, 375 (2017).28208646 10.3390/ijms18020375
294. Brázda V Fojta M The rich world of p53 DNA binding targets: the role of DNA structure Int. J. Mol. Sci. 2019 20 5605 10.3390/ijms20225605 31717504
Brázda, V. & Fojta, M. The rich world of p53 DNA binding targets: the role of DNA structure. Int. J. Mol. Sci. 20, 5605 (2019).31717504 10.3390/ijms20225605
295. Klein C NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA J. Biol. Chem. 2001 276 49020 49027 10.1074/jbc.M107516200 11606582
Klein, C. et al. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276, 49020–49027 (2001).11606582 10.1074/jbc.M107516200
296. Rippin TM Freund SMV Veprintsev DB Fersht AR Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding J. Mol. Biol. 2002 319 351 358 10.1016/S0022-2836(02)00326-1 12051912
Rippin, T. M., Freund, S. M. V., Veprintsev, D. B. & Fersht, A. R. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J. Mol. Biol. 319, 351–358 (2002).12051912 10.1016/S0022-2836(02)00326-1
297. Ho WC Fitzgerald MX Marmorstein R Structure of the p53 core domain dimer bound to DNA J. Biol. Chem. 2006 281 20494 20502 10.1074/jbc.M603634200 16717092
Ho, W. C., Fitzgerald, M. X. & Marmorstein, R. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem. 281, 20494–20502 (2006).16717092 10.1074/jbc.M603634200
298. Chen Y Dey R Chen L Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer Structure 2010 18 246 256 10.1016/j.str.2009.11.011 20159469
Chen, Y., Dey, R. & Chen, L. Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure 18, 246–256 (2010).20159469 10.1016/j.str.2009.11.011
299. Kitayner M Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs Nat. Struct. Mol. Biol. 2010 17 423 429 10.1038/nsmb.1800 20364130
Kitayner, M. et al. Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat. Struct. Mol. Biol. 17, 423–429 (2010).20364130 10.1038/nsmb.1800
300. Golovenko D New insights into the role of DNA shape on its recognition by p53 proteins Structure 2018 26 1237 1250 10.1016/j.str.2018.06.006 30057026
Golovenko, D. et al. New insights into the role of DNA shape on its recognition by p53 proteins. Structure 26, 1237–1250 (2018).30057026 10.1016/j.str.2018.06.006
301. Petty TJ An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity EMBO J. 2011 30 2167 2176 10.1038/emboj.2011.127 21522129
Petty, T. J. et al. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J. 30, 2167–2176 (2011).21522129 10.1038/emboj.2011.127
302. Vainer R Structural basis for p53 Lys120-acetylation-dependent DNA-binding mode J. Mol. Biol. 2016 428 3013 3025 10.1016/j.jmb.2016.06.009 27338200
Vainer, R. et al. Structural basis for p53 Lys120-acetylation-dependent DNA-binding mode. J. Mol. Biol. 428, 3013–3025 (2016).27338200 10.1016/j.jmb.2016.06.009
303. Iwabuchi K Two cellular proteins that bind to wild-type but not mutant p53 Proc. Natl. Acad. Sci. USA 1994 91 6098 6102 10.1073/pnas.91.13.6098 8016121
Iwabuchi, K. et al. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA 91, 6098–6102 (1994).8016121 10.1073/pnas.91.13.6098
304. Baldock RA ATM localization and heterochromatin repair depend on direct interaction of the 53BP1-BRCT2 domain with γH2AX Cell Rep. 2015 13 2081 2089 10.1016/j.celrep.2015.10.074 26628370
Baldock, R. A. et al. ATM localization and heterochromatin repair depend on direct interaction of the 53BP1-BRCT2 domain with γH2AX. Cell Rep. 13, 2081–2089 (2015).26628370 10.1016/j.celrep.2015.10.074
305. Gorina S Pavletich NP Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 Science 1996 274 1001 1005 10.1126/science.274.5289.1001 8875926
Gorina, S. & Pavletich, N. P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001–1005 (1996).8875926 10.1126/science.274.5289.1001
306. Derbyshire DJ Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor EMBO J. 2002 21 3863 3872 10.1093/emboj/cdf383 12110597
Derbyshire, D. J. et al. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J. 21, 3863–3872 (2002).12110597 10.1093/emboj/cdf383
307. Samuels-Lev Y ASPP proteins specifically stimulate the apoptotic function of p53 Mol. Cell. 2001 8 781 794 10.1016/S1097-2765(01)00367-7 11684014
Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell. 8, 781–794 (2001).11684014 10.1016/S1097-2765(01)00367-7
308. Chen S iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition Proc. Natl. Acad. Sci. USA 2019 116 17470 17479 10.1073/pnas.1909393116 31395738
Chen, S. et al. iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. Proc. Natl. Acad. Sci. USA 116, 17470–17479 (2019).31395738 10.1073/pnas.1909393116
309. Follis AV The DNA-binding domain mediates both nuclear and cytosolic functions of p53 Nat. Struct. Mol. Biol. 2014 21 535 p543 10.1038/nsmb.2829 24814347
Follis, A. V. et al. The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat. Struct. Mol. Biol. 21, 535–p543 (2014).24814347 10.1038/nsmb.2829
310. Lilyestrom W Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor Genes Dev. 2006 20 2373 2382 10.1101/gad.1456306 16951253
Lilyestrom, W. et al. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 20, 2373–2382 (2006).16951253 10.1101/gad.1456306
311. Martinez-Zapien D Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53 Nature 2016 529 541 545 10.1038/nature16481 26789255
Martinez-Zapien, D. et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature 529, 541–545 (2016).26789255 10.1038/nature16481
312. Scheffner M The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell 1990 63 1129 1136 10.1016/0092-8674(90)90409-8 2175676
Scheffner, M. et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136 (1990).2175676 10.1016/0092-8674(90)90409-8
313. Jeffrey PD Gorina S Pavletich NP Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms Science 1995 267 1498 1502 10.1126/science.7878469 7878469
Jeffrey, P. D., Gorina, S. & Pavletich, N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498–1502 (1995).7878469 10.1126/science.7878469
314. Lee W Solution structure of the tetrameric minimum transforming domain of p53 Nat. Struct. Biol. 1994 1 877 890 10.1038/nsb1294-877 7773777
Lee, W. et al. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1, 877–890 (1994).7773777 10.1038/nsb1294-877
315. Clore GM Interhelical angles in the solution structure of the oligomerization domain of p53: correction Science 1995 267 1515 1516 10.1126/science.7878474 7878474
Clore, G. M. et al. Interhelical angles in the solution structure of the oligomerization domain of p53: correction. Science 267, 1515–1516 (1995).7878474 10.1126/science.7878474
316. Kamada R Tetramer formation of tumor suppressor protein p53: Structure, function, and applications Biopolymers 2016 106 598 612 10.1002/bip.22772 26572807
Kamada, R. et al. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications. Biopolymers 106, 598–612 (2016).26572807 10.1002/bip.22772
317. Higashimoto Y Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer Biochemistry 2006 45 1608 1619 10.1021/bi051192j 16460008
Higashimoto, Y. et al. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry 45, 1608–1619 (2006).16460008 10.1021/bi051192j
318. Stommel JM A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking EMBO J. 1999 18 1660 1672 10.1093/emboj/18.6.1660 10075936
Stommel, J. M. et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660–1672 (1999).10075936 10.1093/emboj/18.6.1660
319. Chène P The role of tetramerization in p53 function Oncogene 2001 20 2611 2617 10.1038/sj.onc.1204373 11420672
Chène, P. The role of tetramerization in p53 function. Oncogene 20, 2611–2617 (2001).11420672 10.1038/sj.onc.1204373
320. Laptenko O Tong DR Manfredi J Prives C The tail that wags the dog: how the disordered c-terminal domain controls the transcriptional activities of the p53 tumor-suppressor protein Trends Biochem. Sci. 2016 41 1022 1034 10.1016/j.tibs.2016.08.011 27669647
Laptenko, O., Tong, D. R., Manfredi, J. & Prives, C. The tail that wags the dog: how the disordered c-terminal domain controls the transcriptional activities of the p53 tumor-suppressor protein. Trends Biochem. Sci. 41, 1022–1034 (2016).27669647 10.1016/j.tibs.2016.08.011
321. Tong Q Structural plasticity of methyllysine recognition by the tandem tudor domain of 53BP1 Structure 2015 23 312 321 10.1016/j.str.2014.11.013 25579814
Tong, Q. et al. Structural plasticity of methyllysine recognition by the tandem tudor domain of 53BP1. Structure 23, 312–321 (2015).25579814 10.1016/j.str.2014.11.013
322. Liou S-H Structure of the p53/RNA polymerase II assembly Commun. Biol. 2021 4 397 10.1038/s42003-021-01934-4 33767390
Liou, S.-H. et al. Structure of the p53/RNA polymerase II assembly. Commun. Biol. 4, 397 (2021).33767390 10.1038/s42003-021-01934-4
323. Veprintsev DB Core domain interactions in full-length p53 in solution Proc. Natl. Acad. Sci. USA 2006 103 2115 2119 10.1073/pnas.0511130103 16461914
Veprintsev, D. B. et al. Core domain interactions in full-length p53 in solution. Proc. Natl. Acad. Sci. USA 103, 2115–2119 (2006).16461914 10.1073/pnas.0511130103
324. Tidow H Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex Proc. Natl. Acad. Sci. USA 2007 104 12324 12329 10.1073/pnas.0705069104 17620598
Tidow, H. et al. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl. Acad. Sci. USA 104, 12324–12329 (2007).17620598 10.1073/pnas.0705069104
325. Arlt C Ihling CH Sinz A Structure of full-length p53 tumor suppressor probed by chemical cross-linking and mass spectrometry Proteomics 2015 15 2746 2755 10.1002/pmic.201400549 25728495
Arlt, C., Ihling, C. H. & Sinz, A. Structure of full-length p53 tumor suppressor probed by chemical cross-linking and mass spectrometry. Proteomics 15, 2746–2755 (2015).25728495 10.1002/pmic.201400549
326. Thornton JM Laskowski RA Borkakoti N AlphaFold heralds a data-driven revolution in biology and medicine Nat. Med. 2021 27 1666 1669 10.1038/s41591-021-01533-0 34642488
Thornton, J. M., Laskowski, R. A. & Borkakoti, N. AlphaFold heralds a data-driven revolution in biology and medicine. Nat. Med. 27, 1666–1669 (2021).34642488 10.1038/s41591-021-01533-0
327. Jumper J Highly accurate protein structure prediction with AlphaFold Nature 2021 596 583 589 10.1038/s41586-021-03819-2 34265844
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).34265844 10.1038/s41586-021-03819-2
328. Tunyasuvunakool K Highly accurate protein structure prediction for the human proteome Nature 2021 596 590 596 10.1038/s41586-021-03828-1 34293799
Tunyasuvunakool, K. et al. Highly accurate protein structure prediction for the human proteome. Nature 596, 590–596 (2021).34293799 10.1038/s41586-021-03828-1
329. Callaway E What’s next for AlphaFold and the AI protein-folding revolution Nature 2022 604 234 238 10.1038/d41586-022-00997-5 35418629
Callaway, E. What’s next for AlphaFold and the AI protein-folding revolution. Nature 604, 234–238 (2022).35418629 10.1038/d41586-022-00997-5
330. Buel GR Walters KJ Can AlphaFold2 predict the impact of missense mutations on structure? Nat. Struct. Mol. Biol. 2022 29 1 2 10.1038/s41594-021-00714-2 35046575
Buel, G. R. & Walters, K. J. Can AlphaFold2 predict the impact of missense mutations on structure? Nat. Struct. Mol. Biol. 29, 1–2 (2022).35046575 10.1038/s41594-021-00714-2
331. Mullard A What does AlphaFold mean for drug discovery? Nat. Rev. Drug. Discov. 2021 20 725 727 10.1038/d41573-021-00161-0 34522032
Mullard, A. What does AlphaFold mean for drug discovery? Nat. Rev. Drug. Discov. 20, 725–727 (2021).34522032 10.1038/d41573-021-00161-0
332. Humphreys IR Computed structures of core eukaryotic protein complexes Science 2021 374 eabm4805 10.1126/science.abm4805 34762488
Humphreys, I. R. et al. Computed structures of core eukaryotic protein complexes. Science 374, eabm4805 (2021).34762488 10.1126/science.abm4805
333. Binder JL AlphaFold illuminates half of the dark human proteins Curr. Opin. Struct. Biol. 2022 74 102372 10.1016/j.sbi.2022.102372 35439658
Binder, J. L. et al. AlphaFold illuminates half of the dark human proteins. Curr. Opin. Struct. Biol. 74, 102372 (2022).35439658 10.1016/j.sbi.2022.102372
334. Manfredi JJ Mdm2 and MdmX: partners in p53 destruction Cancer Res 2021 81 1633 1634 10.1158/0008-5472.CAN-21-0145 34003788
Manfredi, J. J. Mdm2 and MdmX: partners in p53 destruction. Cancer Res 81, 1633–1634 (2021).34003788 10.1158/0008-5472.CAN-21-0145
335. Freedman DA Wu L Levine AJ Functions of the MDM2 oncoprotein Cell. Mol. Life Sci. 1999 55 96 107 10.1007/s000180050273 10065155
Freedman, D. A., Wu, L. & Levine, A. J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55, 96–107 (1999).10065155 10.1007/s000180050273
336. Deng L The role of ubiquitination in tumorigenesis and targeted drug discovery Signal Transduct. Target Ther. 2020 5 11 10.1038/s41392-020-0107-0 32296023
Deng, L. et al. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target Ther. 5, 11 (2020).32296023 10.1038/s41392-020-0107-0
337. Linke K Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans Cell Death Differ. 2008 15 841 848 10.1038/sj.cdd.4402309 18219319
Linke, K. et al. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 15, 841–848 (2008).18219319 10.1038/sj.cdd.4402309
338. Iyappan S Turning the RING domain protein MdmX into an active ubiquitin-protein ligase J. Biol. Chem. 2010 285 33065 33072 10.1074/jbc.M110.115113 20705607
Iyappan, S. et al. Turning the RING domain protein MdmX into an active ubiquitin-protein ligase. J. Biol. Chem. 285, 33065–33072 (2010).20705607 10.1074/jbc.M110.115113
339. Wade M Wang YV Wahl GM The p53 orchestra: Mdm2 and Mdmx set the tone Trends Cell Biol. 2010 20 299 309 10.1016/j.tcb.2010.01.009 20172729
Wade, M., Wang, Y. V. & Wahl, G. M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20, 299–309 (2010).20172729 10.1016/j.tcb.2010.01.009
340. Bhattacharya S Chakraborty D Basu M Ghosh MK Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases Signal Transduct. Target Ther. 2018 3 17 10.1038/s41392-018-0012-y 29967688
Bhattacharya, S., Chakraborty, D., Basu, M. & Ghosh, M. K. Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases. Signal Transduct. Target Ther. 3, 17 (2018).29967688 10.1038/s41392-018-0012-y
341. Vu B Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development ACS Med. Chem. Lett. 2013 4 466 469 10.1021/ml4000657 24900694
Vu, B. et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 4, 466–469 (2013).24900694 10.1021/ml4000657
342. Sun D Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development J. Med. Chem. 2014 57 1454 1472 10.1021/jm401753e 24456472
Sun, D. et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57, 1454–1472 (2014).24456472 10.1021/jm401753e
343. Tovar C MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models Cancer Res 2013 73 2587 2597 10.1158/0008-5472.CAN-12-2807 23400593
Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 73, 2587–2597 (2013).23400593 10.1158/0008-5472.CAN-12-2807
344. Ding Q Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 2013 56 5979 5983 10.1021/jm400487c 23808545
Ding, Q. et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979–5983 (2013).23808545 10.1021/jm400487c
345. Khurana A Shafer DA MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) Onco Targets Ther. 2019 12 2903 2910 10.2147/OTT.S172315 31289443
Khurana, A. & Shafer, D. A. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 12, 2903–2910 (2019).31289443 10.2147/OTT.S172315
346. Fan X MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma Cancer Biol. Ther. 2019 20 1328 1336 10.1080/15384047.2019.1638677 31311404
Fan, X. et al. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma. Cancer Biol. Ther. 20, 1328–1336 (2019).31311404 10.1080/15384047.2019.1638677
347. Cui Y Zhou J Rong F Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway Biochem. Biophys. Res. Commun. 2020 533 665 671 10.1016/j.bbrc.2020.09.135 33051060
Cui, Y., Zhou, J. & Rong, F. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway. Biochem. Biophys. Res. Commun. 533, 665–671 (2020).33051060 10.1016/j.bbrc.2020.09.135
348. Berberich A Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib Clin. Cancer Res 2019 25 253 265 10.1158/1078-0432.CCR-18-1580 30274984
Berberich, A. et al. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Clin. Cancer Res 25, 253–265 (2019).30274984 10.1158/1078-0432.CCR-18-1580
349. Skalniak L Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells Cancers (Basel) 2018 10 396 10.3390/cancers10110396 30352966
Skalniak, L. et al. Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells. Cancers (Basel) 10, 396 (2018).30352966 10.3390/cancers10110396
350. Rew Y Sun D Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer J. Med. Chem. 2014 57 6332 6341 10.1021/jm500627s 24967612
Rew, Y. & Sun, D. Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J. Med. Chem. 57, 6332–6341 (2014).24967612 10.1021/jm500627s
351. Her N-G Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells Cell Death Dis. 2018 9 792 10.1038/s41419-018-0825-1 30022047
Her, N.-G. et al. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death Dis. 9, 792 (2018).30022047 10.1038/s41419-018-0825-1
352. Sahin I AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing Cell Death Disco. 2020 6 57 10.1038/s41420-020-0292-1
Sahin, I. et al. AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Disco. 6, 57 (2020).10.1038/s41420-020-0292-1
353. Erba HP Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia Blood Adv. 2019 3 1939 1949 10.1182/bloodadvances.2019030916 31253596
Erba, H. P. et al. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Adv. 3, 1939–1949 (2019).31253596 10.1182/bloodadvances.2019030916
354. Wang S SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression Cancer Res 2014 74 5855 5865 10.1158/0008-5472.CAN-14-0799 25145672
Wang, S. et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res 74, 5855–5865 (2014).25145672 10.1158/0008-5472.CAN-14-0799
355. de Jonge M A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours Eur. J. Cancer 2017 76 144 151 10.1016/j.ejca.2017.02.005 28324749
de Jonge, M. et al. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur. J. Cancer 76, 144–151 (2017).28324749 10.1016/j.ejca.2017.02.005
356. de Weger VA A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours Br. J. Cancer 2019 120 286 293 10.1038/s41416-018-0355-8 30585255
de Weger, V. A. et al. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. Br. J. Cancer 120, 286–293 (2019).30585255 10.1038/s41416-018-0355-8
357. Jung J TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma Nat. Commun. 2016 7 12609 10.1038/ncomms12609 27576846
Jung, J. et al. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat. Commun. 7, 12609 (2016).27576846 10.1038/ncomms12609
358. Holzer P Discovery of a dihydroisoquinolinone derivative (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors J. Med. Chem. 2015 58 6348 6358 10.1021/acs.jmedchem.5b00810 26181851
Holzer, P. et al. Discovery of a dihydroisoquinolinone derivative (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors. J. Med. Chem. 58, 6348–6358 (2015).26181851 10.1021/acs.jmedchem.5b00810
359. Weisberg E Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097 Mol. Cancer Ther. 2015 14 2249 2259 10.1158/1535-7163.MCT-15-0429 26206331
Weisberg, E. et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol. Cancer Ther. 14, 2249–2259 (2015).26206331 10.1158/1535-7163.MCT-15-0429
360. Maser T The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma Cancer Med 2020 9 8144 8158 10.1002/cam4.3407 33034426
Maser, T. et al. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Cancer Med 9, 8144–8158 (2020).33034426 10.1002/cam4.3407
361. Portman N MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer Breast Cancer Res 2020 22 87 10.1186/s13058-020-01318-2 32787886
Portman, N. et al. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Res 22, 87 (2020).32787886 10.1186/s13058-020-01318-2
362. Carvajal LA Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia Sci. Transl. Med. 2018 10 eaao3003 10.1126/scitranslmed.aao3003 29643228
Carvajal, L. A. et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci. Transl. Med. 10, eaao3003 (2018).29643228 10.1126/scitranslmed.aao3003
363. Saleh MN Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type Clin Cancer Res 2021 27 5236 5247 10.1158/1078-0432.CCR-21-0715 34301750
Saleh, M. N. et al. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type. Clin Cancer Res 27, 5236–5247 (2021).34301750 10.1158/1078-0432.CCR-21-0715
364. Kannan S Partridge AW Lane DP Verma CS The dual interactions of p53 with MDM2 and p300: implications for the design of MDM2 inhibitors Int. J. Mol. Sci. 2019 20 5996 10.3390/ijms20235996 31795143
Kannan, S., Partridge, A. W., Lane, D. P. & Verma, C. S. The dual interactions of p53 with MDM2 and p300: implications for the design of MDM2 inhibitors. Int. J. Mol. Sci. 20, 5996 (2019).31795143 10.3390/ijms20235996
365. Stein EM Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia Clin. Cancer Res 2022 28 870 881 10.1158/1078-0432.CCR-21-1295 34862243
Stein, E. M. et al. Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia. Clin. Cancer Res 28, 870–881 (2022).34862243 10.1158/1078-0432.CCR-21-1295
366. Stachyra-Valat T Abstract 1239: NVP-HDM201: Biochemical and biophysical profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2 Cancer Res 2016 76 1239 1239 10.1158/1538-7445.AM2016-1239
Stachyra-Valat, T. et al. Abstract 1239: NVP-HDM201: Biochemical and biophysical profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2. Cancer Res 76, 1239–1239 (2016).10.1158/1538-7445.AM2016-1239
367. Ravandi F A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) Leuk. Res 2016 48 92 100 10.1016/j.leukres.2016.07.004 27544076
Ravandi, F. et al. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leuk. Res 48, 92–100 (2016).27544076 10.1016/j.leukres.2016.07.004
368. Wagner AJ Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors J. Clin. Oncol. 2017 35 1304 1311 10.1200/JCO.2016.70.7117 28240971
Wagner, A. J. et al. Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors. J. Clin. Oncol. 35, 1304–1311 (2017).28240971 10.1200/JCO.2016.70.7117
369. Kang MH Initial testing (stage 1) of MK-8242-A novel MDM2 inhibitor-by the pediatric preclinical testing program Pediatr. Blood Cancer 2016 63 1744 1752 10.1002/pbc.26064 27238606
Kang, M. H. et al. Initial testing (stage 1) of MK-8242-A novel MDM2 inhibitor-by the pediatric preclinical testing program. Pediatr. Blood Cancer 63, 1744–1752 (2016).27238606 10.1002/pbc.26064
370. Cornillie J Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification Clin. Transl. Oncol. 2020 22 546 554 10.1007/s12094-019-02158-z 31201607
Cornillie, J. et al. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. Clin. Transl. Oncol. 22, 546–554 (2020).31201607 10.1007/s12094-019-02158-z
371. Zhou J The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity Nat. Immunol. 2021 22 460 470 10.1038/s41590-021-00888-3 33767425
Zhou, J. et al. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat. Immunol. 22, 460–470 (2021).33767425 10.1038/s41590-021-00888-3
372. Aguilar, A. et al. Discovery of 4-((3’R,4’S,5’R)-6″-Chloro-4’-(3-chloro-2-fluorophenyl)-1’-ethyl-2″-oxodispiro[cyclohexane-1,2’-pyrrolidine-3’,3″-indoline]-5’-carboxamido)bicyclo[2.2.2]octane-1-carboxylicAcid (AA-115/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development. J. Med. Chem. 60, 2819–2839 (2017).
373. Yi H A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma J. Exp. Clin. Cancer Res. 2018 37 97 10.1186/s13046-018-0765-8 29716622
Yi, H. et al. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. J. Exp. Clin. Cancer Res. 37, 97 (2018).29716622 10.1186/s13046-018-0765-8
374. Takahashi S Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study Cancer Sci. 2021 112 2361 2370 10.1111/cas.14875 33686772
Takahashi, S. et al. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Sci. 112, 2361–2370 (2021).33686772 10.1111/cas.14875
375. Han X Wei W Sun Y PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective Acta Mater. Med 2022 1 244 259 35734447
Han, X., Wei, W. & Sun, Y. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Mater. Med 1, 244–259 (2022).35734447
376. Wang B Development of selective small molecule MDM2 degraders based on nutlin Eur. J. Med. Chem. 2019 176 476 491 10.1016/j.ejmech.2019.05.046 31128449
Wang, B. et al. Development of selective small molecule MDM2 degraders based on nutlin. Eur. J. Med. Chem. 176, 476–491 (2019).31128449 10.1016/j.ejmech.2019.05.046
377. Wang B Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries Eur. J. Med. Chem. 2021 219 113425 10.1016/j.ejmech.2021.113425 33862513
Wang, B. et al. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries. Eur. J. Med. Chem. 219, 113425 (2021).33862513 10.1016/j.ejmech.2021.113425
378. Li Y Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression J. Med. Chem. 2019 62 448 466 10.1021/acs.jmedchem.8b00909 30525597
Li, Y. et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J. Med. Chem. 62, 448–466 (2019).30525597 10.1021/acs.jmedchem.8b00909
379. Terzian T The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss Genes Dev. 2008 22 1337 1344 10.1101/gad.1662908 18483220
Terzian, T. et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337–1344 (2008).18483220 10.1101/gad.1662908
380. de Andrade KC The TP53 database: transition from the international agency for research on cancer to the US national cancer institute Cell Death Differ. 2022 29 1071 1073 10.1038/s41418-022-00976-3 35352025
de Andrade, K. C. et al. The TP53 database: transition from the international agency for research on cancer to the US national cancer institute. Cell Death Differ. 29, 1071–1073 (2022).35352025 10.1038/s41418-022-00976-3
381. Yu X Narayanan S Vazquez A Carpizo DR Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis 2014 19 1055 1068 10.1007/s10495-014-0990-3 24756955
Yu, X., Narayanan, S., Vazquez, A. & Carpizo, D. R. Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis 19, 1055–1068 (2014).24756955 10.1007/s10495-014-0990-3
382. Miller JJ Gaiddon C Storr T A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer Chem. Soc. Rev. 2020 49 6995 7014 10.1039/D0CS00163E 32869798
Miller, J. J., Gaiddon, C. & Storr, T. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer. Chem. Soc. Rev. 49, 6995–7014 (2020).32869798 10.1039/D0CS00163E
383. Lopes EA Gomes S Saraiva L Santos MMM Small molecules targeting mutant P53: a promising approach for cancer treatment Curr. Med. Chem. 2019 26 7323 7336 10.2174/0929867325666181116124308 30444195
Lopes, E. A., Gomes, S., Saraiva, L. & Santos, M. M. M. Small molecules targeting mutant P53: a promising approach for cancer treatment. Curr. Med. Chem. 26, 7323–7336 (2019).30444195 10.2174/0929867325666181116124308
384. Silva JL Recent synthetic approaches towards small molecule reactivators of p53 Biomolecules 2020 10 635 10.3390/biom10040635 32326087
Silva, J. L. et al. Recent synthetic approaches towards small molecule reactivators of p53. Biomolecules 10, 635 (2020).32326087 10.3390/biom10040635
385. Binayke A Awakening the guardian of genome: reactivation of mutant p53 Cancer Chemother. Pharmacol. 2019 83 1 15 10.1007/s00280-018-3701-x 30324219
Binayke, A. et al. Awakening the guardian of genome: reactivation of mutant p53. Cancer Chemother. Pharmacol. 83, 1–15 (2019).30324219 10.1007/s00280-018-3701-x
386. Bykov VJN Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 2002 8 282 288 10.1038/nm0302-282 11875500
Bykov, V. J. N. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282–288 (2002).11875500 10.1038/nm0302-282
387. Wang T Lee K Rehman A Daoud SS PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax Biochem. Biophys. Res. Commun. 2007 352 203 212 10.1016/j.bbrc.2006.11.006 17113036
Wang, T., Lee, K., Rehman, A. & Daoud, S. S. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochem. Biophys. Res. Commun. 352, 203–212 (2007).17113036 10.1016/j.bbrc.2006.11.006
388. Wiman KG Pharmacological reactivation of mutant p53: from protein structure to the cancer patient Oncogene 2010 29 4245 4252 10.1038/onc.2010.188 20498645
Wiman, K. G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29, 4245–4252 (2010).20498645 10.1038/onc.2010.188
389. Bykov VJN PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis Oncogene 2005 24 3484 3491 10.1038/sj.onc.1208419 15735745
Bykov, V. J. N. et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24, 3484–3491 (2005).15735745 10.1038/sj.onc.1208419
390. Zandi R PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53 Clin. Cancer Res. 2011 17 2830 2841 10.1158/1078-0432.CCR-10-3168 21415220
Zandi, R. et al. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 17, 2830–2841 (2011).21415220 10.1158/1078-0432.CCR-10-3168
391. Saha MN PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa Mol. Cancer Ther. 2013 12 2331 2341 10.1158/1535-7163.MCT-12-1166 24030633
Saha, M. N. et al. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol. Cancer Ther. 12, 2331–2341 (2013).24030633 10.1158/1535-7163.MCT-12-1166
392. Müller M Combining APR-246 and HDAC-inhibitors: a novel targeted treatment option for neuroblastoma Cancers (Basel) 2021 13 4476 10.3390/cancers13174476 34503286
Müller, M. et al. Combining APR-246 and HDAC-inhibitors: a novel targeted treatment option for neuroblastoma. Cancers (Basel) 13, 4476 (2021).34503286 10.3390/cancers13174476
393. Liu DSH APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma Gut 2015 64 1506 1516 10.1136/gutjnl-2015-309770 26187504
Liu, D. S. H. et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut 64, 1506–1516 (2015).26187504 10.1136/gutjnl-2015-309770
394. Mohell N APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells Cell Death Dis. 2015 6 e1794 10.1038/cddis.2015.143 26086967
Mohell, N. et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 6, e1794 (2015).26086967 10.1038/cddis.2015.143
395. Kobayashi T APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation Br. J. Cancer 2021 125 1523 1532 10.1038/s41416-021-01561-0 34599296
Kobayashi, T. et al. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation. Br. J. Cancer 125, 1523–1532 (2021).34599296 10.1038/s41416-021-01561-0
396. Ceder S Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells Cell Death Dis. 2021 12 709 10.1038/s41419-021-03988-y 34267184
Ceder, S. et al. Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell Death Dis. 12, 709 (2021).34267184 10.1038/s41419-021-03988-y
397. Nahi H Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion Br. J. Haematol. 2004 127 285 291 10.1111/j.1365-2141.2004.05210.x 15491287
Nahi, H. et al. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br. J. Haematol. 127, 285–291 (2004).15491287 10.1111/j.1365-2141.2004.05210.x
398. Nahi H Mutated and non-mutated TP53 as targets in the treatment of leukaemia Br. J. Haematol. 2008 141 445 453 10.1111/j.1365-2141.2008.07046.x 18341636
Nahi, H. et al. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br. J. Haematol. 141, 445–453 (2008).18341636 10.1111/j.1365-2141.2008.07046.x
399. Chipuk JE Maurer U Green DR Schuler M Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription Cancer Cell 2003 4 371 381 10.1016/S1535-6108(03)00272-1 14667504
Chipuk, J. E., Maurer, U., Green, D. R. & Schuler, M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4, 371–381 (2003).14667504 10.1016/S1535-6108(03)00272-1
400. Lambert JMR Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis Oncogene 2010 29 1329 1338 10.1038/onc.2009.425 19946333
Lambert, J. M. R. et al. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 29, 1329–1338 (2010).19946333 10.1038/onc.2009.425
401. Ali D APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells Eur. J. Haematol. 2011 86 206 215 10.1111/j.1600-0609.2010.01557.x 21114538
Ali, D. et al. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur. J. Haematol. 86, 206–215 (2011).21114538 10.1111/j.1600-0609.2010.01557.x
402. Li X-L PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms Oncotarget 2015 6 36689 36699 10.18632/oncotarget.5385 26452133
Li, X.-L. et al. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget 6, 36689–36699 (2015).26452133 10.18632/oncotarget.5385
403. Patyka M Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status Oncotarget 2016 7 60245 60269 10.18632/oncotarget.11197 27533246
Patyka, M. et al. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Oncotarget 7, 60245–60269 (2016).27533246 10.18632/oncotarget.11197
404. Menichini, P. et al. Antitumor effects of PRIMA-1 and PRIMA-1 (APR246) in hematological malignancies: still a mutant P53-dependent affair? Cells. 10, (2021).
405. Tessoulin B PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance Blood 2014 124 1626 1636 10.1182/blood-2014-01-548800 25006124
Tessoulin, B. et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 124, 1626–1636 (2014).25006124 10.1182/blood-2014-01-548800
406. Mlakar V PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level J. Exp. Clin. Cancer Res. 2019 38 69 10.1186/s13046-019-1066-6 30755224
Mlakar, V. et al. PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. J. Exp. Clin. Cancer Res. 38, 69 (2019).30755224 10.1186/s13046-019-1066-6
407. Peng X APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase Cell Death Dis. 2013 4 e881 10.1038/cddis.2013.417 24157875
Peng, X. et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 4, e881 (2013).24157875 10.1038/cddis.2013.417
408. Bykov VJN Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy Front. Oncol. 2016 6 21 10.3389/fonc.2016.00021 26870698
Bykov, V. J. N. et al. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front. Oncol. 6, 21 (2016).26870698 10.3389/fonc.2016.00021
409. Haffo L Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 Sci. Rep. 2018 8 12671 10.1038/s41598-018-31048-7 30140002
Haffo, L. et al. Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Sci. Rep. 8, 12671 (2018).30140002 10.1038/s41598-018-31048-7
410. Birsen R APR-246 induces early cell death by ferroptosis in acute myeloid leukemia Haematologica 2022 107 403 416 10.3324/haematol.2020.259531 33406814
Birsen, R. et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica 107, 403–416 (2022).33406814 10.3324/haematol.2020.259531
411. Liu DS Inhibiting the system x/glutathione axis selectively targets cancers with mutant-p53 accumulation Nat. Commun. 2017 8 14844 10.1038/ncomms14844 28348409
Liu, D. S. et al. Inhibiting the system x/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 8, 14844 (2017).28348409 10.1038/ncomms14844
412. Fujihara KM Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction Sci. Adv. 2022 8 eabm9427 10.1126/sciadv.abm9427 36103522
Fujihara, K. M. et al. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Sci. Adv. 8, eabm9427 (2022).36103522 10.1126/sciadv.abm9427
413. Teoh PJ PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation Oncotarget 2016 7 61806 61819 10.18632/oncotarget.11241 27533450
Teoh, P. J. et al. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget 7, 61806–61819 (2016).27533450 10.18632/oncotarget.11241
414. Ali D Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells Br. J. Haematol. 2016 174 117 126 10.1111/bjh.14036 26991755
Ali, D. et al. Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells. Br. J. Haematol. 174, 117–126 (2016).26991755 10.1111/bjh.14036
415. Sallman DA Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes J. Clin. Oncol. 2021 39 1584 1594 10.1200/JCO.20.02341 33449813
Sallman, D. A. et al. Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes. J. Clin. Oncol. 39, 1584–1594 (2021).33449813 10.1200/JCO.20.02341
416. Cluzeau T Eprenetapopt plus azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe Francophone des Myélodysplasies (GFM) J. Clin. Oncol. 2021 39 1575 1583 10.1200/JCO.20.02342 33600210
Cluzeau, T. et al. Eprenetapopt plus azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe Francophone des Myélodysplasies (GFM). J. Clin. Oncol. 39, 1575–1583 (2021).33600210 10.1200/JCO.20.02342
417. Lehmann S Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer J. Clin. Oncol. 2012 30 3633 3639 10.1200/JCO.2011.40.7783 22965953
Lehmann, S. et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 30, 3633–3639 (2012).22965953 10.1200/JCO.2011.40.7783
418. Gourley C PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC) J. Clin. Oncol. 2016 34 5571 5571 10.1200/JCO.2016.34.15_suppl.5571
Gourley, C. et al. PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). J. Clin. Oncol. 34, 5571–5571 (2016).10.1200/JCO.2016.34.15_suppl.5571
419. Mishra, A. et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for -mutant acute myeloid leukemia and myelodysplastic syndromes. J. Clin. Oncol., JCO2200181 (2022).
420. Maslah N Synergistic effects of PRIMA-1 (APR-246) and 5-azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemia Haematologica 2020 105 1539 1551 10.3324/haematol.2019.218453 31488557
Maslah, N. et al. Synergistic effects of PRIMA-1 (APR-246) and 5-azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica 105, 1539–1551 (2020).31488557 10.3324/haematol.2019.218453
421. Welch JS TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes N. Engl. J. Med. 2016 375 2023 2036 10.1056/NEJMoa1605949 27959731
Welch, J. S. et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N. Engl. J. Med. 375, 2023–2036 (2016).27959731 10.1056/NEJMoa1605949
422. Lambert JMR PRIMA-1 reactivates mutant p53 by covalent binding to the core domain Cancer Cell 2009 15 376 388 10.1016/j.ccr.2009.03.003 19411067
Lambert, J. M. R. et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376–388 (2009).19411067 10.1016/j.ccr.2009.03.003
423. Sun XZ Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization Antioxid. Redox Signal 2003 5 655 665 10.1089/152308603770310338 14580323
Sun, X. Z. et al. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid. Redox Signal 5, 655–665 (2003).14580323 10.1089/152308603770310338
424. Wassman CD Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 Nat. Commun. 2013 4 1407 10.1038/ncomms2361 23360998
Wassman, C. D. et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat. Commun. 4, 1407 (2013).23360998 10.1038/ncomms2361
425. Degtjarik O Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ) Nat. Commun. 2021 12 7057 10.1038/s41467-021-27142-6 34862374
Degtjarik, O. et al. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat. Commun. 12, 7057 (2021).34862374 10.1038/s41467-021-27142-6
426. Soignet SL Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N. Engl. J. Med. 1998 339 1341 1348 10.1056/NEJM199811053391901 9801394
Soignet, S. L. et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339, 1341–1348 (1998).9801394 10.1056/NEJM199811053391901
427. Zhang X-W Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML Science 2010 328 240 243 10.1126/science.1183424 20378816
Zhang, X.-W. et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240–243 (2010).20378816 10.1126/science.1183424
428. Liu Q Hilsenbeck S Gazitt Y Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL Blood 2003 101 4078 4087 10.1182/blood-2002-10-3231 12531793
Liu, Q., Hilsenbeck, S. & Gazitt, Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101, 4078–4087 (2003).12531793 10.1182/blood-2002-10-3231
429. Zheng T Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma Mol. Cancer 2014 13 133 10.1186/1476-4598-13-133 24884809
Zheng, T. et al. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Mol. Cancer 13, 133 (2014).24884809 10.1186/1476-4598-13-133
430. Li Y Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation Cancer Lett. 2009 284 208 215 10.1016/j.canlet.2009.04.035 19457607
Li, Y. et al. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 284, 208–215 (2009).19457607 10.1016/j.canlet.2009.04.035
431. Chen, S. et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell. 39 (2021).
432. Tang Y Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations Cell Rep. 2022 39 110622 10.1016/j.celrep.2022.110622 35417717
Tang, Y. et al. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Rep. 39, 110622 (2022).35417717 10.1016/j.celrep.2022.110622
433. Liarte DB Murta SMF Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species Parasitol. Res. 2010 107 205 212 10.1007/s00436-010-1852-8 20372925
Liarte, D. B. & Murta, S. M. F. Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species. Parasitol. Res. 107, 205–212 (2010).20372925 10.1007/s00436-010-1852-8
434. Dumetz, F. et al. Molecular preadaptation to antimony resistance in leishmania donovani on the indian subcontinent. mSphere. 3 (2018).
435. Wang B The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer J. Pharmacol. Exp. Ther. 2015 352 129 138 10.1124/jpet.114.218644 25352499
Wang, B. et al. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer. J. Pharmacol. Exp. Ther. 352, 129–138 (2015).25352499 10.1124/jpet.114.218644
436. Zhang Y-K Establishment and characterization of arsenic trioxide resistant KB/ATO cells Acta Pharm. Sin. B 2017 7 564 570 10.1016/j.apsb.2017.04.001 28924550
Zhang, Y.-K. et al. Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharm. Sin. B 7, 564–570 (2017).28924550 10.1016/j.apsb.2017.04.001
437. Lecureur V Lagadic-Gossmann D Fardel O Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells Int. J. Oncol. 2002 20 1071 1076 11956606
Lecureur, V., Lagadic-Gossmann, D. & Fardel, O. Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells. Int. J. Oncol. 20, 1071–1076 (2002).11956606
438. Lecureur V Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells Br. J. Haematol. 2002 119 608 615 10.1046/j.1365-2141.2002.03863.x 12437633
Lecureur, V. et al. Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells. Br. J. Haematol. 119, 608–615 (2002).12437633 10.1046/j.1365-2141.2002.03863.x
439. Butler JS Loh SN Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain Biochemistry 2003 42 2396 2403 10.1021/bi026635n 12600206
Butler, J. S. & Loh, S. N. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 42, 2396–2403 (2003).12600206 10.1021/bi026635n
440. Bullock AN Thermodynamic stability of wild-type and mutant p53 core domain Proc. Natl Acad. Sci. USA 1997 94 14338 14342 10.1073/pnas.94.26.14338 9405613
Bullock, A. N. et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl Acad. Sci. USA 94, 14338–14342 (1997).9405613 10.1073/pnas.94.26.14338
441. Yu X Vazquez A Levine AJ Carpizo DR Allele-specific p53 mutant reactivation Cancer Cell 2012 21 614 625 10.1016/j.ccr.2012.03.042 22624712
Yu, X., Vazquez, A., Levine, A. J. & Carpizo, D. R. Allele-specific p53 mutant reactivation. Cancer Cell 21, 614–625 (2012).22624712 10.1016/j.ccr.2012.03.042
442. Yu X Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism Oncotarget 2014 5 8879 8892 10.18632/oncotarget.2432 25294809
Yu, X. et al. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5, 8879–8892 (2014).25294809 10.18632/oncotarget.2432
443. Yu X Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53 Mol. Pharmacol. 2017 91 567 p575 10.1124/mol.116.107409 28320780
Yu, X. et al. Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53. Mol. Pharmacol. 91, 567–p575 (2017).28320780 10.1124/mol.116.107409
444. Blanden AR Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore Mol. Pharmacol. 2015 87 825 831 10.1124/mol.114.097550 25710967
Blanden, A. R. et al. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol. Pharmacol. 87, 825–831 (2015).25710967 10.1124/mol.114.097550
445. Na B BRCA1Therapeutic targeting of and mutant breast cancer through mutant p53 reactivation NPJ breast cancer 2019 5 14 10.1038/s41523-019-0110-1 30993195
Na, B. et al. BRCA1Therapeutic targeting of and mutant breast cancer through mutant p53 reactivation. NPJ breast cancer 5, 14 (2019).30993195 10.1038/s41523-019-0110-1
446. Yu X Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics Clin. Cancer Res. 2018 24 4505 4517 10.1158/1078-0432.CCR-18-0822 29914895
Yu, X. et al. Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics. Clin. Cancer Res. 24, 4505–4517 (2018).29914895 10.1158/1078-0432.CCR-18-0822
447. Zaman S Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding Mol. Cancer Ther. 2019 18 1355 1365 10.1158/1535-7163.MCT-18-1080 31196889
Zaman, S. et al. Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding. Mol. Cancer Ther. 18, 1355–1365 (2019).31196889 10.1158/1535-7163.MCT-18-1080
448. Salim KY Maleki Vareki S Danter WR Koropatnick J COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo Oncotarget 2016 7 41363 41379 10.18632/oncotarget.9133 27150056
Salim, K. Y., Maleki Vareki, S., Danter, W. R. & Koropatnick, J. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7, 41363–41379 (2016).27150056 10.18632/oncotarget.9133
449. Lindemann A COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent Mechanisms Clin. Cancer Res. 2019 25 5650 5662 10.1158/1078-0432.CCR-19-0096 31308060
Lindemann, A. et al. COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent Mechanisms. Clin. Cancer Res. 25, 5650–5662 (2019).31308060 10.1158/1078-0432.CCR-19-0096
450. Bormio Nunes J Cancer cell resistance against the clinically investigated thiosemicarbazone COTI-2 is based on formation of intracellular copper complex glutathione adducts and ABCC1-mediated efflux J. Med. Chem. 2020 63 13719 13732 10.1021/acs.jmedchem.0c01277 33190481
Bormio Nunes, J. et al. Cancer cell resistance against the clinically investigated thiosemicarbazone COTI-2 is based on formation of intracellular copper complex glutathione adducts and ABCC1-mediated efflux. J. Med. Chem. 63, 13719–13732 (2020).33190481 10.1021/acs.jmedchem.0c01277
451. Synnott NC O’Connell D Crown J Duffy MJ COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells Breast Cancer Res. Treat. 2020 179 47 56 10.1007/s10549-019-05435-1 31538264
Synnott, N. C., O’Connell, D., Crown, J. & Duffy, M. J. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Res. Treat. 179, 47–56 (2020).31538264 10.1007/s10549-019-05435-1
452. Guo Y Zhu X Sun X COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203 Bioengineered 2020 11 201 208 10.1080/21655979.2020.1729927 32063077
Guo, Y., Zhu, X. & Sun, X. COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203. Bioengineered 11, 201–208 (2020).32063077 10.1080/21655979.2020.1729927
453. Maleki Vareki S Salim K Danter W Koropatnick J Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines PLoS One 2018 13 e0191766 10.1371/journal.pone.0191766 29364966
Maleki Vareki, S., Salim, K., Danter, W. & Koropatnick, J. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS One 13, e0191766 (2018).29364966 10.1371/journal.pone.0191766
454. Foster BA Coffey HA Morin MJ Rastinejad F Pharmacological rescue of mutant p53 conformation and function Science 1999 286 2507 2510 10.1126/science.286.5449.2507 10617466
Foster, B. A., Coffey, H. A., Morin, M. J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999).10617466 10.1126/science.286.5449.2507
455. Rippin TM Characterization of the p53-rescue drug CP-31398 in vitro and in living cells Oncogene 2002 21 2119 2129 10.1038/sj.onc.1205362 11948395
Rippin, T. M. et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21, 2119–2129 (2002).11948395 10.1038/sj.onc.1205362
456. Wischhusen J CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death Oncogene 2003 22 8233 8245 10.1038/sj.onc.1207198 14614447
Wischhusen, J. et al. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22, 8233–8245 (2003).14614447 10.1038/sj.onc.1207198
457. Wang W Takimoto R Rastinejad F El-Deiry WS Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding Mol. Cell. Biol. 2003 23 2171 2181 10.1128/MCB.23.6.2171-2181.2003 12612087
Wang, W., Takimoto, R., Rastinejad, F. & El-Deiry, W. S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23, 2171–2181 (2003).12612087 10.1128/MCB.23.6.2171-2181.2003
458. Zache N Mutant p53 targeting by the low molecular weight compound STIMA-1 Mol. Oncol. 2008 2 70 80 10.1016/j.molonc.2008.02.004 19383329
Zache, N. et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2, 70–80 (2008).19383329 10.1016/j.molonc.2008.02.004
459. Bykov VJN Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs J. Biol. Chem. 2005 280 30384 30391 10.1074/jbc.M501664200 15998635
Bykov, V. J. N. et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 280, 30384–30391 (2005).15998635 10.1074/jbc.M501664200
460. Bou-Hanna C Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis Cancer Lett. 2015 359 211 217 10.1016/j.canlet.2015.01.014 25617798
Bou-Hanna, C. et al. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett. 359, 211–217 (2015).25617798 10.1016/j.canlet.2015.01.014
461. Saha M Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents Br. J. Cancer 2014 110 2224 2231 10.1038/bjc.2014.164 24691427
Saha, M. et al. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br. J. Cancer 110, 2224–2231 (2014).24691427 10.1038/bjc.2014.164
462. Durairaj, G. et al. Discovery of compounds that reactivate p53 mutants in vitro and in vivo. Cell Chem Biol. 29 (2022).
463. Kaar JL Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding Protein Sci. 2010 19 2267 2278 10.1002/pro.507 20878668
Kaar, J. L. et al. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci. 19, 2267–2278 (2010).20878668 10.1002/pro.507
464. Bauer MR Targeting cavity-creating p53 cancer mutations with small-molecule stabilizers: the Y220X paradigm ACS Chem. Biol. 2020 15 657 668 10.1021/acschembio.9b00748 31990523
Bauer, M. R. et al. Targeting cavity-creating p53 cancer mutations with small-molecule stabilizers: the Y220X paradigm. ACS Chem. Biol. 15, 657–668 (2020).31990523 10.1021/acschembio.9b00748
465. Basse N Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant Chem. Biol. 2010 17 46 56 10.1016/j.chembiol.2009.12.011 20142040
Basse, N. et al. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem. Biol. 17, 46–56 (2010).20142040 10.1016/j.chembiol.2009.12.011
466. Bykov VJN Wiman KG Mutant p53 reactivation by small molecules makes its way to the clinic FEBS Lett. 2014 588 2622 2627 10.1016/j.febslet.2014.04.017 24768524
Bykov, V. J. N. & Wiman, K. G. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 588, 2622–2627 (2014).24768524 10.1016/j.febslet.2014.04.017
467. Boeckler FM Targeted rescue of a destabilized mutant of p53 by an in silico screened drug Proc. Natl. Acad. Sci. USA 2008 105 10360 10365 10.1073/pnas.0805326105 18650397
Boeckler, F. M. et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. USA 105, 10360–10365 (2008).18650397 10.1073/pnas.0805326105
468. Liu X Small molecule induced reactivation of mutant p53 in cancer cells Nucleic Acids Res. 2013 41 6034 6044 10.1093/nar/gkt305 23630318
Liu, X. et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41, 6034–6044 (2013).23630318 10.1093/nar/gkt305
469. Wilcken R Halogen-enriched fragment libraries as leads for drug rescue of mutant p53 J. Am. Chem. Soc. 2012 134 6810 6818 10.1021/ja301056a 22439615
Wilcken, R. et al. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J. Am. Chem. Soc. 134, 6810–6818 (2012).22439615 10.1021/ja301056a
470. Joerger AC Exploiting transient protein states for the design of small-molecule stabilizers of mutant p53 Structure 2015 23 2246 2255 10.1016/j.str.2015.10.016 26636255
Joerger, A. C. et al. Exploiting transient protein states for the design of small-molecule stabilizers of mutant p53. Structure 23, 2246–2255 (2015).26636255 10.1016/j.str.2015.10.016
471. Bauer MR Harnessing fluorine-sulfur contacts and multipolar interactions for the design of p53 mutant Y220C rescue drugs ACS Chem. Biol. 2016 11 2265 2274 10.1021/acschembio.6b00315 27267810
Bauer, M. R. et al. Harnessing fluorine-sulfur contacts and multipolar interactions for the design of p53 mutant Y220C rescue drugs. ACS Chem. Biol. 11, 2265–2274 (2016).27267810 10.1021/acschembio.6b00315
472. Baud MGJ Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines Eur. J. Med. Chem. 2018 152 101 114 10.1016/j.ejmech.2018.04.035 29702446
Baud, M. G. J. et al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur. J. Med. Chem. 152, 101–114 (2018).29702446 10.1016/j.ejmech.2018.04.035
473. Bauer MR A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C Future Med. Chem. 2019 11 2491 2504 10.4155/fmc-2019-0181 31633398
Bauer, M. R. et al. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. Future Med. Chem. 11, 2491–2504 (2019).31633398 10.4155/fmc-2019-0181
474. Raghavan V Agrahari M Gowda D Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics Comput. Biol. Chem. 2019 80 398 408 10.1016/j.compbiolchem.2019.05.005 31128451
Raghavan, V., Agrahari, M. & Gowda, D. Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics. Comput. Biol. Chem. 80, 398–408 (2019).31128451 10.1016/j.compbiolchem.2019.05.005
475. Miller J Multifunctional compounds for activation of the p53-Y220C mutant in cancer Chemistry 2018 24 17734 17742 10.1002/chem.201802677 30230059
Miller, J. et al. Multifunctional compounds for activation of the p53-Y220C mutant in cancer. Chemistry 24, 17734–17742 (2018).30230059 10.1002/chem.201802677
476. Dong T Hybrid molecular dynamics for elucidating cooperativity between halogen bond and water molecules during the interaction of p53-Y220C and the PhiKan5196 complex Front. Chem. 2020 8 344 10.3389/fchem.2020.00344 32457871
Dong, T. et al. Hybrid molecular dynamics for elucidating cooperativity between halogen bond and water molecules during the interaction of p53-Y220C and the PhiKan5196 complex. Front. Chem. 8, 344 (2020).32457871 10.3389/fchem.2020.00344
477. Synnott, N. C. et al. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 414 (2018).
478. Bauer MR Joerger AC Fersht AR 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells Proc. Natl. Acad. Sci. USA 2016 113 E5271 E5280 10.1073/pnas.1610421113 27551077
Bauer, M. R., Joerger, A. C. & Fersht, A. R. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc. Natl. Acad. Sci. USA 113, E5271–E5280 (2016).27551077 10.1073/pnas.1610421113
479. Dumble M Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development Cancer Res 2021 81 LB006 LB006 10.1158/1538-7445.AM2021-LB006
Dumble, M. et al. Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development. Cancer Res 81, LB006–LB006 (2021).10.1158/1538-7445.AM2021-LB006
480. Dumbrava EE First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation J. Clin. Oncol. 2022 40 3003 3003 10.1200/JCO.2022.40.16_suppl.3003 35594490
Dumbrava, E. E. et al. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. J. Clin. Oncol. 40, 3003–3003 (2022).35594490 10.1200/JCO.2022.40.16_suppl.3003
481. Wang G Fersht AR First-order rate-determining aggregation mechanism of p53 and its implications Proc. Natl. Acad. Sci. USA 2012 109 13590 13595 10.1073/pnas.1211557109 22869710
Wang, G. & Fersht, A. R. First-order rate-determining aggregation mechanism of p53 and its implications. Proc. Natl. Acad. Sci. USA 109, 13590–13595 (2012).22869710 10.1073/pnas.1211557109
482. Stenger JE p53 oligomerization and DNA looping are linked with transcriptional activation EMBO J. 1994 13 6011 6020 10.1002/j.1460-2075.1994.tb06947.x 7813439
Stenger, J. E. et al. p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J. 13, 6011–6020 (1994).7813439 10.1002/j.1460-2075.1994.tb06947.x
483. Wang G Fersht AR Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding Proc. Natl. Acad. Sci. USA 2015 112 2443 2448 10.1073/pnas.1500262112 25675527
Wang, G. & Fersht, A. R. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding. Proc. Natl. Acad. Sci. USA 112, 2443–2448 (2015).25675527 10.1073/pnas.1500262112
484. Levy CB Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors Int. J. Biochem. Cell Biol. 2011 43 60 64 10.1016/j.biocel.2010.10.017 21056685
Levy, C. B. et al. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int. J. Biochem. Cell Biol. 43, 60–64 (2011).21056685 10.1016/j.biocel.2010.10.017
485. Xu J Gain of function of mutant p53 by coaggregation with multiple tumor suppressors Nat. Chem. Biol. 2011 7 285 295 10.1038/nchembio.546 21445056
Xu, J. et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 7, 285–295 (2011).21445056 10.1038/nchembio.546
486. Eisenberg D Jucker M The amyloid state of proteins in human diseases Cell 2012 148 1188 1203 10.1016/j.cell.2012.02.022 22424229
Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–1203 (2012).22424229 10.1016/j.cell.2012.02.022
487. Nelson R Structure of the cross-beta spine of amyloid-like fibrils Nature 2005 435 773 778 10.1038/nature03680 15944695
Nelson, R. et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773–778 (2005).15944695 10.1038/nature03680
488. Ghosh S Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53 Biochemistry 2014 53 5995 6010 10.1021/bi500825d 25181279
Ghosh, S. et al. Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53. Biochemistry 53, 5995–6010 (2014).25181279 10.1021/bi500825d
489. Lei J Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant Phys. Chem. Chem. Phys. 2016 18 8098 8107 10.1039/C5CP06538K 26923710
Lei, J. et al. Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant. Phys. Chem. Chem. Phys. 18, 8098–8107 (2016).26923710 10.1039/C5CP06538K
490. Soragni, A. et al. A designed inhibitor of p53 Aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell. 29 (2016).
491. Lei J Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation Phys. Chem. Chem. Phys. 2021 23 23032 23041 10.1039/D1CP03094A 34612239
Lei, J. et al. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation. Phys. Chem. Chem. Phys. 23, 23032–23041 (2021).34612239 10.1039/D1CP03094A
492. Zhang Y Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC Prostate Cancer Prostatic Dis. 2020 23 160 171 10.1038/s41391-019-0172-z 31471556
Zhang, Y. et al. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. Prostate Cancer Prostatic Dis. 23, 160–171 (2020).31471556 10.1038/s41391-019-0172-z
493. Neal, A. et al. Combining ReACp53 with carboplatin to target high-grade serous ovarian cancers. Cancers (Basel). 13 (2021).
494. Zhang Y Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp Oncogene 2017 36 5473 5483 10.1038/onc.2017.152 28534505
Zhang, Y. et al. Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp. Oncogene 36, 5473–5483 (2017).28534505 10.1038/onc.2017.152
495. Wang G Fersht AR Multisite aggregation of p53 and implications for drug rescue Proc. Natl. Acad. Sci. USA 2017 114 E2634 E2643 28292898
Wang, G. & Fersht, A. R. Multisite aggregation of p53 and implications for drug rescue. Proc. Natl. Acad. Sci. USA 114, E2634–E2643 (2017).28292898
496. Palanikumar L Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function Nat. Commun. 2021 12 3962 10.1038/s41467-021-23985-1 34172723
Palanikumar, L. et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat. Commun. 12, 3962 (2021).34172723 10.1038/s41467-021-23985-1
497. Kumar S Hamilton AD α-helix mimetics as modulators of Aβ self-assembly J. Am. Chem. Soc. 2017 139 5744 5755 10.1021/jacs.6b09734 28273416
Kumar, S. & Hamilton, A. D. α-helix mimetics as modulators of Aβ self-assembly. J. Am. Chem. Soc. 139, 5744–5755 (2017).28273416 10.1021/jacs.6b09734
498. Kumar S Islet amyloid-induced cell death and bilayer integrity loss share a molecular origin targetable with oligopyridylamide-based α-helical mimetics Chem. Biol. 2015 22 369 378 10.1016/j.chembiol.2015.01.006 25754474
Kumar, S. et al. Islet amyloid-induced cell death and bilayer integrity loss share a molecular origin targetable with oligopyridylamide-based α-helical mimetics. Chem. Biol. 22, 369–378 (2015).25754474 10.1016/j.chembiol.2015.01.006
499. Miller JJ Bifunctional ligand design for modulating mutant p53 aggregation in cancer Chem. Sci. 2019 10 10802 10814 10.1039/C9SC04151F 32055386
Miller, J. J. et al. Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chem. Sci. 10, 10802–10814 (2019).32055386 10.1039/C9SC04151F
500. Li Y Prives C Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007 26 2220 2225 10.1038/sj.onc.1210311 17401431
Li, Y. & Prives, C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26, 2220–2225 (2007).17401431 10.1038/sj.onc.1210311
501. Wiech M Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2 PLoS One 2012 7 e51426 10.1371/journal.pone.0051426 23251530
Wiech, M. et al. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One 7, e51426 (2012).23251530 10.1371/journal.pone.0051426
502. Muller P Chaperone-dependent stabilization and degradation of p53 mutants Oncogene 2008 27 3371 3383 10.1038/sj.onc.1211010 18223694
Muller, P. et al. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27, 3371–3383 (2008).18223694 10.1038/sj.onc.1211010
503. Tutuska K Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins Cell Death Dis. 2020 11 274 10.1038/s41419-020-2466-4 32332697
Tutuska, K. et al. Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins. Cell Death Dis. 11, 274 (2020).32332697 10.1038/s41419-020-2466-4
504. Alexandrova EM Xu S Moll UM Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner Cell Death Dis. 2017 8 e2683 10.1038/cddis.2017.108 28300840
Alexandrova, E. M., Xu, S. & Moll, U. M. Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. Cell Death Dis. 8, e2683 (2017).28300840 10.1038/cddis.2017.108
505. Cooper B Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs) Chem. Soc. Rev. 2021 50 1480 1494 10.1039/D0CS00556H 33346298
Cooper, B. et al. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem. Soc. Rev. 50, 1480–1494 (2021).33346298 10.1039/D0CS00556H
506. Saw P Xu X Kim S Jon S Biomedical Applications of a Novel Class of High-Affinity Peptides Acc. Chem. Res. 2021 54 3576 3592 10.1021/acs.accounts.1c00239 34406761
Saw, P., Xu, X., Kim, S. & Jon, S. Biomedical Applications of a Novel Class of High-Affinity Peptides. Acc. Chem. Res. 54, 3576–3592 (2021).34406761 10.1021/acs.accounts.1c00239
507. Friedler A A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants Proc. Natl. Acad. Sci. USA 2002 99 937 942 10.1073/pnas.241629998 11782540
Friedler, A. et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA 99, 937–942 (2002).11782540 10.1073/pnas.241629998
508. Friedler A Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for “mutant conformation” J. Mol. Biol. 2004 336 187 196 10.1016/j.jmb.2003.12.005 14741214
Friedler, A. et al. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for “mutant conformation”. J. Mol. Biol. 336, 187–196 (2004).14741214 10.1016/j.jmb.2003.12.005
509. Friedler A Veprintsev D Hansson L Fersht A Kinetic instability of p53 core domain mutants: implications for rescue by small molecules J. Biol. Chem. 2003 278 24108 24112 10.1074/jbc.M302458200 12700230
Friedler, A., Veprintsev, D., Hansson, L. & Fersht, A. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J. Biol. Chem. 278, 24108–24112 (2003).12700230 10.1074/jbc.M302458200
510. Issaeva N Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide Proc. Natl Acad. Sci. USA 2003 100 13303 13307 10.1073/pnas.1835733100 14595027
Issaeva, N. et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl Acad. Sci. USA 100, 13303–13307 (2003).14595027 10.1073/pnas.1835733100
511. Tal P Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides Oncotarget 2016 7 11817 11837 10.18632/oncotarget.7857 26943582
Tal, P. et al. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget 7, 11817–11837 (2016).26943582 10.18632/oncotarget.7857
512. Yamada T A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells Mol. Cancer Ther. 2009 8 2947 2958 10.1158/1535-7163.MCT-09-0444 19808975
Yamada, T. et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. Cancer Ther. 8, 2947–2958 (2009).19808975 10.1158/1535-7163.MCT-09-0444
513. Taylor BN Noncationic peptides obtained from azurin preferentially enter cancer cells Cancer Res 2009 69 537 546 10.1158/0008-5472.CAN-08-2932 19147567
Taylor, B. N. et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 69, 537–546 (2009).19147567 10.1158/0008-5472.CAN-08-2932
514. Yamada T Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity Cell. Microbiol. 2005 7 1418 1431 10.1111/j.1462-5822.2005.00567.x 16153242
Yamada, T. et al. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cell. Microbiol. 7, 1418–1431 (2005).16153242 10.1111/j.1462-5822.2005.00567.x
515. Bizzarri AR Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy Int J. Nanomed. 2011 6 3011 3019 10.2147/IJN.S26155
Bizzarri, A. R. et al. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy. Int J. Nanomed. 6, 3011–3019 (2011).10.2147/IJN.S26155
516. Signorelli S Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies Biochim Biophys. Acta Gen. Subj. 2017 1861 910 921 10.1016/j.bbagen.2017.01.022 28126403
Signorelli, S. et al. Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies. Biochim Biophys. Acta Gen. Subj. 1861, 910–921 (2017).28126403 10.1016/j.bbagen.2017.01.022
517. Yamada T p28, a first in class peptide inhibitor of cop1 binding to p53 Br. J. Cancer 2013 108 2495 2504 10.1038/bjc.2013.266 23736031
Yamada, T. et al. p28, a first in class peptide inhibitor of cop1 binding to p53. Br. J. Cancer 108, 2495–2504 (2013).23736031 10.1038/bjc.2013.266
518. Yamada T Das Gupta TK Beattie CW p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation Mol. Pharm. 2013 10 3375 3383 10.1021/mp400221r 23952735
Yamada, T., Das Gupta, T. K. & Beattie, C. W. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol. Pharm. 10, 3375–3383 (2013).23952735 10.1021/mp400221r
519. Yamada T Das Gupta T Beattie C p28-mediated activation of p53 in G2-M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy Cancer Res 2016 76 2354 2365 10.1158/0008-5472.CAN-15-2355 26921335
Yamada, T., Das Gupta, T. & Beattie, C. p28-mediated activation of p53 in G2-M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy. Cancer Res. 76, 2354–2365 (2016).26921335 10.1158/0008-5472.CAN-15-2355
520. Warso MA A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours Br. J. Cancer 2013 108 1061 1070 10.1038/bjc.2013.74 23449360
Warso, M. A. et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer 108, 1061–1070 (2013).23449360 10.1038/bjc.2013.74
521. Lulla RR Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study Neuro Oncol. 2016 18 1319 1325 10.1093/neuonc/now047 27022131
Lulla, R. R. et al. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro Oncol. 18, 1319–1325 (2016).27022131 10.1093/neuonc/now047
522. Jia L Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination Cancer Chemother. Pharmacol. 2011 68 513 524 10.1007/s00280-010-1518-3 21085965
Jia, L. et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 68, 513–524 (2011).21085965 10.1007/s00280-010-1518-3
523. Hamers-Casterman C Naturally occurring antibodies devoid of light chains Nature 1993 363 446 448 10.1038/363446a0 8502296
Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446–448 (1993).8502296 10.1038/363446a0
524. Hu X A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease J. Nanobiotechnology 2022 20 237 10.1186/s12951-022-01456-z 35590366
Hu, X. et al. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. J. Nanobiotechnology 20, 237 (2022).35590366 10.1186/s12951-022-01456-z
525. Zeng, Z. et al. Activatable cancer sono-immunotherapy using semiconducting polymer nanobodies. Adv Mater. e2203246, (2022).
526. Hong J Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants Proc. Natl. Acad. Sci. USA 2022 119 e2201433119 10.1073/pnas.2201433119 35476528
Hong, J. et al. Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants. Proc. Natl. Acad. Sci. USA 119, e2201433119 (2022).35476528 10.1073/pnas.2201433119
527. Bethuyne J A nanobody modulates the p53 transcriptional program without perturbing its functional architecture Nucleic Acids Res. 2014 42 12928 12938 10.1093/nar/gku962 25324313
Bethuyne, J. et al. A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. Nucleic Acids Res. 42, 12928–12938 (2014).25324313 10.1093/nar/gku962
528. Danilova L The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity Cancer Immunol. Res 2018 6 888 899 10.1158/2326-6066.CIR-18-0129 29895573
Danilova, L. et al. The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol. Res 6, 888–899 (2018).29895573 10.1158/2326-6066.CIR-18-0129
529. Hsiue, E. H.-C. et al. Targeting a neoantigen derived from a common mutation. Science. 371 (2021).
530. Malekzadeh P Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers J. Clin. Invest 2019 129 1109 1114 10.1172/JCI123791 30714987
Malekzadeh, P. et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J. Clin. Invest 129, 1109–1114 (2019).30714987 10.1172/JCI123791
531. Nikolova PV Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations EMBO J. 2000 19 370 378 10.1093/emboj/19.3.370 10654936
Nikolova, P. V. et al. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19, 370–378 (2000).10654936 10.1093/emboj/19.3.370
532. Suad O Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations J. Mol. Biol. 2009 385 249 265 10.1016/j.jmb.2008.10.063 18996393
Suad, O. et al. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J. Mol. Biol. 385, 249–265 (2009).18996393 10.1016/j.jmb.2008.10.063
533. Otsuka K The screening of the second-site suppressor mutations of the common p53 mutants Int. J. Cancer 2007 121 559 566 10.1002/ijc.22724 17417775
Otsuka, K. et al. The screening of the second-site suppressor mutations of the common p53 mutants. Int. J. Cancer 121, 559–566 (2007).17417775 10.1002/ijc.22724
534. Joerger AC Allen MD Fersht AR Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations J. Biol. Chem. 2004 279 1291 1296 10.1074/jbc.M309732200 14534297
Joerger, A. C., Allen, M. D. & Fersht, A. R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 279, 1291–1296 (2004).14534297 10.1074/jbc.M309732200
535. Odell AF A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation J. Biol. Chem. 2013 288 16704 16714 10.1074/jbc.M112.443168 23612969
Odell, A. F. et al. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J. Biol. Chem. 288, 16704–16714 (2013).23612969 10.1074/jbc.M112.443168
536. Eldar A Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions Nucleic Acids Res 2013 41 8748 8759 10.1093/nar/gkt630 23863845
Eldar, A. et al. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Nucleic Acids Res 41, 8748–8759 (2013).23863845 10.1093/nar/gkt630
537. Brachmann RK Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations EMBO J. 1998 17 1847 1859 10.1093/emboj/17.7.1847 9524109
Brachmann, R. K. et al. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17, 1847–1859 (1998).9524109 10.1093/emboj/17.7.1847
538. Joerger AC Fersht AR Structure-function-rescue: the diverse nature of common p53 cancer mutants Oncogene 2007 26 2226 2242 10.1038/sj.onc.1210291 17401432
Joerger, A. C. & Fersht, A. R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 2226–2242 (2007).17401432 10.1038/sj.onc.1210291
539. Nikolova PV Henckel J Lane DP Fersht AR Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability Proc. Natl. Acad. Sci. USA 1998 95 14675 14680 10.1073/pnas.95.25.14675 9843948
Nikolova, P. V., Henckel, J., Lane, D. P. & Fersht, A. R. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc. Natl. Acad. Sci. USA 95, 14675–14680 (1998).9843948 10.1073/pnas.95.25.14675
540. Demir Ö Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants PLoS Comput. Biol. 2011 7 e1002238 10.1371/journal.pcbi.1002238 22028641
Demir, Ö. et al. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comput. Biol. 7, e1002238 (2011).22028641 10.1371/journal.pcbi.1002238
541. Merabet A Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights Biochem. J. 2010 427 225 236 10.1042/BJ20091888 20113312
Merabet, A. et al. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. Biochem. J. 427, 225–236 (2010).20113312 10.1042/BJ20091888
542. Chattopadhyay G Mechanistic insights into global suppressors of protein folding defects PLoS Genet 2022 18 e1010334 10.1371/journal.pgen.1010334 36037221
Chattopadhyay, G. et al. Mechanistic insights into global suppressors of protein folding defects. PLoS Genet 18, e1010334 (2022).36037221 10.1371/journal.pgen.1010334
543. Kamaraj B Bogaerts A Structure and function of p53-DNA complexes with inactivation and rescue mutations: a molecular dynamics simulation study PLoS One 2015 10 e0134638 10.1371/journal.pone.0134638 26244575
Kamaraj, B. & Bogaerts, A. Structure and function of p53-DNA complexes with inactivation and rescue mutations: a molecular dynamics simulation study. PLoS One 10, e0134638 (2015).26244575 10.1371/journal.pone.0134638
544. Ramani RG Jacob SG Prediction of cancer rescue p53 mutants in silico using Naïve Bayes learning methodology Protein Pept. Lett. 2013 20 1280 1291 10.2174/09298665113209990046 23772609
Ramani, R. G. & Jacob, S. G. Prediction of cancer rescue p53 mutants in silico using Naïve Bayes learning methodology. Protein Pept. Lett. 20, 1280–1291 (2013).23772609 10.2174/09298665113209990046
545. Wallentine BD Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue Acta Crystallogr 2013 69 2146 2156
Wallentine, B. D. et al. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue. Acta Crystallogr 69, 2146–2156 (2013).
546. Joerger AC Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations J. Biol. Chem. 2005 280 16030 16037 10.1074/jbc.M500179200 15703170
Joerger, A. C. et al. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 280, 16030–16037 (2005).15703170 10.1074/jbc.M500179200
547. Viadiu H Fronza G Inga A Structural studies on mechanisms to activate mutant p53 Subcell. Biochem. 2014 85 119 132 10.1007/978-94-017-9211-0_7 25201192
Viadiu, H., Fronza, G. & Inga, A. Structural studies on mechanisms to activate mutant p53. Subcell. Biochem. 85, 119–132 (2014).25201192 10.1007/978-94-017-9211-0_7
548. Selivanova G Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain Nat. Med. 1997 3 632 638 10.1038/nm0697-632 9176489
Selivanova, G. et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3, 632–638 (1997).9176489 10.1038/nm0697-632
549. Selivanova G Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain Mol. Cell. Biol. 1999 19 3395 3402 10.1128/MCB.19.5.3395 10207063
Selivanova, G. et al. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell. Biol. 19, 3395–3402 (1999).10207063 10.1128/MCB.19.5.3395
550. Kaldmäe, M. et al. A “spindle and thread” mechanism unblocks p53 translation by modulating N-terminal disorder. Structure 30, (2022).
551. Wang T-H Li W-T Yu S-H Au L-C The use of 10-23 DNAzyme to selectively destroy the allele of mRNA with a unique purine-pyrimidine dinucleotide Oligonucleotides 2008 18 295 299 10.1089/oli.2008.0138 18699741
Wang, T.-H., Li, W.-T., Yu, S.-H. & Au, L.-C. The use of 10-23 DNAzyme to selectively destroy the allele of mRNA with a unique purine-pyrimidine dinucleotide. Oligonucleotides 18, 295–299 (2008).18699741 10.1089/oli.2008.0138
552. Iyer SV Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities Oncotarget 2016 7 5401 5415 10.18632/oncotarget.6634 26700961
Iyer, S. V. et al. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. Oncotarget 7, 5401–5415 (2016).26700961 10.18632/oncotarget.6634
553. Hoffman-Luca CG Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo Clin. Cancer Res 2015 21 2558 2568 10.1158/1078-0432.CCR-14-2506 25754349
Hoffman-Luca, C. G. et al. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. Clin. Cancer Res 21, 2558–2568 (2015).25754349 10.1158/1078-0432.CCR-14-2506
554. Decaudin, D. et al. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. Eur. J. Cancer. 126 (2020).
555. Han X Nonsense-mediated mRNA decay: a ‘nonsense’ pathway makes sense in stem cell biology Nucleic Acids Res. 2018 46 1038 1051 10.1093/nar/gkx1272 29272451
Han, X. et al. Nonsense-mediated mRNA decay: a ‘nonsense’ pathway makes sense in stem cell biology. Nucleic Acids Res. 46, 1038–1051 (2018).29272451 10.1093/nar/gkx1272
556. Pan Y RNA dysregulation: an expanding source of cancer immunotherapy targets Trends Pharmacol. Sci. 2021 42 268 282 10.1016/j.tips.2021.01.006 33711255
Pan, Y. et al. RNA dysregulation: an expanding source of cancer immunotherapy targets. Trends Pharmacol. Sci. 42, 268–282 (2021).33711255 10.1016/j.tips.2021.01.006
557. Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug. Discov. (2022).
558. Floquet C Deforges J Rousset J-P Bidou L Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides Nucleic Acids Res 2011 39 3350 3362 10.1093/nar/gkq1277 21149266
Floquet, C., Deforges, J., Rousset, J.-P. & Bidou, L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 39, 3350–3362 (2011).21149266 10.1093/nar/gkq1277
559. Bidou L Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells RNA Biol. 2017 14 378 388 10.1080/15476286.2017.1285480 28145797
Bidou, L. et al. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biol. 14, 378–388 (2017).28145797 10.1080/15476286.2017.1285480
560. Gudikote JP Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers J. Biol. Chem. 2021 297 101163 10.1016/j.jbc.2021.101163 34481841
Gudikote, J. P. et al. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. J. Biol. Chem. 297, 101163 (2021).34481841 10.1016/j.jbc.2021.101163
561. Lindeboom RGH Vermeulen M Lehner B Supek F The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy Nat. Genet. 2019 51 1645 1651 10.1038/s41588-019-0517-5 31659324
Lindeboom, R. G. H., Vermeulen, M., Lehner, B. & Supek, F. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat. Genet. 51, 1645–1651 (2019).31659324 10.1038/s41588-019-0517-5
562. Khajavi M Inoue K Lupski JR Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease Eur. J. Hum. Genet. 2006 14 1074 1081 10.1038/sj.ejhg.5201649 16757948
Khajavi, M., Inoue, K. & Lupski, J. R. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur. J. Hum. Genet. 14, 1074–1081 (2006).16757948 10.1038/sj.ejhg.5201649
563. Chen J p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish Genes Dev. 2009 23 278 290 10.1101/gad.1761609 19204115
Chen, J. et al. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev. 23, 278–290 (2009).19204115 10.1101/gad.1761609
564. Bourdon J-C p53 isoforms can regulate p53 transcriptional activity Genes Dev. 2005 19 2122 2137 10.1101/gad.1339905 16131611
Bourdon, J.-C. et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122–2137 (2005).16131611 10.1101/gad.1339905
565. Senturk S p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state Proc. Natl Acad. Sci. USA 2014 111 E3287 E3296 10.1073/pnas.1321640111 25074920
Senturk, S. et al. p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc. Natl Acad. Sci. USA 111, E3287–E3296 (2014).25074920 10.1073/pnas.1321640111
566. Khoury MP Bourdon J-C p53 isoforms: an intracellular microprocessor? Genes Cancer 2011 2 453 465 10.1177/1947601911408893 21779513
Khoury, M. P. & Bourdon, J.-C. p53 isoforms: an intracellular microprocessor? Genes Cancer 2, 453–465 (2011).21779513 10.1177/1947601911408893
567. Bourdon JC p53 isoforms change p53 paradigm Mol. Cell Oncol. 2014 1 e969136 10.4161/23723548.2014.969136 27308370
Bourdon, J. C. p53 isoforms change p53 paradigm. Mol. Cell Oncol. 1, e969136 (2014).27308370 10.4161/23723548.2014.969136
568. Marcel V Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript FEBS Lett. 2010 584 4463 4468 10.1016/j.febslet.2010.10.005 20937277
Marcel, V. et al. Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett. 584, 4463–4468 (2010).20937277 10.1016/j.febslet.2010.10.005
569. Mondal AM Δ133p53α, a natural p53 isoform, contributes to conditional reprogramming and long-term proliferation of primary epithelial cells Cell Death Dis. 2018 9 750 10.1038/s41419-018-0767-7 29970881
Mondal, A. M. et al. Δ133p53α, a natural p53 isoform, contributes to conditional reprogramming and long-term proliferation of primary epithelial cells. Cell Death Dis. 9, 750 (2018).29970881 10.1038/s41419-018-0767-7
570. Burslem GM Crews CM Proteolysis-targeting chimeras as therapeutics and tools for biological discovery Cell 2020 181 102 114 10.1016/j.cell.2019.11.031 31955850
Burslem, G. M. & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181, 102–114 (2020).31955850 10.1016/j.cell.2019.11.031
571. Li Z Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds Nature 2019 575 203 209 10.1038/s41586-019-1722-1 31666698
Li, Z. et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature 575, 203–209 (2019).31666698 10.1038/s41586-019-1722-1
572. Takahashi, D. et al. AUTACs: cargo-specific degraders using selective autophagy. Mol. Cell. 76 (2019).
573. Banik SM Lysosome-targeting chimaeras for degradation of extracellular proteins Nature 2020 584 291 297 10.1038/s41586-020-2545-9 32728216
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).32728216 10.1038/s41586-020-2545-9
574. Chapeau EA Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf mouse model Proc. Natl. Acad. Sci. USA 2017 114 3151 3156 10.1073/pnas.1620262114 28265066
Chapeau, E. A. et al. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf mouse model. Proc. Natl. Acad. Sci. USA 114, 3151–3156 (2017).28265066 10.1073/pnas.1620262114
575. Wang S Chen F-E Small-molecule MDM2 inhibitors in clinical trials for cancer therapy Eur. J. Med. Chem. 2022 236 114334 10.1016/j.ejmech.2022.114334 35429910
Wang, S. & Chen, F.-E. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur. J. Med. Chem. 236, 114334 (2022).35429910 10.1016/j.ejmech.2022.114334
576. Sabapathy K Lane DP Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others Nat. Rev. Clin. Oncol. 2018 15 13 30 10.1038/nrclinonc.2017.151 28948977
Sabapathy, K. & Lane, D. P. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat. Rev. Clin. Oncol. 15, 13–30 (2018).28948977 10.1038/nrclinonc.2017.151
577. Vlatković N Crawford K Rubbi CP Boyd MT Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all Curr. Pharm. Des. 2011 17 618 630 10.2174/138161211795222568 21391912
Vlatković, N., Crawford, K., Rubbi, C. P. & Boyd, M. T. Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all. Curr. Pharm. Des. 17, 618–630 (2011).21391912 10.2174/138161211795222568
578. Gallo D CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition Nature 2022 604 749 756 10.1038/s41586-022-04638-9 35444283
Gallo, D. et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 604, 749–756 (2022).35444283 10.1038/s41586-022-04638-9
579. Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 6 (2020).
580. Canon J The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity Nature 2019 575 217 223 10.1038/s41586-019-1694-1 31666701
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).31666701 10.1038/s41586-019-1694-1
581. Awad MM Acquired resistance to KRAS inhibition in cancer N. Engl. J. Med. 2021 384 2382 2393 10.1056/NEJMoa2105281 34161704
Awad, M. M. et al. Acquired resistance to KRAS inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).34161704 10.1056/NEJMoa2105281
